Therapeutic agent containing nucleic acid and TCR-modified immune cells and its application
By expressing marker polypeptides and exogenous MHC class I molecules in tumor cells, combining oncolytic viruses and TCR-modified immune cells, the problems of antigen expression in TCR-T therapy are solved, and the problem of antigen expression is reduced. The identification and killing efficacy of the therapy has been achieved, the scope of application is expanded, and the risk of toxicity is reduced.
Patent Information
- Application Number
- CN201810972316.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2018-08-24
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-02-17
AI Technical Summary
TCR-T therapy faces problems of antigen expression inhomogeneity and HLA expression loss when identifying and killing tumor cells, resulting in limited efficacy, and CAR-T therapy has severe cytokine storm toxicity and the risk of identifying normal tissues.
By expressing marker peptides and exogenous MHC class I molecules in tumor cells, using oncolytic viruses as a vector, combined with TCR-modified immune cells for combined treatment, the presentation and recognition of antigen epitope peptides is significantly enhanced and the immune cells are enhanced. Identification and killing ability to avoid HLA restriction.
It improves the recognition sensitivity and killing efficacy of TCR-T therapy, expands the scope of treatment application, reduces the risk of cytokine storms, and enhances the tumor immune response through synergistic effects, achieving more effective tumor killing.
Smart Images

Figure GDA0004569937760000261 
Figure GDA0004569937760000271 
Figure GDA0004569937760000281
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and specifically, relates to a therapeutic agent comprising nucleic acid and TCR-modified immune cells, a marker polypeptide, an encoding nucleic acid, an expression vector, an oncolytic virus, a drug kit and applications thereof. Background Art
[0002] With the significant anti-tumor efficacy of immune checkpoint inhibitors such as CTLA-4 and PD-1 / PD-L1 in clinical trials (see the reference "Cancer Cell 27, 450-461 (2015)"), and the long-term effective therapeutic effect of adoptive T cell therapy represented by CAR-T (chimeric antigen receptor-T cells) on B-cell blood tumors (see the reference "N Engl J Med 2017; 377: 2545-2554"), tumor immunotherapy has become one of the most promising fields, which is expected to transform malignant tumors into controllable chronic diseases and even cure some advanced cancers. Tumor immunotherapy mainly stimulates the function of endogenous anti-tumor T cells or adoptively transfers tumor-specific T cells cultured in vitro to achieve the effect of killing and clearing cancer cells in the body. Early tumor vaccines targeted tumor-associated antigens (TAAs) derived from self-proteins, attempting to induce specific anti-tumor immune responses in vivo, but most related clinical trials were unsuccessful (see the literature "Nat Rev Clin Oncol. 2014 Nov; 11 (11): 630-2."). One of the main reasons is that most of the high-affinity T cells targeting these tumor-associated antigens are eliminated by the central tolerance mechanism of the thymus during development and differentiation. Even with the help of strong adjuvants, such as using mature dendritic cells to present antigens, the specific T cells induced in vivo are mostly low-affinity T cells that cannot recognize tumor cells (see the literature "J Immunol. 2008 Feb
[0003] 01; 180(3): 1526-34”). To overcome this obstacle, the development of personalized vaccines targeting tumor neoantigens derived from gene mutations is a development trend, and preliminary efficacy has been seen in clinical trials, but more clinical trials are needed to further verify the efficacy of such tumor vaccines (see the literature "Nat Rev Drug Discov. 2018 May 30; 17(6): 393"; "Front Immunol. 2017; 8: 1848"). Another obstacle to tumor immunotherapy is the immunosuppressive microenvironment generated during the occurrence and development of tumors. The tumor microenvironment (TME) has a strong inhibitory effect on the differentiation and proliferation of specific T cells and their anti-tumor function (see the literature "Curr Opin Immunol. 2016 Apr; 39: 1-6").
[0004] To address these issues, an effective treatment strategy is to adoptively transfer T cells obtained in vitro that can effectively recognize tumor antigens. These T cells are derived from infiltrating T lymphocytes (TILs) of tumor tissues, or they can be peripheral blood T cells (TCR-T) that can effectively recognize tumor antigens after being modified with antigen-specific T cell receptor (TCR) genes. In vitro culture avoids the inhibitory microenvironment of tumor tissues and provides optimized culture conditions, so that a sufficient number of anti-tumor T cells can be obtained for adoptive transfer therapy (see the literature "Adv Immunol. 2016; 130: 279-94"). Adoptive T cell therapy includes CAR-T therapy based on chimeric antigen receptors and TCR-T therapy based on T cell receptors. CAR-T mainly targets tumor antigens expressed on the cell surface. Although the number of tumor antigens recognized is limited, CAR-T targeting CD19 has shown significant clinical efficacy against blood tumors including B-cell leukemia and lymphoma, and some products have been approved by the FDA for marketing (see the document "N Engl J Med. 2017 Oct 05; 377(14): 1313-1315"). For the treatment of solid tumors, CAR-T has not yet seen clear clinical efficacy. TCR-T mainly targets polypeptide antigens presented by human major histocompatibility antigen HLA molecules. Epitope polypeptides can be derived from intracellular proteins and cell membrane surface proteins. The types and number of target antigens are much greater than the tumor antigens recognized by CAR-T (see the document "Int Immunol. 201607; 28(7): 349-53"). TCR-T therapy is considered to be the most promising immune cell gene therapy for solid tumors (see the document "Adv Immunol. 2016; 130: 279-94"). TCR-T targeting NY-ESO-1 antigen for solid tumor treatment has also shown clear efficacy in Phase II clinical trials (see the literature "Front Immunol. 2018; 9: 947"). Her2 / neu protein is overexpressed in a variety of epithelial cancer cells, such as breast cancer, gastric cancer, colorectal cancer, ovarian cancer, pancreatic cancer, lung cancer, esophageal cancer, bladder cancer, kidney cancer, etc. (see the literature "Trends in Molecular Med, 2013; 19: 677"), making Her2 / neu an appropriate target for immunotherapy. T cells that specifically recognize Her2 / neu epitope peptide 369-377 can be successfully isolated from ovarian cancer ascites with high expression of Her2 / neu (see the literature "J. Exp. Med. 1995; 181: 2109–2117").A tumor vaccine targeting Her2 / neu369-377 peptide antigen entered clinical trials, but the Phase III clinical trial did not reach the predetermined goal of prolonging patient survival (http: / / www.onclive.com / web-exclusives / phase-iii-nelipepimuts-study-in-breast-cancer-halted-after-futility-review). Adoptive transfer of in vitro cultured CAR-T cells targeting Her2 / neu antigen entered clinical trials as the first CAR-T therapy for solid tumors, but was terminated due to the generation of a strong cytokine storm (cytokine release syndrome, CRS) that led to patient death (see the literature "Nature Med, 2016; 22:26"). Severe cytokine storm and neurotoxicity are common toxic reactions in CAR-T therapy (see the literature "Blood, 2016; 127:3321"). TCR-T therapy in clinical trials has not yet shown the severe cytokine storm toxicity shown in CAR-T therapy. TCR-T targeting Her2 / neu antigens for solid tumor treatment may avoid severe cytokine storms. Her2 / neu is a tumor-associated antigen derived from self-proteins. Most T cells that recognize such antigens are eliminated by the central tolerance selection mechanism. Therefore, it is very difficult to obtain natural T cells that specifically recognize tumor cells from peripheral blood. The induced peptide-specific T cells often cannot effectively recognize tumor-associated antigens expressed at low levels on the surface of tumor cells (see the document "Cancer Res. 1998; 58 (21): 4902-8"). In order to obtain TCRs for preparing TCR-T and effectively identifying tumor cells, it is generally performed by gene point mutation of the complementarity determining regions (CDRs) on the TCR, or by inducing from a humanized mouse T cell library that has not been screened by the central tolerance mechanism to obtain high-affinity antigen-specific TCRs (see the document "Front Immunol. 2013; 4: 363"). However, the TCR-T prepared by the high-affinity TCR obtained based on this strategy has produced serious off-target toxicity reactions against normal tissue cells in clinical trials (see the document "SciRep. 2016Jan 13; 6: 18851"). In addition, the targets recognized by TCR-T are the antigen complex formed by the HLA molecules on the cell surface, β2-microglobulin (beta2-Microglobulin) and antigen peptides (where HLA protein and β2-microglobulin pair to form MHC class I molecules).The antigen recognition ability of TCR-T is not only limited by HLA molecules, but also closely related to the expression of HLA molecules and tumor antigens in tumor cells, as well as the integrity of the HLA antigen peptide presentation pathway. However, during the development of tumors, the expression of HLA molecules in tumor cells often decreases, or the function of related molecules in the HLA antigen presentation pathway in the cytoplasm is lost, resulting in the inability of antigen peptides to be effectively presented by HLA molecules to the surface of tumor cells and recognized by T cells (see the document "Cancer Gene Ther. 2002 Dec; 9 (12): 1043-55"). The loss of this HLA class I antigen presentation pathway (i.e., MHC class I antigen presentation pathway) is a mechanism of tumor immune evasion, which is related to the gene mutation or abnormal expression of antigen presenting molecules such as HLA, β2-microglobulin, TAP, tapasin, LMP, ERAP, etc. in tumor cells, and may also be related to the excessive functional activation of tumor transformation molecules such as RAS, MYC, MOS and Her2 / Neu (see the literature "Trends in Molecular Medicine, 2013, 19 (11): 677-681"). In addition, the diversity of tumor tissues is also manifested in the heterogeneity of tumor antigen expression. Tumor cells that low-express or do not express tumor antigens may escape TCR-T recognition and killing, thereby affecting the efficacy of TCR-T (see the literature "Trends Immunol. 201606; 37 (6): 349-351").
[0005] Therefore, one of the challenges facing TCR-T therapy is how to enable TCR-T targeting tumor-associated antigens to effectively recognize and kill tumor cells. Summary of the invention
[0006] In order to solve the problems existing in the above-mentioned prior art, the present invention provides a therapeutic agent, a labeled polypeptide, an encoding nucleic acid, an expression vector, an oncolytic virus, a drug kit and applications thereof.
[0007] Specifically, the present invention provides:
[0008] (1) A therapeutic agent for treating tumors and / or cancers, comprising:
[0009] (a) a first composition, wherein the first composition comprises a first active ingredient in a first pharmaceutically acceptable carrier, the first active ingredient comprising or containing a nucleic acid having a marker polypeptide coding sequence for introduction into tumor cells and / or cancer cells; the marker polypeptide having an amino acid sequence of one or more antigen epitope polypeptides, the antigen epitope polypeptides being capable of being presented on the surface of the tumor cells and / or cancer cells by MHC class I molecules; and
[0010] (b) a second composition, wherein the second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier, wherein the second active ingredient comprises a T cell receptor-modified immune cell; the T cell receptor-modified immune cell can specifically recognize and bind to the antigen epitope polypeptide presented by the MHC class I molecule.
[0011] (2) The therapeutic agent according to (1), wherein the amino acid sequence of the antigen epitope polypeptide is derived from the amino acid sequence of a protein existing in nature, or is an artificially synthesized amino acid sequence that does not exist in nature; preferably, the protein existing in nature includes human proteins and proteins of species other than humans.
[0012] (3) The therapeutic agent according to (1), wherein the amino acid sequence of the antigen epitope polypeptide is derived from the amino acid sequence of a tumor-associated antigen or a tumor-specific antigen.
[0013] (4) The therapeutic agent according to (1), wherein the marker polypeptide comprises the following amino acid sequences operably linked in series: an amino acid sequence of an N-terminal signal peptide, an amino acid sequence of one or more of the antigenic epitope polypeptides, and an optional amino acid sequence of an endoplasmic reticulum retention signal at the C-terminal endoplasmic reticulum, wherein when the marker polypeptide comprises the amino acid sequences of a plurality of the antigenic epitope polypeptides, every two adjacent amino acid sequences of the antigenic epitope polypeptides are linked by an amino acid sequence of a cleavable linker polypeptide.
[0014] (5) The therapeutic agent according to (4), wherein the amino acid sequence of the antigen epitope polypeptide includes Her2 / neu 369-377, NY-ESO-1157-165, NY-ESO-1 1-11, NY-ESO-1 53-62, NY-ESO-1 18-27, N-ras55-64, K-ras 224-232, K-ras 10-18, K-ras 10-19, H3.3K27M 26-35, SSX-2 41-49, MAGE-C2 336-344, MAGE-C2 191-200, MAGE-C2307-315, MAGE-C2 42-50, MAGE-A1 120-129, MAGE-A1 230-238, MAGE-A1 161-169, KK-LC-1 76-84, p53 99-107, HPV16-E6 29-38, HPV16-E7 11-19, HPV16-E7 11-19, EBV-LMP1 51-59, EBV-LMP1125-133.
[0015] (6) The therapeutic agent according to (1), wherein the nucleic acid further comprises an HLA protein coding sequence, wherein the HLA protein coding sequence and the marker polypeptide coding sequence are respectively under the control of their own promoters, or the HLA protein coding sequence and the marker polypeptide coding sequence are under the control of the same promoter and the HLA protein coding sequence is operably linked to the marker polypeptide coding sequence via a cleavable linker polypeptide coding sequence.
[0016] (7) The therapeutic agent according to (6), wherein the HLA protein is HLA-A2 protein, and the amino acid sequence of HLA-A2 is shown in SEQ ID NO:29.
[0017] (8) The therapeutic agent according to (1), wherein the first composition and the second composition are each independently present in the therapeutic agent without mixing with each other.
[0018] (9) The therapeutic agent according to (1), wherein the nucleic acid includes DNA or RNA; and the RNA includes mRNA transcribed from the DNA.
[0019] (10) The therapeutic agent according to (1), wherein the first active ingredient is a recombinant virus, the genome of which has the marker polypeptide coding sequence and an optional HLA protein coding sequence; wherein the recombinant virus includes a selectively replicable recombinant oncolytic virus or a replication-deficient recombinant virus.
[0020] (11) The therapeutic agent according to (10), wherein the replication-deficient recombinant virus is derived from adenovirus, adenovirus-associated virus (AAV), herpes simplex virus, poxvirus, influenza virus, alphavirus, or Sendai virus.
[0021] (12) The therapeutic agent according to (10), wherein the replication-deficient recombinant virus is a recombinant adenovirus obtained by genetically modifying type 5 adenovirus, the E1 gene is deleted in the genome of the recombinant adenovirus, and the marker polypeptide coding sequence and the optional HLA protein coding sequence are contained in the position of the deleted E1 gene.
[0022] (13) The therapeutic agent according to (10), wherein the selectively replicable recombinant oncolytic virus is derived from a genetically mutated virus with oncolytic effect and a wild-type virus with oncolytic effect; preferably, the selectively replicable recombinant oncolytic virus is derived from an oncolytic adenovirus, poxvirus, herpes simplex virus, measles virus, Semliki Forest virus, vesicular stomatitis virus, poliovirus, retrovirus, reovirus, Seneca Valley virus, echovirus, coxsackievirus, Newcastle disease virus and Maraba virus.
[0023] (14) The therapeutic agent according to (10), wherein the selective replication-competent recombinant oncolytic virus is a recombinant oncolytic adenovirus obtained by genetically modifying type 5 adenovirus, the genome of the recombinant oncolytic adenovirus is missing the E1B-55K gene and / or the E1B-19K gene, and the genome of the recombinant oncolytic adenovirus contains the E1A gene coding sequence; preferably, the E1A gene coding sequence is under the control of an exogenous promoter.
[0024] (15) The therapeutic agent according to (10) or (14), wherein the recombinant oncolytic virus is a recombinant oncolytic adenovirus obtained by genetically modifying type 5 adenovirus, and the E1A gene of the recombinant oncolytic adenovirus is changed so that the expressed E1A protein cannot bind to the pRb protein; preferably, the E1A gene is under the control of an exogenous promoter.
[0025] (16) The therapeutic agent according to (14) or (15), wherein the E3 gene of the recombinant oncolytic adenovirus is completely or partially deleted.
[0026] (17) The therapeutic agent according to (1), wherein the immune cells include primitive T cells or precursor cells thereof, NKT cells, or T cell lines.
[0027] (18) The therapeutic agent according to (9), wherein the first composition comprises a therapeutically effective amount of the DNA or a therapeutically effective amount of the mRNA.
[0028] (19) The therapeutic agent according to (10), wherein the first composition comprises a therapeutically effective amount of the recombinant virus.
[0029] (20) The therapeutic agent according to (1), wherein the second composition comprises a therapeutically effective amount of the T cell receptor-modified immune cells.
[0030] (21) The therapeutic agent according to (9), wherein the DNA is formulated for administration by intratumoral injection; and the mRNA is formulated for administration by intratumoral injection.
[0031] (22) The therapeutic agent according to (10), wherein the recombinant virus is formulated for administration by intratumoral injection, intraperitoneal administration, subarachnoid administration, or intravenous administration.
[0032] (23) The therapeutic agent according to (1), wherein the immune cells are formulated for administration via an artery, vein, subcutaneous, intradermal, intratumoral, intralymphatic, intralymphatic, subarachnoid, intramedullary, intramuscular or intraperitoneal route.
[0033] (24) The therapeutic agent according to (1), wherein the therapeutic agent consists of the first composition and the second composition.
[0034] (25) Use of the therapeutic agent according to any one of (1) to (24) in the preparation of a medicament for treating tumors and / or cancer.
[0035] (26) The use according to (25), wherein the tumor and / or cancer includes: breast cancer, head and neck tumors, synovial cancer, renal cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.
[0036] (27) A marker polypeptide, comprising the following amino acid sequences operably linked in series: an amino acid sequence of an N-terminal signal peptide, an amino acid sequence of one or more antigenic epitope polypeptides, and an optional amino acid sequence of an endoplasmic reticulum retention signal at the C-terminal endoplasmic reticulum, wherein when the marker polypeptide comprises amino acid sequences of a plurality of said antigenic epitope polypeptides, every two adjacent amino acid sequences of said antigenic epitope polypeptides are linked by an amino acid sequence of a cleavable linking polypeptide; preferably, the cleavable linking polypeptide is a furin enzyme cleavage recognition polypeptide.
[0037] (28) The marker polypeptide according to (27), wherein the amino acid sequence of the antigen epitope polypeptide comprises Her2 / neu 369-377, NY-ESO-1157-165, NY-ESO-1 1-11, NY-ESO-1 53-62, NY-ESO-1 18-27, N-ras55-64, K-ras 224-232, K-ras 10-18, K-ras 10-19, H3.3K27M26-35, SSX-2 41-49, MAGE-C2 336-344, MAGE-C2 191-200, MAGE-C2307-315, MAGE-C2 42-50, MAGE-A1 120-129, MAGE-A1 230-238, MAGE-A1 161-169, KK-LC-1 76-84, p53 99-107, HPV16-E6 29-38, HPV16-E7 11-19, HPV16-E7 11-19, EBV-LMP1 51-59, EBV-LMP1125-133.
[0038] (29) The marker polypeptide according to (27), wherein the amino acid sequence of the marker polypeptide has at least 98% identity with the amino acid sequence shown in SEQ ID NO:24, SEQ ID NO:36, SEQ ID NO:56, or SEQ ID NO:60; preferably, the amino acid sequence of the marker polypeptide is as shown in SEQ ID NO:24, SEQ ID NO:36, SEQ ID NO:56, or SEQ ID NO:60.
[0039] (30) An isolated nucleic acid having a coding sequence for a marker polypeptide according to any one of (27) to (29).
[0040] (31) The nucleic acid according to (30), wherein the nucleic acid also has an HLA protein coding sequence, wherein the HLA protein coding sequence and the marker polypeptide coding sequence are respectively under the control of their own promoters, or the HLA protein coding sequence and the marker polypeptide coding sequence are under the control of the same promoter and the HLA protein coding sequence is operably linked to the marker polypeptide coding sequence via a cleavable linker polypeptide coding sequence.
[0041] (32) The nucleic acid according to (30), wherein the nucleic acid comprises DNA and mRNA.
[0042] (33) The nucleic acid according to (32), wherein the nucleic acid is DNA, and its nucleotide sequence is shown in SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:57, SEQ ID NO:58, or SEQ ID NO:61.
[0043] (34) A recombinant expression vector comprising the nucleic acid according to any one of (30) to (33), and / or its complementary sequence.
[0044] (35) An isolated recombinant virus, wherein the genome of the recombinant virus has the nucleic acid according to any one of (30)-(33); and the recombinant virus comprises a selectively replicable recombinant oncolytic virus or a replication-deficient recombinant virus.
[0045] (36) The recombinant virus according to (35), wherein the replication-deficient recombinant virus is derived from adenovirus, adenovirus-associated virus (AAV), herpes simplex virus, poxvirus, influenza virus, alphavirus, or Sendai virus.
[0046] (37) The recombinant virus according to (35), wherein the replication-deficient recombinant virus is a recombinant adenovirus obtained by genetically modifying type 5 adenovirus, the E1 gene is deleted in the genome of the recombinant adenovirus, and the marker polypeptide coding sequence and the optional HLA protein coding sequence are contained in the position of the deleted E1 gene.
[0047] (38) The recombinant virus according to (35), wherein the recombinant virus is a selectively replicative recombinant oncolytic virus, and the selectively replicative recombinant oncolytic virus is derived from a genetically mutated virus with oncolytic effect and a wild-type virus with oncolytic effect; preferably, the selectively replicative recombinant oncolytic virus is derived from an oncolytic adenovirus, poxvirus, herpes simplex virus, measles virus, Semliki Forest virus, vesicular stomatitis virus, poliovirus, retrovirus, reovirus, Seneca Valley virus, echovirus, coxsackievirus, Newcastle disease virus and Maraba virus.
[0048] (39) The recombinant virus according to (35), wherein the selective replication-competent recombinant oncolytic virus is a recombinant oncolytic adenovirus obtained by genetically modifying type 5 adenovirus, the genome of the recombinant oncolytic adenovirus lacks the E1B-55K and / or E1B-19K genes, and the genome of the recombinant oncolytic adenovirus contains the E1A gene coding sequence; preferably, the E1A gene coding sequence is under the control of an exogenous promoter.
[0049] (40) The recombinant virus according to (35) or (39), wherein the selective replication-type recombinant oncolytic virus is a recombinant oncolytic adenovirus obtained by genetically modifying type 5 adenovirus, and the E1A gene of the recombinant oncolytic adenovirus is changed so that the expressed E1A protein cannot bind to the pRb protein; preferably, the E1A gene is under the control of an exogenous promoter.
[0050] (41) The recombinant virus according to (39) or (40), wherein the E3 gene of the selective replication-type recombinant oncolytic virus is completely or partially deleted.
[0051] (42) A kit of combined drugs with synergistic effects for treating tumors and / or cancers, comprising:
[0052] A first container containing a first composition of the therapeutic agent according to any one of (1) to (24);
[0053] a second container containing a second composition of the therapeutic agent according to any one of (1) to (24), wherein the first container and the second container are separate; and
[0054] Instructions for use that specify when and how to administer the drug.
[0055] (43) Use of the nucleic acid according to any one of (30) to (33) in the preparation of a medicament for treating or preventing tumors and / or cancer.
[0056] (44) Use of the recombinant expression vector according to (34) in the preparation of a drug for treating or preventing tumors and / or cancer.
[0057] (45) Use of the recombinant virus according to any one of (35) to (41) in the preparation of a medicament for treating or preventing tumors and / or cancer.
[0058] (46) Use of the drug kit according to (42) in the preparation of a drug for treating or preventing tumors and / or cancer.
[0059] (47) The use according to any one of (43) to (46), wherein the tumor and / or cancer includes: breast cancer, head and neck tumor, synovial cancer, renal cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.
[0060] (48) A method for treating tumors and / or cancers, comprising:
[0061] administering the first composition of the therapeutic agent according to any one of (1) to (24) to a tumor and / or cancer patient; and
[0062] The second composition of the therapeutic agent according to any one of (1) to (24) is administered to the tumor and / or cancer patient.
[0063] (49) The method according to (48) comprises the following steps performed in sequence:
[0064] 1) administering the first composition to the tumor and / or cancer patient; and
[0065] 2) After administering the first composition, administering the second composition of the therapeutic agent to the tumor and / or cancer patient.
[0066] (50) The method according to (48), wherein the tumor and / or cancer includes: breast cancer, head and neck tumors, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.
[0067] Compared with the prior art, the present invention has the following advantages and positive effects:
[0068] In order to improve the effect of TCR-modified immune cells in treating tumors and increase the scope of application of TCR-modified immune cells in treating tumors, the present invention proposes expressing exogenous antigen epitope peptides and / or exogenous MHC class I molecules in tumor cells to significantly enhance the number of antigen epitope peptide / MHC class I molecule complexes on the surface of tumor cells, and adopting TCR-modified immune cells specifically targeting the antigen epitope peptide for combined treatment. When an oncolytic virus is used as a carrier to mediate the expression of exogenous antigen epitope peptides and / or exogenous MHC class I molecules in tumor cells, the killing of tumors by oncolytic viruses and the killing of tumors by TCR-modified immune cells can also produce a synergistic therapeutic effect.
[0069] Specifically, since TCR-modified immune cells (especially TCR-modified T cells) recognize antigen epitope peptides / MHC class I molecule complexes presented through the MHC class I antigen presentation pathway, simply expressing exogenous antigens in tumor cells through conventional exogenous gene expression cannot significantly enhance the presentation of antigen epitope peptides on the surface of tumor cells, especially when tumor cells often have defects in the MHC class I antigen presentation pathway. To this end, the present invention first designs a marker polypeptide amino acid sequence containing one or more antigen epitope peptide amino acid sequences, and a nucleic acid having a coding sequence of the marker polypeptide, so that after the nucleic acid is transfected into tumor cells and / or cancer cells, or after the nucleic acid is inserted into the viral genome and the resulting recombinant virus infects tumor cells and / or cancer cells, the marker antigen epitope polypeptide chain can be expressed in the cell, and introduced into the endoplasmic reticulum (ER) through the amino terminal signal peptide, and then cut / processed into the required antigen epitope polypeptide fragment, which can be finally presented on the surface of tumor cells and / or cancer cells by MHC class I molecules, thereby achieving the effect of significantly enhancing the presentation of antigen epitope peptides on the surface of tumor cells, effectively solving the problem of low antigen expression caused by the defect of antigen presentation pathway brought about by tumor immune escape mechanism. The present invention further inserts an HLA protein coding sequence into the nucleic acid to solve the problem of low or missing endogenous HLA expression. The present invention also proposes to use an active ingredient including or containing the nucleic acid encoding the marker polypeptide in combination with T cell receptor-modified immune cells that recognize antigen epitope peptides, thereby improving the recognition sensitivity of T cell receptor-modified immune cells to tumor cells, thereby further improving the ability of T cell receptor-modified immune cells to kill tumor cells.
[0070] Further, the present invention introduces the marker polypeptide and / or HLA protein encoding nucleic acid into tumor cells and / or cancer cells through an oncolytic virus, while playing the role of oncolytic virus in killing tumor cells and / or cancer cells, further enhancing the above-mentioned significant enhancement of the presentation of exogenous antigen epitope peptides on the surface of tumor cells and the synergistic therapeutic effect achieved by combining with T cell receptor-modified immune cells. In addition, while killing tumors, oncolytic viruses can also alleviate the immunosuppressive state of the tumor microenvironment and improve the homing of T cell receptor-modified immune cells; in addition, T cell receptor-modified immune cells can also effectively remove tumor cells that cannot complete the replication cycle and produce a sufficient number of sub-viruses and lyse after being infected by oncolytic viruses; thereby achieving further synergistic effects. In addition, the antigens released by tumor cells lysed by oncolytic viruses can further activate the body's own anti-tumor immunity, thereby achieving better tumor killing effects than using oncolytic viruses or T cell receptor-modified immune cells alone, and achieving synergistic therapeutic effects.
[0071] The present invention provides a new approach for tumor treatment through the above-mentioned inventive concept.
[0072] definition
[0073] In the present invention, the terms "tumor", "cancer", "tumor cell" and "cancer cell" include the meanings generally recognized in the art.
[0074] As used herein, the term "oncolytic virus" refers to a virus that is able to selectively replicate in tumor cells and lyse tumor cells.
[0075] The term "therapeutically effective amount" used herein refers to the amount of a functional agent or pharmaceutical composition that can exhibit a detectable therapeutic effect or inhibitory effect, or an amount that exerts an anti-tumor effect. The effect can be detected by any test method known in the art.
[0076] As used herein, the term "administration" or "administering" refers to providing a compound, complex or composition (including viruses and cells) to a subject.
[0077] The term "patient" as used herein refers to a human or non-human organism. Therefore, the methods and compositions described herein are applicable to both human and veterinary diseases. In some embodiments, the patient suffers from a tumor. In some instances, the patient suffers from one or more types of cancer at the same time.
[0078] As used herein, the term "synergistic effect" refers to the effect of two or more agents working together, which is greater than the sum of the individual effects of each agent.
[0079] The term "pfu" or "plague forming unit" used herein means: the amount of virus that produces one plaque is called one plaque forming unit (pfu).
[0080] The term "VP" as used herein refers to the number of viral particles.
[0081] The term "VP / kg" as used herein refers to the number of viral particles per kilogram of patient body weight.
[0082] The term "TCID50" as used herein refers to the median tissue culture infectious dose, which refers to the viral dose that infects half of the tissue cultures and causes cytopathic effects.
[0083] The term "MOI" or "multiplicity of infection" as used herein, i.e., the ratio of virus to cell number, refers to the number of virus particles that are used to initiate virus infection per cell. MOI = pfu / cell, i.e., number of cells x MOI = total PFU. BRIEF DESCRIPTION OF THE DRAWINGS
[0084] Figure 1 The results of Example 1 of the present invention show that + Phenotypic and functional test results of Her2 / neu 369-377 polypeptide (Her2-E75)-specific cytotoxic T cells induced from normal donor PBMC (specifically #1 PBMC). Figure 1 A is the result of flow cytometric analysis of PBMC cells after two rounds of in vitro stimulation with Her2-E75 antigen peptide, stained with CD8-APC antibody and Her2-E75 pentamer-PE. The right picture shows cells stimulated with peptide, and the results of flow cytometric analysis of PBMC cells after two rounds of in vitro stimulation with Her2-E75 antigen peptide, stained with CD8-APC antibody and Her2-E75 pentamer-PE. + Pentamer + The killer T cell population was sorted by FACS to obtain T cell clones. The left picture shows the control group cells without peptide stimulation. The horizontal axis represents the fluorescence intensity of CD8 molecule expression, and the vertical axis represents the fluorescence intensity of the bound Her2-E75 pentamer. Figure 1 B is CD8 + E75-tetramer + Phenotypic analysis of killer T cell clones by flow cytometry after staining with CD8-APC and Her2-E75 tetramer-PE. The right figure shows CD8 + Her2 tetramer + T cell clone Her2 CTL 6A5 is a purified Her2-E75 peptide-specific CTL cell clone. The left picture shows the control group CTL cells without peptide stimulation. The horizontal axis represents the fluorescence intensity of CD8 molecule expression, and the vertical axis represents the fluorescence intensity of the bound Her2-E75 tetramer. Figure 1 C shows the main functional fragments of the constructed lentiviral vector carrying the Her2 TCR-6A5-mC gene (i.e., "pCDH-EF1α-Her2 TCR vector"). The fragments shown express the TCR gene driven by the EF-1α promoter, and the constant region fragments of the β chain and α chain of each TCR are mouse constant region fragments, and the β chain and α chain of the TCR are linked by the coding sequence of the cleavable connecting polypeptide (furin-F2A).
[0085] Figure 2 Shown are the phenotypic and functional test results of peripheral blood mononuclear cells (PBMCs) transfected with the Her2 TCR-6A5-mC TCR gene. Figure 2A shows the results of flow cytometric analysis of PBMCs from two different donors transfected with a lentiviral vector encoding Her2 TCR-6A5-mC and stained with Her2-E75 tetramer-PE and anti-CD8-APC antibodies. First, lymphocyte populations were separated according to cell morphology and size. + The cell population is a cell expressing Her2 TCR-6A5-mC TCR. The horizontal axis represents the fluorescence intensity of CD8 molecule expression, and the vertical axis represents the fluorescence intensity of the bound Her2-E75 tetramer. The percentages shown are the ratios of each positive cell population to the number of lymphocytes separated. The left figure relates to peripheral blood mononuclear cells provided by one donor (#1PBMC), and the right figure relates to PBMC provided by another different donor (#2PBMC). CD8 + Her2-E75 tetramer + The cells are cytotoxic T cells expressing Her2TCR-6A5-mC. CD8 - Her2-E75 tetramer + The cells may be CD4 expressing Her2TCR-6A5-mC + Helper T cells. Figure 2 B shows that T cells expressing Her2TCR-6A5-mC can recognize the Her2-E75 peptide presented by T2 cells. PBMCs from two different donors transfected with the lentiviral vector encoding Her2 TCR-6A5-mC were mixed and cultured with T2 cells presenting different concentration gradients of Her2-E75 peptide for 16 hours, and the cell supernatant was taken for IFN-γ ELISA analysis. The target cells in the control group were T2 cells presenting the EBV virus antigen peptide LMP2 426-434 that can bind to the HLA-A2 molecule (not shown in the figure). In the figure, "0.1 μg / ml" indicates a T2 cell group presenting 0.1 μg / ml of Her2-E75 polypeptide, "0.01 μg / ml" indicates a T2 cell group presenting 0.01 μg / ml of Her2-E75 polypeptide, "0.001 μg / ml" indicates a T2 cell group presenting 0.001 μg / ml of Her2-E75 polypeptide, and "0.0001 μg / ml" indicates a T2 cell group presenting 0.0001 μg / ml of Her2-E75 polypeptide. The ordinate indicates the concentration of IFN-γ secreted by T cells. Figure 2C shows the results of the CD8 antibody blocking test of T cell function. Among them, anti-human CD8 antibodies were added when #2PBMCs transfected with the lentiviral vector encoding Her2 TCR-6A5-mC were co-cultured with the Her2-E75 antigen polypeptide presented by T2 cells to detect whether the function of T cells to secrete IFN-γ was inhibited. In the figure, "T2+Her2-E75" represents the T2 cell group that presented 0.1μg / ml of Her2-E75 polypeptide without the addition of anti-human CD8 antibodies, and "T2+Her2-E75+anti-CD8" represents the T2 cell group that presented 0.1μg / ml of Her2-E75 polypeptide with the addition of anti-human CD8 antibodies. The horizontal axis represents different experimental groups, and the vertical axis represents the concentration of IFN-γ secreted by T cells. "ns" means that there is no significant difference between the two experimental groups. Figure 2 Each experimental group and control group in B and 2C were duplicate wells, and the results are shown as mean ± SEM.
[0086] Figure 3 The results of functional detection of tumor cell lines by peripheral blood mononuclear cells (PBMCs) transfected with Her2 TCR-6A5-mC TCR gene are shown. Figure 3 A shows the expression of HLA-A2 and Her2 / neu in different tumor cell lines. The horizontal axis represents different human tumor cell lines. "Colo205" and "HCT116" are colon cancer cells; "MDA-MB-231" and "MCF-7" are breast cancer cells; "PANC-1" is a pancreatic cancer cell; "U87MG" is a glioma cell; "NCI-H446" is a lung cancer cell. The vertical axis "MFI" represents the mean fluorescence intensity of the cells after staining with anti-HLA-A2 fluorescent antibody or anti-Her2 / neu fluorescent antibody. The white bars are the expression of Her2 / neu on the cell surface, and the black bars are the expression of HLA-A2 on the cell surface. Figure 3 B shows the results of ELISA analysis of IFN-γ in #2PBMC transfected with a lentiviral vector encoding the Her2 TCR-6A5-mC TCR gene and mixed with cells of different tumor cell lines for 24 hours, and the cell supernatant was taken. Each experimental group and control group had three wells, and the results were shown as mean ± SME. The horizontal axis shows different target cells, and the vertical axis shows the concentration of IFN-γ secreted by T cells. The effector-target ratio E:T is 5:1. The white bars show that the effector cells are control peripheral blood mononuclear cells that are not transfected with the Her2 TCR-6A5-mC TCR gene, and the black bars show that the effector cells are peripheral blood mononuclear cells transfected with the Her2 TCR-6A5-mC TCR gene. Figure 3C, D, E, F, G, H, I, J, and K show the cytotoxic activity of #2 PBMCs against different tumor cell lines after being transfected with a lentiviral vector encoding the Her2 TCR-6A5-mC TCR gene. Figure 3 The killing activity of C-3G was obtained by counting the viable cells. Figure 3 The killing activity of H-3K was determined by the MTT method, and the reaction time was 24 hours. Figure 3 C and 3H show the results for the tumor cell line MCF-7. Figure 3 D shows the results for the tumor cell line HCT116. Figure 3 E shows the results for the tumor cell line U87MG. Figure 3 F shows the results for the tumor cell line NCI-H446. Figure 3 G shows the results for the tumor cell line SKOV3. Figure 3 I shows the results for the tumor cell line PANC-1, Figure 3 J shows the results for tumor cell line HEPG2, Figure 3 K shows the results for the tumor cell line HT-29. Each test group and control group consisted of three wells, and the results are shown as mean ± SME. The horizontal axis shows different effector-target ratios E:T. The vertical axis shows the percentage of T cell killing of target cells. The dot graph shows that the effector cells are control peripheral blood mononuclear cells that are not transfected with the Her2 TCR-6A5-mC TCR gene, and the upper triangle graph shows that the effector cells are peripheral blood mononuclear cells that are transfected with the Her2 TCR-6A5-mC TCR gene. In the MTT killing experiment, another group was added with 10 μM paclitaxel as a positive control ( Figure 3 H-3K shows a single lower triangle point).
[0087] Figure 4 It was shown that target cells transfected with a vector carrying the HLA-A2 gene and the Her2-E75 minigene can express HLA-A2, and the expressed Her2-E75 polypeptide can form an antigen complex with HLA-A2 that is recognized by the Her2 TCR-6A5-mC TCR. Figure 4 A shows that HLA-A2 negative Her2 / neu negative 293T cells can activate PBMCs transfected with Her2 TCR-6A5-mC TCR after being transfected with a lentiviral plasmid vector that can express the HLA-A2 gene and the Her2-E75 minigene (without KDEL at the C-terminus). Each test group and control group are duplicate wells, and the results are shown as mean ± SME. The abscissa shows that 293T cells as target cells are transfected with different gene vectors. The ordinate represents the concentration of IFN-γ secreted by T cells. The effector-target ratio E:T is 10:1. Figure 4The upper figure of B shows the main functional fragments of the constructed lentiviral vector carrying HLA-A2 and Her2-E75 minigenes (without KDEL at the C-terminus) (i.e., "pCDH-EF1p-A2-PKGp-E75 vector"). The fragments shown express the HLA-A2 gene driven by the EF-1α promoter and the Her2-E75 minigene driven by the PKG promoter (without KDEL at the C-terminus). Figure 4 The lower figure of B shows the structure of the Her2-E75 minigene (without KDEL at the C-terminus), which consists of the INSL5 signal peptide, 8 Her2-E75 antigen epitope peptide coding sequences and the furin enzyme cleavage fragments therebetween. Figure 4 D shows the main functional fragments of the constructed recombinant adenovirus vector (i.e., "Adeasy-A2E75 vector") carrying HLA-A2 and Her2-E75 minigenes (with KDEL at the C-terminus). The adenovirus is a type 5 adenovirus genome with defects in the E1 gene and the E3 gene. An expression element consisting of the HLA-A2 and Her2-E75 minigenes driven by the CMV promoter and the Furin-F2A connecting fragment between them is inserted into the E1 region. The Her2-E75 minigene consists of the INSL5 signal peptide, 8 Her2-E75 antigen epitope peptide coding sequences and the furin enzyme fragment between them, and the endoplasmic reticulum retention signal peptide KDEL at the carboxyl terminus. Figure 4 C shows SKOV3 infection of HLA-A2 negative cells Figure 4 The vector carrying HLA-A2 and Her2-E75 minigenes (with KDEL at the C-terminus) shown in D can express HLA-A2. The horizontal axis shows SKOV3 cells infected with different recombinant adenoviruses. "Adeasy-A2E75" is an adenovirus expressing HLA-A2 and Her2-E75 polypeptides; "Ad control" is a control adenovirus that does not carry HLA-A2 and Her2-E75 minigenes. The vertical axis "HLA-A2 + "MFI" means the mean fluorescence intensity of cells after staining with anti-HLA-A2 fluorescent antibody. "MOI" means the multiplicity of virus infection.
[0088] Figure 5 It was shown that infection of tumor cells with a replication-deficient adenovirus carrying the HLA-A2 gene and the Her2 E75 minigene could increase the recognition sensitivity of the Her2 TCR-6A5-mC TCR to different target cells. Figure 5A shows that T cells expressing Her2 TCR-6A5-mC TCR can be activated by different tumor cell lines infected with adenovirus carrying the HLA-A2 gene and the Her2 E75 minigene, and secrete IFN-γ. The effector cells are peripheral blood mononuclear cells infected with a replication-deficient lentivirus carrying the Her2TCR-6A5-mC TCR gene. The target cells are HLA-A2-negative Her2 / neu-positive ovarian cancer cells SKOV3, HLA-A2-positive Her2 / neu-positive breast cancer cells MCF-7, and HLA-A2-negative Her2 / neu-negative small cell lung cancer cells NCI-H446. The horizontal axis shows that different tumor cell lines as target cells have been treated differently. "Adeasy-A2E75" refers to target cells infected with replication-defective adenovirus carrying HLA-A2 gene and Her2 E75 minigene alone; "PBMC control" refers to target cells co-cultured with control peripheral blood mononuclear cells that were not transfected with Her2 TCR-6A5-mC TCR gene; "PBMC control + Adeasy-A2E75" refers to target cells infected with replication-defective adenovirus carrying HLA-A2 gene and Her2 E75 minigene and co-cultured with control peripheral blood mononuclear cells that were not transfected with Her2 TCR-6A5-mC TCR gene 24 hours later; "PBMC with Her2 TCR-6A5" refers to target cells co-cultured with peripheral blood mononuclear cells transfected with Her2 TCR-6A5-mC TCR gene; "PBMC with Her2 TCR-6A5+Adeasy-A2E75" refers to target cells infected with replication-defective adenovirus carrying HLA-A2 gene and Her2 After 24 hours, the replication-deficient adenovirus expressing the E75 minigene was mixed with peripheral blood mononuclear cells transfected with the Her2 TCR-6A5-mC TCR gene. The vertical axis shows the concentration of IFN-γ secreted by T cells. The effector-target ratio E:T was 5:1, and the adenovirus infection multiplicity was MOI=10. "****" indicates that compared with the replication-deficient adenovirus group expressing HLA-A2 and Her2 E75 polypeptides alone, or compared with the peripheral blood mononuclear cell group expressing Her2 TCR-6A5-mC TCR alone, the combination group showed that the replication-deficient adenovirus expressing HLA-A2 and Her2 E75 polypeptides can significantly increase the recognition activity of peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR to different target cells (p<=0.0001), regardless of whether the target cells themselves express HLA-A2 and Her2 / neu antigens. Each experimental group and control group were three wells, and the results are shown as mean ± SME. Figure 5B shows that T cells expressing Her2 TCR-6A5-mC TCR can specifically kill tumor cell lines infected with adenovirus carrying HLA-A2 gene and Her2 E75 minigene. The horizontal axis shows different tumor cell lines treated differently as target cells, and Figure 5 The groups shown in the horizontal axis of A are the same. The effector-target ratio E:T is 8:1, and the adenovirus infection multiplicity is MOI=10. The vertical axis shows the killing rate of T cells against target cells, killing rate (Cytotoxicity) %=((the number of viable cells of the initial target cells-the number of viable cells of the target cells at the end of the culture) / the number of viable cells of the initial target cells)×100. "***" and "**" show that compared with the group using replication-deficient adenovirus expressing HLA-A2 and Her2 E75 polypeptides alone, or compared with the group using peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone, the combination group shows that peripheral blood mononuclear cells expressing Her2TCR-6A5-mC TCR have significant specific killing of target cells infected with adenovirus expressing HLA-A2 and Her2 E75 polypeptides. "***" indicates p<=0.001, and "**" indicates p<=0.01. Each experimental group and control group were tested in triplicate, and the results were shown as mean ± SME.
[0089] Figure 6 It was shown that the oncolytic adenovirus carrying the Her2-E75 minigene could increase the recognition sensitivity of Her2TCR-6A5-mC TCR to target cells expressing HLA-A2 after infecting tumor cells. Figure 6A shows that T cells expressing Her2 TCR-6A5-mCTCR can be activated by tumor cell lines infected with oncolytic adenovirus carrying the Her2-E75 minigene and expressing HLA-A2, and secrete IFN-γ. Effector cells are peripheral blood mononuclear cells infected with lentivirus carrying the Her2 TCR-6A5-mC TCR gene. Target cells are HLA-A2-negative Her2 / neu-positive ovarian cancer cells SKOV3, HLA-A2-positive Her2 / neu-positive breast cancer cells MCF-7, and HLA-A2-negative Her2 / neu-negative small cell lung cancer cells NCI-H446. The horizontal axis shows that different tumor cell lines as target cells have been treated differently. “Ad-E75” refers to target cells infected with oncolytic adenovirus carrying the Her2-E75 minigene alone; “PBMC control” refers to target cells co-cultured with control peripheral blood mononuclear cells that were not transfected with the Her2 TCR-6A5-mC TCR gene; “PBMC control+Ad-E75” refers to target cells infected with oncolytic adenovirus carrying the Her2-E75 minigene for 24 hours and co-cultured with control peripheral blood mononuclear cells that were not transfected with the Her2 TCR-6A5-mC TCR gene; “PBMC with Her2 TCR-6A5” refers to target cells co-cultured with peripheral blood mononuclear cells transfected with the Her2 TCR-6A5-mC TCR gene; “PBMC with Her2 TCR-6A5+Ad-E75” refers to target cells infected with oncolytic adenovirus carrying the Her2-E75 minigene for 24 hours and co-cultured with control peripheral blood mononuclear cells that were not transfected with the Her2 TCR-6A5-mC TCR gene. Peripheral blood mononuclear cells transfected with TCR genes were mixed and cultured. The ordinate shows the concentration of IFN-γ secreted by T cells. The effect-target ratio E:T is 5:1, and the adenovirus infection multiplicity is MOI=10. "**" shows that compared with the oncolytic adenovirus group expressing Her2-E75 polypeptide alone, or compared with the peripheral blood mononuclear cell group expressing Her2TCR-6A5-mC TCR alone, the combination group shows that the oncolytic adenovirus expressing Her2-E75 polypeptide can significantly increase the recognition activity of peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR to HLA-A2 target cells (p<=0.01), in which the target cells themselves mainly express HLA-A2 antigens. Each experimental group and control group had three wells, and the results were shown as mean ± SME. Figure 6 B shows that T cells expressing Her2TCR-6A5-mC TCR can specifically kill tumor cell lines infected with oncolytic adenovirus carrying Her2-E75 minigene. The horizontal axis shows different tumor cell lines treated differently as target cells, and Figure 6The groups shown in the horizontal axis of A are the same. The ordinate shows the killing rate of T cells against target cells, killing rate (Cytotoxicity) % = ((the number of viable cells of the initial target cells-the number of viable cells of the target cells at the end of the culture) / the number of viable cells of the initial target cells) × 100. The effect-target ratio E: T is 5: 1, and the adenovirus infection multiplicity is MOI = 10. "**" and "***" show that compared with the oncolytic adenovirus group expressing the Her2-E75 polypeptide alone, or compared with the peripheral blood mononuclear cell group expressing the Her2 TCR-6A5-mC TCR alone, the combination group shows that the peripheral blood mononuclear cells expressing the Her2 TCR-6A5-mC TCR have significant specific killing to the target cells infected with the oncolytic adenovirus expressing the Her2-E75 polypeptide. "**" means p <= 0.01, and "***" means p <= 0.001. Each experimental group and control group are three wells, and the results are shown as mean ± SME.
[0090] Figure 7 It was shown that replication-deficient adenovirus carrying HLA-A2 and Her2-E75 minigenes could increase the recognition sensitivity of Her2 TCR-6A5-mC TCR to different target cells after infecting tumor cells. Figure 7 A and Figure 7 B is the same experimental reaction, Figure 7 A is the factor level detection of the supernatant, Figure 7 B is the cell-related killing count detection. Figure 7A shows that T cells expressing Her2TCR-6A5-mC TCR can be activated by tumor cell lines infected with replication-defective adenovirus carrying HLA-A2 and Her2-E75 minigenes and expressing HLA-A2, and secrete IFN-γ. Effector cells are peripheral blood mononuclear cells infected with lentivirus carrying the Her2 TCR-6A5-mC TCR gene. Target cells are HLA-A2-negative Her2 / neu-positive large cell lung cancer NCI-H460, HLA-A2-negative Her2 / neu-positive colon cancer cells HT-29, and HLA-A2-positive Her2 / neu-negative glioma cells U87MG. The horizontal axis shows that different tumor cell lines used as target cells have been treated differently. "Adeasy-A2E75" refers to target cells infected with oncolytic adenovirus carrying HLA-A2 and Her2-E75 minigenes alone; "PBMC control" refers to target cells co-cultured with control peripheral blood mononuclear cells that were not transfected with the Her2TCR-6A5-mC TCR gene; "PBMC control + Adeasy-A2E75" refers to target cells infected with adenovirus carrying HLA-A2 and Her2-E75 minigenes and co-cultured with control peripheral blood mononuclear cells that were not transfected with the Her2 TCR-6A5-mC TCR gene 24 hours later; "PBMC with Her2TCR-6A5" refers to target cells co-cultured with peripheral blood mononuclear cells transfected with the Her2 TCR-6A5-mC TCR gene; "PBMC with Her2TCR-6A5" refers to target cells co-cultured with peripheral blood mononuclear cells transfected with the Her2 TCR-6A5-mC TCR gene; "PBMC+Adeasy-A2E75 of TCR-6A5" is a target cell infected with a replication-deficient adenovirus carrying HLA-A2 and Her2-E75 minigenes and then mixed with peripheral blood mononuclear cells transfected with the Her2 TCR-6A5-mC TCR gene for 24 hours. The ordinate shows the concentration of IFN-γ secreted by T cells. The effector-target ratio E:T is 10:1, and the adenovirus infection multiplicity is MOI=10. "**" indicates that compared with the replication-deficient adenovirus group expressing HLA-A2 and Her2-E75 polypeptides alone, or compared with the peripheral blood mononuclear cell group expressing Her2 TCR-6A5-mC TCR alone, the combination group shows that the replication-deficient adenovirus expressing HLA-A2 and Her2-E75 polypeptides can significantly increase the recognition activity of peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR to different target cells (p<=0.01), regardless of whether the target cells themselves express HLA-A2 and Her2 / Neu antigens. Each experimental group and control group are three wells, and the results are shown as mean ± SME. Figure 7B shows that T cells expressing Her2TCR-6A5-mC TCR can specifically kill tumor cell lines infected with replication-deficient adenovirus carrying HLA-A2 and Her2-E75 minigenes. The horizontal axis shows different tumor cell lines treated differently as target cells. The vertical axis shows the killing rate of T cells against target cells, killing rate (Cytotoxicity) % = ((the number of viable cells of the initial target cells-the number of viable cells of the target cells at the end of the culture) / the number of viable cells of the initial target cells) × 100. The effector-target ratio E:T is 10:1, and the adenovirus infection multiplicity is MOI = 10. "***", "**" and "*" show that compared with the group using replication-defective adenovirus expressing HLA-A2 and Her2-E75 polypeptides alone, or compared with the group using peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone, the combination group shows that peripheral blood mononuclear cells expressing Her2 TCR have significant specific killing of target cells infected with replication-defective adenovirus expressing HLA-A2 and Her2-E75 polypeptides. "***" indicates p<=0.001, "**" indicates p<=0.01, and "*" indicates p<=0.05. Each experimental group and control group are three wells, and the results are shown as mean ± SME. Figure 7 C shows the flow cytometry results of cells. The horizontal axis shows the target cell group. The vertical axis "HLA-A2 + "(MFI)" indicates the mean fluorescence intensity of cells after staining with anti-HLA-A2 fluorescent antibody. Infection of tumor cell lines with oncolytic adenovirus Ad-E75A2 carrying the Her2-E75 minigene and HLA-A2 and replication-deficient adenovirus Adeasy-A2E75 carrying the HLA-A2 and Her2-E75 minigenes can increase their HLA-A2 expression and promote their sensitivity to TCR-T.
[0091] Figure 8 It was shown that oncolytic adenovirus carrying the Her2-E75 minigene and HLA-A2 could increase the recognition sensitivity of Her2 TCR-6A5-mC TCR to different target cells after infecting tumor cells. Figure 8 A and Figure 8 B is the same experimental reaction, Figure 8 A is the factor level detection of the supernatant, Figure 8 B is the cell-related killing count detection. Figure 8A shows that T cells expressing Her2TCR-6A5-mC TCR can be activated by different tumor cell lines infected with oncolytic adenovirus carrying Her2-E75 minigene and HLA-A2, and secrete IFN-γ. Effector cells are peripheral blood mononuclear cells infected with lentivirus carrying Her2 TCR-6A5-mC TCR gene. Target cells are HLA-A2 negative Her2 / neu positive large cell lung cancer NCI-H460, HLA-A2 negative Her2 / neu positive colon cancer cell HT-29, and HLA-A2 positive Her2 / neu negative glioma cell U87MG. The horizontal axis shows that different tumor cell lines as target cells have been treated differently. "Ad-E75A2" refers to target cells infected with oncolytic adenovirus carrying the Her2-E75 minigene and HLA-A2 alone; "PBMC control" refers to target cells co-cultured with control peripheral blood mononuclear cells that were not transfected with the Her2 TCR-6A5-mCTCR gene; "PBMC control + Ad-E75A2" refers to target cells infected with oncolytic adenovirus carrying the Her2-E75 minigene and HLA-A2 for 24 hours and then co-cultured with control peripheral blood mononuclear cells that were not transfected with the Her2TCR-6A5-mC TCR gene; "PBMC with Her2 TCR-6A5" refers to target cells co-cultured with peripheral blood mononuclear cells transfected with the Her2 TCR-6A5-mC TCR gene; "PBMC with Her2 "PBMC+Ad-E75A2 of TCR-6A5" means that the target cells were infected with oncolytic adenovirus carrying Her2-E75 minigene and HLA-A2 for 24 hours and then mixed with peripheral blood mononuclear cells transfected with Her2TCR-6A5-mC TCR gene. The ordinate shows the concentration of IFN-γ secreted by T cells. The effector-target ratio E:T was 10:1, and the adenovirus infection multiplicity was MOI=10. "***" and "****" show that compared with the group using oncolytic adenovirus expressing Her2-E75 polypeptide and HLA-A2 alone, or compared with the group using peripheral blood mononuclear cells expressing Her2 TCR-6A5-mCTCR alone, the combination group shows that the oncolytic adenovirus expressing Her2-E75 polypeptide and HLA-A2 can significantly increase the recognition activity of peripheral blood mononuclear cells expressing Her2 TCR-6A5-mCTCR to different target cells, regardless of whether the target cells themselves express HLA-A2 and Her2 / Neu antigens. "***" indicates p <= 0.001, and "****" indicates p <= 0.0001. Each experimental group and control group had three wells, and the results were shown as mean ± SME. Figure 8B shows that T cells expressing Her2 TCR-6A5-mC TCR can specifically kill tumor cell lines infected with oncolytic adenovirus carrying Her2-E75 minigene and HLA-A2. The horizontal axis shows that different tumor cell lines are treated differently as target cells. The vertical axis shows the killing rate of T cells on target cells, killing rate (Cytotoxicity) % = ((the number of viable cells of the initial target cells-the number of viable cells of the target cells at the end of the culture) / the number of viable cells of the initial target cells) × 100. The effect-target ratio E: T is 10: 1, and the adenovirus infection multiplicity is MOI = 10. "**" and "*" show that compared with the group using oncolytic adenovirus expressing Her2-E75 polypeptide and HLA-A2 alone, or compared with the group using peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone, the combination group shows that peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR have significant specific killing of target cells infected with oncolytic adenovirus expressing Her2-E75 polypeptide and HLA-A2. "**" indicates p<=0.01, and "*" indicates p<=0.05. Each experimental group and control group had three wells, and the results are shown as mean ± SME.
[0092] Fig. 9 A schematic diagram showing the main structure of the type 5 oncolytic adenovirus backbone vector pShuttle-MCS-CMV-E1A-SV40pA constructed according to one embodiment of the present invention.
[0093] Fig.10 Schematic diagram showing the main structure of type 5 oncolytic adenovirus genomic DNA expressing a marker polypeptide alone (i.e., "OAd-E75", upper figure) and type 5 oncolytic adenovirus genomic DNA co-expressing a marker polypeptide and HLA-A2 (i.e., "OAd-E75-A2", lower figure) constructed according to one embodiment of the present invention. DETAILED DESCRIPTION
[0094] The present invention will be further illustrated below through the description of specific implementation methods and with reference to the accompanying drawings, but this is not a limitation of the present invention. Those skilled in the art can make various modifications or improvements based on the basic idea of the present invention, but as long as they do not deviate from the basic idea of the present invention, they are all within the scope of the present invention.
[0095] The inventors of the present invention have proposed the concept of significantly enhancing the presentation of exogenous antigen epitope peptides on the surface of tumor cells and using TCR-modified immune cells specific for the antigen epitope peptides for combined treatment through theoretical research and experimental verification in view of the problems and difficulties faced by adoptive immune cell therapy and oncolytic virus therapy for tumors. Through this inventive concept, the present invention effectively solves the problem of low antigen expression and / or low or missing HLA expression caused by defects in the antigen presentation pathway brought about by the tumor immune escape mechanism, and improves the recognition sensitivity of tumor cells to T cell receptor-modified immune cells, thereby further improving the homing and killing ability of T cell receptor-modified immune cells. In addition, the present invention also expands the scope of application of adoptive immune cell therapy for tumors based on TCR gene modification, avoiding the limitations of a smaller scope of use brought about by HLA restriction.
[0096] Specifically, the present invention provides a therapeutic agent for treating tumors and / or cancers, comprising:
[0097] (a) a first composition, wherein the first composition comprises a first active ingredient in a first pharmaceutically acceptable carrier, the first active ingredient comprising or containing a nucleic acid having a marker polypeptide coding sequence for introduction into tumor cells and / or cancer cells; the marker polypeptide having an amino acid sequence of one or more antigen epitope polypeptides, the antigen epitope polypeptides being capable of being presented on the surface of the tumor cells and / or cancer cells by MHC class I molecules; and
[0098] (b) a second composition, wherein the second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier, wherein the second active ingredient comprises a T cell receptor-modified immune cell; the T cell receptor-modified immune cell can specifically recognize and bind to the antigen epitope polypeptide presented by the MHC class I molecule.
[0099] Usually, antigenic proteins expressed in the cytoplasm can enter the MHC class I antigen presentation pathway. After being hydrolyzed by a series of proteases, the short peptides (containing antigen epitope polypeptides) are transduced into the endoplasmic reticulum through the TAP molecules on the endoplasmic reticulum membrane, and then form trimers with the HLA protein and β2-microglobulin therein, and are presented on the cell surface (where the HLA protein and β2-microglobulin pair to form MHC class I molecules), thereby being recognized by immune cells. Due to the frequent functional loss of the MHC class I antigen presentation pathway in tumor cells, tumor antigens expressed in the cytoplasm cannot effectively form epitope polypeptides or enter the endoplasmic reticulum and bind to HLA and β2-microglobulin to form complexes.
[0100] In the present invention, by introducing the nucleic acid having the marker polypeptide coding sequence into tumor cells and / or cancer cells, the exogenous marker polypeptide expressed in the tumor cells and / or cancer cells can enter the MHC class I antigen presentation pathway, thereby increasing the expression level of the HLA / antigen epitope polypeptide complex on the surface of the tumor cells, thereby enhancing the recognition sensitivity of the T cell receptor-modified immune cells to tumor cells and / or cancer cells.
[0101] The amino acid sequence of the antigenic epitope polypeptide may be derived from the amino acid sequence of a protein existing in nature, or may be an artificially synthesized amino acid sequence that does not exist in nature. Preferably, the protein existing in nature includes human proteins and proteins of species other than humans. More preferably, the amino acid sequence of the antigenic epitope polypeptide is derived from the amino acid sequence of a tumor-associated antigen or a tumor-specific antigen.
[0102] "Tumor-associated antigens" usually refer to normal proteins derived from the body itself, but are overexpressed or abnormally expressed in tumor cells, including carcinoembryonic antigen, tumor-testis antigen (CT antigen), etc.
[0103] "Tumor-specific antigens" usually refer to mutant proteins derived from one's own body or allogeneic viral proteins that are associated with the occurrence and development of tumors.
[0104] In the present invention, "tumor-associated antigens" and "tumor-specific antigens" are sometimes collectively referred to as "tumor antigens".
[0105] The tumor antigen may be a tumor antigen as described in the Cancer Antigenic Peptide Database (https: / / caped.icp.ucl.ac.be). Preferably, the tumor antigen may be a tumor antigen as described in Table 1 below. Also preferably, the tumor antigen may be human Her2 / neu, NY-ESO-1, N-ras, K-ras, H3.3K27M, SSX-2, MAGE-C2, MAGE-A1, KK-LC-1, p53. The amino acid sequence of Her2 / neu is shown in SEQ ID NO:21.
[0106] The antigenic epitope polypeptide can be a peptide segment with 8-11 amino acids that can be presented by MHC class I molecules. The antigenic epitope polypeptide can be an antigenic epitope polypeptide as described in the Cancer Antigenic Peptide Database (website https: / / caped.icp.ucl.ac.be). Preferably, the antigenic epitope polypeptide can be an antigenic epitope polypeptide as described in Table 1 below. In other embodiments, the antigenic epitope polypeptide is an antigenic epitope polypeptide having 4-9 consecutive identical amino acids (e.g., 4, 5, 6, 7, 8 or 9 consecutive identical amino acids) with the antigenic epitope polypeptide as described in Table 1 below, and the length of these polypeptides is 8-11 amino acids. Also preferably, the antigenic epitope polypeptide includes but is not limited to Her2 / neu 369-377 as shown in SEQ ID NO:3, Her2 / neu 373-382 as shown in SEQ ID NO:22, NY-ESO-1 157-165, NY-ESO-1 1-11, NY-ESO-1 53-62, NY-ESO-1 18-27, N-ras 55-64, K-ras 224-232, K-ras 10-18, K-ras 10-19, H3.3K27M 26-35, SSX-2 41-49, MAGE-C2336-344, MAGE-C2 191-200, MAGE-C2 307-315, MAGE-C2 42-50, MAGE-A1 120-129, MAGE-A1 230-238, MAGE-A1 161-169, KK-LC-176-84, p53 99-107, HPV16-E6 29-38, HPV16-E7 11-19, HPV16-E7 11-19, EBV-LMP1 51-59, EBV-LMP1 125-133.
[0107] Table 1 Preferred tumor antigens and antigen epitope polypeptides
[0108]
[0109]
[0110]
[0111]
[0112] In certain embodiments, each of the antigenic epitope polypeptides has flexible connecting segments at both ends, which serve as cleavage sites for proteolytic enzymes in the cytoplasm to release the antigenic epitope polypeptide. The flexible connecting segments include GSGSR, AGSGSR and AGSGS.
[0113] In certain embodiments, the marker polypeptide has a signal peptide at the amino terminus of the one or more antigen epitope polypeptide amino acid sequences that can introduce the marker polypeptide into the endoplasmic reticulum. The core of the signal peptide contains a long segment of hydrophobic amino acids to form a single α-helix. The amino terminus of the signal peptide often starts with a short positively charged amino acid sequence, and there is usually an amino acid cleavage site at the end of the signal peptide that is recognized and cut by a signal peptidase. After the connected exogenous polypeptide enters the endoplasmic reticulum, the signal peptide is recognized and cut by a signal peptidase, and the exogenous polypeptide is released in the endoplasmic reticulum. Therefore, the marker polypeptide carrying the signal peptide can directly enter the endoplasmic reticulum without protease hydrolysis in the MHC class I antigen presentation pathway and transport by TAP molecules. The signal peptide can be a signal peptide composed of the 1st to 22nd amino acids of the amino terminus of insulin-like protein (INSL5) (SEQID NO: 28).
[0114] In the case where the marker polypeptide has a plurality of the antigenic epitope polypeptides, every two of the antigenic epitope polypeptides may be connected by a cleavable linking polypeptide. The cleavable linking polypeptide includes a furin enzyme cleavage recognition polypeptide, which has a standard four-amino acid motif that can be cleaved by the furin enzyme, namely, the RX-[KR]-R amino acid sequence (see the document "Molecular Therapy 2007; vol.15no.6, 1153-1159"). Preferably, the amino acid sequence of the cleavable linking polypeptide is RRKR. After the marker polypeptide is introduced into the endoplasmic reticulum by the above-mentioned signal peptide, the antigenic epitope polypeptide connected by the RX-[KR]-R amino acid sequence is cleaved and hydrolyzed by the furin enzyme in the endoplasmic reticulum, releasing the antigenic epitope polypeptide, and forming an antigen complex with HLA and β2-microglobulin in the endoplasmic reticulum. Aminopeptidases and carboxypeptidases in the endoplasmic reticulum may also participate in the enzymatic degradation and release of antigen epitope polypeptides (see the document “J Immunol. 2009 November 1; 183(9): 5526-5536”). Therefore, the cleavable linker polypeptide may also include aminopeptidase and carboxypeptidase cleavage recognition polypeptides.
[0115] In order to allow the marker polypeptide introduced into the endoplasmic reticulum by the signal peptide to be retained in the endoplasmic reticulum cavity, so as to facilitate the release of the antigen epitope polypeptide and to combine with HLA and β2 microglobulin to form an antigen complex, in certain embodiments, the marker polypeptide has an endoplasmic reticulum retention signal peptide at the carboxyl end of the one or more antigen epitope polypeptide amino acid sequences. The amino acid sequence of the endoplasmic reticulum retention signal (ER retention signal) of a soluble polypeptide (i.e., a non-transmembrane protein) is KDEL, and the endoplasmic reticulum retention signal of an ER membrane protein is KKXX (see the document "Molecular Biology of the Cell. 2003; 14 (3): 889-902"). In the present invention, the marker polypeptide is a soluble polypeptide. Therefore, it is preferred that the endoplasmic reticulum retention signal peptide is a KDEL fragment composed of lysine-aspartic acid-glutamic acid-leucine residues.
[0116] In a specific embodiment, the marker polypeptide includes the following amino acid sequences that are operably connected and sequentially connected in series: an amino acid sequence of an N-terminal signal peptide, an amino acid sequence of one or more of the antigenic epitope polypeptides, and an optional amino acid sequence of an endoplasmic reticulum retention signal at the C-terminus, wherein when the marker polypeptide includes amino acid sequences of multiple antigenic epitope polypeptides, each two adjacent amino acid sequences of the antigenic epitope polypeptides are connected by an amino acid sequence of a cleavable linking polypeptide; the amino acid sequence of the antigenic epitope polypeptide and the optional amino acid sequence of the endoplasmic reticulum retention signal at the C-terminus can be connected by an amino acid sequence of a cleavable linking polypeptide. Preferably, the marker polypeptide includes the amino acid sequence of the endoplasmic reticulum retention signal at the C-terminus.
[0117] Preferably, the marker polypeptide comprises n antigen epitope polypeptides (preferably Her2 / neu 369-377 epitope polypeptides) connected by a cleavable linker polypeptide RRKR, wherein n is an integer greater than or equal to 1, for example, n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12... Preferably, n is an integer between 1-20 (for example, an integer between 2-20); further preferably, n is an integer between 1-10 (for example, an integer between 2-10); further preferably, n=8.
[0118] Considering that HLA proteins in tumor cells and / or cancer cells often have expression defects, including complete deletion, haplotype deletion or allele deletion, and the deletion range of different tumor types varies from 65% to 90% (see the document "Immunol Today. 1997; 18: 89-95"), therefore, in one embodiment, the nucleic acid also has an HLA protein coding sequence, wherein the HLA protein coding sequence and the marker polypeptide coding sequence are respectively under the control of their respective promoters, or the HLA protein coding sequence and the marker polypeptide coding sequence are under the control of the same promoter and the HLA protein coding sequence is operably linked to the marker polypeptide coding sequence via a cleavable linker polypeptide coding sequence. Preferably, the phenotype of the HLA protein is consistent with the phenotype of the HLA protein to which the marker polypeptide can bind. The promoter can be a eukaryotic promoter, including a constitutively expressing promoter and an inducible expressing promoter, including (for example): PGK1 promoter, EF-1α promoter, CMV promoter, SV40 promoter, Ubc promoter, CAG promoter, TRE promoter, CaMKIIa promoter, human beta actin promoter.
[0119] In this way, the present invention further increases the expression level of the MHC / antigen epitope polypeptide complex on the surface of tumor cells, thereby enhancing the recognition sensitivity of the T cell receptor-modified immune cells to tumor cells.
[0120] More specifically, the MHC protein is an HLA class I protein. More specifically, the HLA includes HLA-A, B, and C. Preferably, the HLA protein is an HLA-A2 protein, and the amino acid sequence of HLA-A2 is shown in SEQ ID NO:29.
[0121] Examples of the cleavable linking polypeptide connecting the HLA protein and the marker polypeptide are known in the art, such as 2A polypeptides, including but not limited to F2A polypeptides from picornaviruses, and similar 2A polypeptides from other viruses; it can also be a Furin-F2A linker fragment.
[0122] Preferably, in the therapeutic agent of the present invention, the first composition and the second composition are each independently present in the therapeutic agent without being mixed with each other.
[0123] Preferably, in the therapeutic agent of the present invention, the nucleic acid includes DNA or RNA; and the RNA includes mRNA transcribed from the DNA.
[0124] In one embodiment, the first active ingredient is a recombinant virus, the genome of which has a marker polypeptide coding sequence and an optional HLA protein coding sequence; wherein the recombinant virus includes a selectively replicable recombinant oncolytic virus or a replication-deficient recombinant virus.
[0125] The replication-deficient recombinant virus is a viral vector lacking one or more essential functional genes related to viral replication, proliferation and viral particle assembly, and the viral vector cannot replicate in normal cells to form progeny viruses, but can express the virus's own or exogenous gene products. The replication-deficient recombinant virus is preferably derived from adenovirus, adenovirus-associated virus (AAV), herpes simplex virus, poxvirus, influenza virus, alphavirus, and Sendai virus.
[0126] Preferably, the replication-deficient recombinant virus is a recombinant adenovirus obtained by genetically modifying type 5 adenovirus, the genome of which lacks the E1 gene, and the coding sequence of the marker polypeptide and an optional HLA protein coding sequence are inserted in the position of the deleted E1 gene.
[0127] The recombinant oncolytic virus can be derived from a genetically mutated virus with oncolytic effect and a wild-type virus with oncolytic effect. Preferably, the recombinant oncolytic virus is derived from an adenovirus, poxvirus, herpes simplex virus, measles virus, Semliki Forest virus, vesicular stomatitis virus, poliovirus, retrovirus, reovirus, Seneca Valley virus, echovirus, coxsackievirus, Newcastle disease virus and Maraba virus with oncolytic effect.
[0128] After oncolytic viruses infect tumor cells, they selectively replicate in tumor cells, and the tumor cells are lysed by a large number of daughter viruses to achieve the effect of specific killing of tumor cells. The released daughter viruses can selectively infect and lyse other tumor cells to remove tumor tissue to the greatest extent (see document "Nat Biotechnol. 2012 Jul 10; 30 (7): 658-70"). Abnormal RAS, TP53, RB1, PTEN, WNT and other signal transduction pathways in tumor cells affect the antiviral mechanism of the cell itself, making the virus easier to replicate in tumor cells, which is the main reason for the formation of tumor selectivity. Due to the complete molecular mechanism of inhibiting viral replication in normal cells, oncolytic viruses cannot effectively replicate and spread after infecting normal cells, thus greatly limiting the damage to normal tissue cells (see document "Nat Rev Cancer. 2017 11; 17 (11): 633"). The tumor selectivity of oncolytic viruses is further enhanced by genetic engineering of the viral genome, and functional exogenous genes can be carried to enhance the anti-tumor activity of oncolytic viruses. In addition to its own oncolytic effect, oncolytic viruses can also change the microenvironment of tumor tissues, mainly by inducing the secretion of cytokines, attracting natural immune cells, releasing tumor antigens, providing immune danger signals, etc., thereby enhancing the local anti-tumor immune response of the tumor (see the document "J.Clin.Invest.2018;128,1258-1260"). Adenovirus as a vector is an early oncolytic virus developed. Ad5 adenovirus H101 based on E1B-55K and E3 gene defects is the first oncolytic virus product approved for marketing (see the document "Hum Gene Ther.2018Feb;29(2):151-159"). The molecular structure and biological characteristics of adenoviruses have been studied in depth, making it easier for adenoviruses to be genetically engineered into oncolytic viruses. Some characteristics of adenovirus, including that its genome modification allows insertion of larger fragments of foreign genes; adenovirus genomic DNA will not integrate into the host genome; it will not cause malignant transformation of human cells; it can infect most human tumor cells; and the preparation of stable high-titer virus particles, make adenovirus more suitable as an oncolytic virus vector (see the document "Curr Opin Virol. 2016 12; 21: 9-15"). The different designs of oncolytic adenoviruses are related to their different mechanisms of tumor selectivity. For example, after the E1B-55K gene-deficient Ad5 adenovirus infects normal cells with p53 function, it will induce cell apoptosis before completing the viral replication cycle, while in about 50% of tumor cells that have lost p53 function due to gene mutation, it will complete replication and lyse the cells (see the document "Nat Med 1998; 4 (9): 1098-72").Oncolytic adenoviruses with partial removal of the E1A gene will also limit their replication in normal cells. The defective protein (E1AΔ24) produced by removing 24 bases from the CR2 region of E1A will lose its function of releasing E2F1 from the E2F1 / pRB complex, and free E2F1 is essential for initiating downstream replication. The pRB pathway in tumor cells is often abnormal, so a large amount of free E2F1 is produced to ensure the selective replication of the virus in tumor cells (see the document "Cell 2000; 100(1): 57-70"). The tumor selectivity of oncolytic adenoviruses carrying VA-RNA gene defects depends on the activated RAS signaling pathway in tumor cells and the incompleteness of the interferon pathway (see the document "Cancer Res. 2003; 63(17): 5544-50"). Another tumor selectivity mechanism of oncolytic adenoviruses is to use tumor-specific gene promoters to drive genes necessary for adenovirus replication. For example, promoters mainly activated in specific tumor cells such as the alpha-fetoprotein promoter in liver cancer cells (see the document "Hum Gene Ther. 1999; 10(10): 1721-33"); the prostate-specific antigen (PSA) promoter in prostate cancer cells (see the document "Cancer Res. 1997; 57(13): 2559-63"), or the osteocalcin (hOC) promoter (see the document "Cancer Res. 2002; 62(11): 3084-92"); or the DF3 / MUC1 promoter in MUC-1-positive breast cancer (see the document "J Clin Invest. 2000; 106(6): 763-71") are used to drive the gene expression of E1A-deficient adenovirus E1A, so as to achieve the purpose of selective replication in these tumor cells. If a promoter whose activity depends on the free E2F1 transcription factor is used, for example, an E2F1 promoter with a palindromic sequence that can bind to E2F1 is inserted to drive the expression of genes essential for viral replication, then only in tumor cells rich in free E2F1 can the downstream molecules of viral replication be effectively expressed, thereby achieving selective lysis of tumor cells (see references "Mol Ther. 2007; 15(9): 1607-15"; "Cancer Cell. 2002; 1(4): 325-37").
[0129] Although the genetically engineered oncolytic adenovirus enhances the selective killing of tumor cells, the oncolytic ability of the virus needs to be further enhanced to improve its clinical efficacy. Since the oncolytic virus needs to rely on the cellular components and unique molecular mechanisms of the host tumor cells to complete the replication cycle, and the diversity of tumors determines that after tumor cells of different growth states and properties are infected by oncolytic viruses, some tumor cells cannot complete the replication cycle and produce a sufficient number of daughter viruses to lyse the cells. In addition, after the oncolytic adenovirus lacks E1B-55K, it may cause the mRNA encoding the late viral protein to be exported from the cell nucleus to the cytoplasm for protein translation. Obstacles occur, thereby affecting the replication of the virus in tumor cells (see the document "Viruses. 2015Nov; 7 (11): 5767-5779"). These factors will limit the clinical efficacy of oncolytic viruses when used alone.
[0130] In one embodiment of the present invention, a nucleic acid containing the marker polypeptide coding sequence and an optional HLA protein coding sequence is introduced into tumor cells and / or cancer cells by an oncolytic virus. While the oncolytic virus plays the role of killing tumor cells and / or cancer cells, immune cells modified with T cell receptors can also effectively eliminate tumor cells that are infected by the oncolytic virus and cannot complete the replication cycle and produce a sufficient number of daughter viruses and undergo lysis, thereby achieving a synergistic effect.
[0131] Preferably, the selective replication-type recombinant oncolytic virus is a recombinant oncolytic adenovirus obtained by genetically modifying adenovirus type 5. In one embodiment, the genome of the recombinant oncolytic adenovirus is deleted from the E1B-55K gene and / or the E1B-19K gene (eg, the E1B-55K gene is deleted, or the E1B-55K gene and the E1B-19K gene are deleted), and the genome of the recombinant oncolytic adenovirus contains an E1A gene coding sequence; preferably, the E1A gene coding sequence is under the control of an exogenous promoter.
[0132] In one embodiment, the coding sequence of the marker polypeptide inserted into the oncolytic adenovirus genome can be expressed in tumor cells under the regulation of the E1B gene promoter, E1B TATA box sequence and E1B polyadenylation signal sequence of the adenovirus itself.
[0133] In another embodiment, the coding sequence of the marker polypeptide inserted into the oncolytic virus genome can be under the control of a eukaryotic cell promoter, including but not limited to CMV promoter, EF1a promoter, SV40 promoter, PGK1 promoter, Ubc promoter, human β-actin promoter.
[0134] The E1A gene of the recombinant oncolytic adenovirus can be changed so that the expressed E1A protein cannot bind to the pRb protein. In a specific embodiment, the nucleic acid sequence encoding the E1A protein CR2 region in the recombinant oncolytic adenovirus genomic DNA lacks 24 nucleotides at positions 923-946 of the type 5 adenovirus genomic DNA (oncolytic adenovirus E1A-δ24), and the amino acid sequence of the encoded E1A protein lacks LTCHEAGF. The deleted amino acid sequence is the binding region of the E1A protein and the Rb protein. The E1A protein lacking this amino acid sequence cannot bind to the Rb protein, causing the oncolytic adenovirus E1A-δ24 to selectively replicate and lyse tumor cells in tumor cells with defects in the Rb / E2F1 pathway.
[0135] Preferably, the E1A gene of the recombinant oncolytic adenovirus is under the control of a tissue-specific promoter or a tumor-specific promoter. The tissue-specific promoter or tumor-specific promoter includes an E2F-1 promoter, a telomerase hTERT promoter, a tyrosinase promoter, a prostate-specific antigen promoter, an alpha-fetoprotein promoter, and a COX-2 promoter. Preferably, the tumor-specific promoter is an E2F-1 promoter (whose nucleotide sequence is SEQ ID NO: 30). In normal cells, due to the binding of E2F-1 to pRb, the expression of E1A regulated by the E2F-1 promoter is inhibited. In tumor cells, due to the absence or hyperphosphorylation of pRb, the level of "free" E2F-1 increases, and the E2F-1 promoter is activated to drive the expression of E1A, and causes the adenovirus to selectively replicate in tumor cells and lyse cells.
[0136] Preferably, the E3 gene of the recombinant oncolytic adenovirus is completely or partially deleted. This can avoid the inhibitory effect of the E3-19K protein on the HLA class I antigen presentation pathway, so that the exogenously introduced antigen epitope polypeptides and endogenous tumor antigens can be more effectively presented on the surface of tumor cells.
[0137] In certain embodiments, at least one immunodominant antigenic epitope recognized by T cells is missing from the structural and functional proteins of the adenovirus. Structural and functional proteins include E1A, E1B, hexon, penton base, fiber protein, capsid protein IX, DNA polymerase, and single-stranded DNA binding protein. In one embodiment, the immunodominant antigenic epitope recognized by T cells on the viral protein is removed by gene point mutation (see patent document "WO2016178167A1").
[0138] In the therapeutic agent of the present invention, the immune cells modified by T cell receptors include primitive T cells or precursor cells thereof, NKT cells, or T cell strains.
[0139] The T cell receptor comprises at least one of an α chain and a β chain, wherein the α chain and the β chain both comprise a variable region and a constant region, and the T cell receptor can specifically recognize the antigen epitope polypeptide on the surface of tumor cells and / or cancer cells.
[0140] Preferably, the amino acid sequence of the variable region of the α chain has at least 98%, preferably at least 98.5%, more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NO: 1, and the amino acid sequence of the variable region of the β chain has at least 98%, preferably at least 98.5%, more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NO: 2, as long as the effect of the present invention is not significantly affected. It is also preferred that the amino acid sequence of the variable region of the α chain is as shown in SEQ ID NO: 1, and the amino acid sequence of the variable region of the β chain is as shown in SEQ ID NO: 2.
[0141] The variable regions of the TCR α chain and β chain are used to bind to antigenic peptides / major histocompatibility complex (MHC I), and each includes three hypervariable regions or complementarity determining regions (CDRs), namely, CDR1, CDR2, and CDR3. Among them, the CDR3 region is crucial for the specific recognition of antigenic peptides presented by MHC molecules. The TCR α chain is formed by the recombination of different V and J gene segments, while the β chain is formed by the recombination of different V, D, and J gene segments. The corresponding CDR3 region formed by the recombination of specific gene segments, as well as the palindromic and random nucleotide additions in the binding region, form the specificity of TCR for antigenic peptide recognition (see the literature "Immunobiology: The immune system in health and disease.5 th edition, Chapter 4, The generation of Lymphocyte antigen receptors”). The MHC class I molecule includes human HLA. The HLA includes: HLA-A, B, and C.
[0142] The exogenous TCR α chain and β chain expressed by T cells may mismatch with the α chain and β chain of the T cell's own TCR, which will not only dilute the expression level of the correctly paired exogenous TCR, but also make the antigen specificity of the mismatched TCR unclear, thus posing a potential risk of recognizing self-antigens. Therefore, it is preferred to modify the constant regions of the TCR α chain and β chain to reduce or avoid mismatching.
[0143] In one embodiment, the constant region of the α chain and / or the constant region of the β chain are derived from humans; preferably, the present invention finds that the constant region of the α chain can be replaced in whole or in part by homologous sequences derived from other species, and / or the constant region of the β chain can be replaced in whole or in part by homologous sequences derived from other species. More preferably, the other species is mouse.
[0144] The replacement can increase the expression level of TCR in cells and can further improve the specificity of cells modified by the TCR to Her2 / neu antigen.
[0145] The constant region of the α chain may be modified with one or more disulfide bonds, and / or the constant region of the β chain may be modified with one or more disulfide bonds, such as 1 or 2.
[0146] In a specific embodiment, two different modified TCRs were prepared, one of which was to add a disulfide bond to the TCR constant region by point mutation, the method described in the document "Cancer Res. 2007Apr 15; 67(8): 3898-903.", which is incorporated herein by reference in its entirety. Her2 TCR-1B5-mC is to replace the corresponding human TCR constant region sequence with the mouse TCR constant region sequence, the method described in the document "Eur. J. Immunol. 2006 36: 3052-3059", which is incorporated herein by reference in its entirety.
[0147] In a specific embodiment, the amino acid sequence of the α chain is shown in SEQ ID NOs: 4, 5 or 6, and the amino acid sequence of the β chain is shown in SEQ ID NOs: 7, 8 or 9.
[0148] Among them, for the α chain with an amino acid sequence as shown in SEQ ID NO:4, its sequence is the original human sequence; for the α chain with an amino acid sequence as shown in SEQ ID NO:5, it is modified with one disulfide bond in the constant region; for the α chain with an amino acid sequence as shown in SEQ ID NO:6, its constant region is replaced with a mouse constant region.
[0149] Among them, for the β chain with an amino acid sequence as shown in SEQ ID NO:7, its sequence is the original human sequence; for the β chain with an amino acid sequence as shown in SEQ ID NO:8, it is modified with one disulfide bond in the constant region; for the β chain with an amino acid sequence as shown in SEQ ID NO:9, its constant region is replaced with a mouse constant region.
[0150] In a specific embodiment, the amino acid sequence of the α chain of the TCR is shown in SEQ ID NO: 4, and the amino acid sequence of the β chain is shown in SEQ ID NO: 7. In another specific embodiment, the amino acid sequence of the α chain of the TCR is shown in SEQ ID NO: 5, and the amino acid sequence of the β chain is shown in SEQ ID NO: 8. In yet another specific embodiment, the amino acid sequence of the α chain of the TCR is shown in SEQ ID NO: 6, and the amino acid sequence of the β chain is shown in SEQ ID NO: 9.
[0151] In other specific embodiments of the present invention, the α chain of the TCR has an amino acid sequence obtained by replacing, deleting, and / or adding one or more amino acids in the amino acid sequence shown in SEQ ID NOs:4, 5 or 6; for example, the α chain has at least 90%, preferably at least 95%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NOs:4, 5 or 6.
[0152] In other specific embodiments of the present invention, the β chain of the TCR has an amino acid sequence obtained by replacing, deleting, and / or adding one or more amino acids in the amino acid sequence shown in SEQ ID NOs:7, 8 or 9; for example, the β chain has at least 90%, preferably at least 95%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NOs:7, 8 or 9.
[0153] The α chain and / or β chain of the TCR of the present invention can also bind to other functional sequences at the end (e.g., C-terminus), such as functional region sequences of co-stimulatory signals CD28, 4-1BB and / or CD3zeta.
[0154] The present invention also relates to an isolated nucleic acid encoding a T cell receptor, comprising a coding sequence for at least one of the α chain and the β chain of the T cell receptor, wherein the α chain coding sequence and the β chain coding sequence both comprise a variable region coding sequence and a constant region coding sequence, and the T cell receptor is capable of specifically recognizing the antigen epitope polypeptide on the surface of tumor cells and / or cancer cells.
[0155] The amino acid sequence encoded by the α chain variable region encoding sequence has at least 98%, preferably at least 98.5%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NO: 1, and the amino acid sequence encoded by the β chain variable region encoding sequence has at least 98%, preferably at least 98.5%, and more preferably at least 99% identity with the amino acid sequence shown in SEQ ID NO: 2, as long as it does not significantly affect the effect of the present invention. It is also preferred that the α chain variable region encoding sequence encodes the amino acid sequence shown in SEQ ID NO: 1, and the β chain variable region encoding sequence encodes the amino acid sequence shown in SEQ ID NO: 2.
[0156] The nucleic acid may be DNA or RNA.
[0157] Preferably, the α chain variable region encoding sequence is shown as SEQ ID NO:10, and the β chain variable region encoding sequence is shown as SEQ ID NO:11.
[0158] In one embodiment, the constant region of the α chain and / or the constant region of the β chain are derived from humans; preferably, the α chain constant region encoding sequence is replaced in whole or in part by a homologous sequence derived from another species, and / or the β chain constant region encoding sequence is replaced in whole or in part by a homologous sequence derived from another species. More preferably, the other species is a mouse. The replacement can increase the expression of TCR in cells, and can further improve the specificity of cells modified by the TCR to Her2 / neu antigen.
[0159] The α chain constant region encoding sequence may comprise one or more disulfide bond encoding sequences, and / or the β chain constant region encoding sequence may comprise one or more disulfide bond encoding sequences.
[0160] In a specific embodiment, the α chain encoding sequence is shown as SEQ ID NOs: 12, 13 or 14, and the β chain encoding sequence is shown as SEQ ID NOs: 15, 16 or 17.
[0161] Among them, for the α chain with a coding sequence as shown in SEQ ID NO:12, its sequence is the original human sequence; for the α chain with a coding sequence as shown in SEQ ID NO:13, its constant region is modified with one disulfide bond; for the α chain with a coding sequence as shown in SEQID NO:14, its constant region is replaced with a mouse constant region.
[0162] Among them, for the β chain with a coding sequence as shown in SEQ ID NO:15, its sequence is the original human sequence; for the β chain with a coding sequence as shown in SEQ ID NO:16, its constant region is modified with one disulfide bond; for the β chain with a coding sequence as shown in SEQID NO:17, its constant region is replaced with a mouse constant region.
[0163] In a specific embodiment, the coding sequence of the α chain of the TCR is shown in SEQ ID NO: 12, and the coding sequence of the β chain is shown in SEQ ID NO: 15. In another specific embodiment, the coding sequence of the α chain of the TCR is shown in SEQ ID NO: 13, and the coding sequence of the β chain is shown in SEQ ID NO: 16. In another specific embodiment, the coding sequence of the α chain of the TCR is shown in SEQ ID NO: 14, and the coding sequence of the β chain is shown in SEQ ID NO: 17.
[0164] In another embodiment, the α chain coding sequence and the β chain coding sequence are connected by a coding sequence of a cleavable linker polypeptide, which can increase the expression of TCR in cells.
[0165] The α chain and β chain constituting the single-chain chimeric TCR may also be replaced in whole or in part by homologous sequences from other species in the constant region (and their corresponding coding sequences) as described above, and / or modified with (encoding) one or more disulfide bonds.
[0166] In a specific embodiment, the sequence of the nucleic acid is shown in SEQ ID NOs:18, 19, or 20.
[0167] Preferably, the nucleotide sequence of the nucleic acid is codon optimized to increase gene expression, protein translation efficiency and protein expression, thereby enhancing the ability of TCR to recognize antigens. Codon optimization includes but is not limited to modification of the translation initiation region, changing the mRNA structural fragment, and using different codons encoding the same amino acid.
[0168] In other embodiments, the sequence of the TCR encoding nucleic acid can be mutated, including removing, inserting and / or replacing one or more amino acid codons, so that the function of the expressed TCR to recognize the antigen epitope polypeptide remains unchanged or enhanced. For example, in one embodiment, conservative amino acid substitution is performed, including replacing an amino acid in the variable region of the above-mentioned TCR α chain and / or β chain with another amino acid with similar structure and / or chemical properties. The term "similar amino acid" refers to amino acid residues with similar polarity, electrical load, solubility, hydrophobicity, hydrophilicity and other properties. The mutated TCR still has the biological activity of recognizing the above-mentioned antigen epitope polypeptide presented by the target cell. In another embodiment, TCR maturation modification is performed, that is, including removing, inserting and / or replacing the amino acids in the complementary determining region 2 (CDR2) and / or CDR3 regions in the variable region of the above-mentioned TCR α chain and / or β chain, thereby changing the affinity of the TCR binding antigen epitope polypeptide.
[0169] The present invention also relates to a recombinant expression vector for expressing the TCR, which contains the nucleic acid (eg DNA) encoding the T cell receptor according to the present invention, and / or its complementary sequence, operably linked to a promoter.
[0170] Preferably, in the recombinant expression vector, the DNA encoding the T cell receptor of the present invention is suitably operably linked to a promoter, an enhancer, a terminator and / or a polyA signal sequence.
[0171] The combination of the above-mentioned functional elements of the recombinant expression vector can promote the transcription and translation of DNA and enhance the stability of mRNA.
[0172] The basic framework of the recombinant expression vector can be any known expression vector, including plasmids or viruses, and viral vectors include, but are not limited to, for example, retroviral vectors (the virus prototype is Moloney murine leukemia virus (MMLV)) and lentiviral vectors (the virus prototype is human immunodeficiency virus type I (HIV)). The recombinant vector expressing the TCR of the present invention can be obtained by conventional recombinant DNA techniques in the art.
[0173] In one embodiment, the expression of the α chain and β chain genes on the recombinant expression vector can be driven by two different promoters, including various known types, such as strong expression, weak expression, continuous expression, inducible, tissue-specific, and differentiation-specific promoters. The promoter can be viral or non-viral (e.g., eukaryotic cell promoter), such as CMV promoter, promoter on LTR of MSCV, EF1-α promoter, and PGK-1 promoter, SV40 promoter, Ubc promoter, CAG promoter, TRE promoter, CaMKIIa promoter, human β-actin promoter. The driving direction of the two promoters can be the same direction or the opposite direction.
[0174] In another embodiment, the expression of the α chain and β chain genes on the recombinant expression vector can be driven by the same promoter. For example, in the case of encoding a single-chain chimeric T cell receptor, the nucleotide sequence of the α chain and the nucleotide sequence of the β chain are connected by the Furin-F2A polypeptide coding sequence.
[0175] In other embodiments, the recombinant expression vector may include coding sequences of other functional molecules in addition to the α chain and β chain genes. One embodiment includes expressing an autofluorescent protein (such as GFP or other fluorescent proteins) for in vivo tracking imaging. Another embodiment includes expressing an inducible suicide gene system, such as inducing the expression of herpes simplex virus-thymidine kinase (HSV-TK) protein, or inducing the expression of Caspase 9 (iCasp9) protein. The expression of these "safety-switches" can increase the safety of cells modified by the TCR gene of the present invention for use in vivo (see the document "Front.Pharmacol., 2014; 5: 1-8). Another embodiment includes expressing human chemokine receptor genes, such as CCR2, which can bind to corresponding chemokine ligands highly expressed in tumor tissues, thereby increasing the homing of cells modified by the TCR gene of the present invention in tumor tissues.
[0176] Preferably, the first composition comprises a therapeutically effective amount of the DNA, or a therapeutically effective amount of the mRNA.
[0177] Preferably, the first composition comprises a therapeutically effective amount of the recombinant virus. Preferably, when the recombinant virus is a recombinant oncolytic adenovirus, the administration dose of the recombinant oncolytic adenovirus is 5×10 7 -5×10 12 vp / day, 1-2 times a day, for 1-7 consecutive days.
[0178] Also preferably, the second composition comprises a therapeutically effective amount of the T cell receptor modified immune cells. Preferably, the total dose range for each course of treatment is 1×10 3 -1×10 9 The T cell receptor modified immune cells are expressed in cells / Kg body weight.
[0179] The DNA can be formulated for administration by intratumoral injection, for example, directly injected into the tumor in the form of a plasmid, or injected into the tumor after packaging with liposomes, or injected into the tumor after being connected to nanoparticles (such as polymers such as poly-L-lysine, polyamino acids, polyethyleneimine and chitosan), or injected into the tumor after intratumoral injection by electrotransfection. The mRNA can also be formulated for administration by intratumoral injection in a similar manner.
[0180] The recombinant virus can be formulated for administration by intratumoral injection, intraperitoneal administration, subarachnoid administration, or intravenous administration.
[0181] The immune cells can be formulated for administration via an artery, vein, subcutaneous, intradermal, intratumoral, intralymphatic, intralymph node, subarachnoid space, intramedullary, intramuscular or intraperitoneal route.
[0182] Preferably, the therapeutic agent consists of the first composition and the second composition.
[0183] Those skilled in the art will appreciate that the therapeutic agents of the present invention may also contain suitable pharmaceutically acceptable excipients, including pharmaceutical or physiological carriers, excipients, diluents (including physiological saline, PBS solution), and various additives, including carbohydrates, lipids, polypeptides, amino acids, antioxidants, adjuvants, preservatives, and the like.
[0184] The present invention also provides use of the therapeutic agent in preparing a medicine for treating tumors and / or cancers.
[0185] The tumors and / or cancers include: head and neck tumors, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, blood cancer, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, esophageal cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, skin cancer, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer. The tumor and / or cancer may include HLA-A2 positive and Her2 / neu negative, HLA-A2 negative and Her2 / neu positive, HLA-A2 and Her2 / neu both positive, or HLA-A2 and Her2 / neu both negative. The therapeutic agent within the scope of the present invention can be administered to the patient according to the actual situation of the tumor and / or cancer patient.
[0186] The present invention also provides the above-mentioned marker polypeptide of the present invention.
[0187] Preferably, the amino acid sequence of the marker polypeptide has at least 98% identity, more preferably at least 98.5%, and even more preferably at least 99% identity to the amino acid sequence shown in SEQ ID NO: 24, SEQ ID NO: 36, SEQ ID NO: 56, or SEQ ID NO: 60. Also preferably, the amino acid sequence of the marker polypeptide is shown in SEQ ID NO: 24, SEQ ID NO: 36, SEQ ID NO: 56, or SEQ ID NO: 60.
[0188] The present invention also provides an isolated nucleic acid having a coding sequence for a marker polypeptide according to the present invention. The amino acid sequence of the marker polypeptide has at least 98% identity, more preferably at least 98.5%, and even more preferably at least 99% identity to the amino acid sequence shown in SEQ ID NO:24, SEQ ID NO:36, SEQ ID NO:56, or SEQ ID NO:60. The various embodiments of the nucleic acid are as described above.
[0189] Preferably, the nucleic acid is DNA, and its nucleotide sequence is shown in SEQ ID NO: 25 (corresponding to a sequence excluding HLA-A2), or SEQ ID NO: 26 (corresponding to a sequence including HLA-A2, wherein HLA-A2 is before the marker polypeptide), or SEQ ID NO: 27 (corresponding to a sequence including HLA-A2, wherein HLA-A2 is after the marker polypeptide), or SEQ ID NO: 57, or SEQ ID NO: 58, or SEQ ID NO: 61. Its corresponding amino acid sequence is shown in SEQ ID NO: 24 (corresponding to a sequence excluding HLA-A2), or SEQ ID NO: 31 (corresponding to a sequence including HLA-A2, wherein HLA-A2 is before the marker polypeptide), or SEQ ID NO: 32 (corresponding to a sequence including HLA-A2, wherein HLA-A2 is after the marker polypeptide), SEQ ID NO: 56, SEQ ID NO: 36, or SEQ ID NO: 60.
[0190] The present invention also provides the use of the nucleic acid in preparing a drug for treating or preventing tumors and / or cancers.
[0191] The present invention also provides a recombinant expression vector containing the nucleic acid according to the present invention and / or its complementary sequence.
[0192] Preferably, in the recombinant expression vector, the nucleic acid of the present invention is suitably operably linked to a promoter, an enhancer, a terminator and / or a polyA signal sequence.
[0193] The combination of the above-mentioned functional elements of the recombinant expression vector of the present invention can promote the transcription and translation of DNA and enhance the stability of mRNA.
[0194] The basic framework of the recombinant expression vector can be any known expression vector, including plasmids or viruses, and viral vectors include, but are not limited to, for example, retroviral vectors (the virus prototype is Moloney murine leukemia virus (MMLV)) and lentiviral vectors (the virus prototype is human immunodeficiency virus type I (HIV)). The recombinant vector expressing the marker polypeptide of the present invention can be obtained by conventional recombinant DNA techniques in the art.
[0195] In some embodiments, the basic framework of the recombinant expression vector is an oncolytic adenovirus. The promoter is an endogenous viral gene promoter, such as an E1A promoter, an E1B promoter, or an E3 promoter. In certain embodiments, the promoter is a tissue-specific or tumor-specific promoter. Preferably, in some embodiments, the promoter is the E2F-1 promoter shown in SEQ ID NO: 30.
[0196] In other embodiments, the recombinant expression vector may also contain, in addition to the nucleic acid described herein, the coding sequence of other functional molecules, such as a reporter gene, which can be used to identify whether the cell is transfected with the recombinant expression vector, and can also be used to measure protein levels and activity, such as by flow cytometry, amplification / expression methods, immunohistochemistry, FISH and shed antigen determination, Southern blotting, Western blotting or PCR technology. Therefore, methods for measuring protein levels in cells are generally known in the art.
[0197] The present invention also provides the use of the recombinant expression vector in preparing a drug for treating or preventing tumors and / or cancers.
[0198] The present invention also provides an isolated recombinant virus, wherein the genome of the recombinant virus has the nucleic acid according to the present invention; and the recombinant virus comprises a selectively replicating recombinant oncolytic virus or a replication-deficient recombinant virus. The embodiments of the isolated recombinant virus are as described above.
[0199] The present invention also provides use of the recombinant virus in preparing a drug for treating or preventing tumors and / or cancers.
[0200] The present invention also provides a medicine kit of a combined drug with synergistic effect for treating tumors and / or cancers, comprising:
[0201] A first container containing a first composition of a therapeutic agent according to the present invention;
[0202] a second container containing a second composition of a therapeutic agent according to the present invention, wherein the first container and the second container are separate; and
[0203] Instructions for use that specify when and how to administer the drug.
[0204] The present invention also provides use of the medicine kit in preparing medicines for treating or preventing tumors and / or cancers.
[0205] The tumors and / or cancers include: head and neck tumors (including nasopharyngeal carcinoma), synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, blood cancer, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, esophageal cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, skin cancer, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer. The tumor and / or cancer may include HLA-A2 positive and Her2 / neu negative, HLA-A2 negative and Her2 / neu positive, HLA-A2 and Her2 / neu both positive, or HLA-A2 and Her2 / neu both negative. The drug kit within the scope of the present invention can be provided to the patient according to the actual situation of the tumor and / or cancer patient.
[0206] The present invention also provides a method for treating tumors and / or cancers, comprising:
[0207] administering the first composition of the therapeutic agent according to the present invention to a tumor and / or cancer patient; and
[0208] The second composition of the therapeutic agent according to the present invention is administered to the tumor and / or cancer patient.
[0209] The first and second compositions of the therapeutic agent can be administered simultaneously (e.g., simultaneously injected intratumorally as a mixture), separately but simultaneously (e.g., administered by intratumoral and intravenous injections, respectively), or sequentially (e.g., first administering the first composition, then administering the second composition; or first administering the second composition, then administering the first composition).
[0210] Preferably, the method comprises the following steps performed in sequence:
[0211] 1) first administering the first composition to the tumor and / or cancer patient; and
[0212] 2) After administering the first composition, administering the second composition of the therapeutic agent to the tumor and / or cancer patient.
[0213] Preferably, the second composition of the therapeutic agent is administered to the tumor and / or cancer patient 1-30 days after the first administration of the first composition.
[0214] The term "administering the second composition of the therapeutic agent to the tumor and / or cancer patient on day 1-30 after first administering the first composition" means that the time interval between the first administration of the second composition and the first administration of the first composition is 1-30 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 days), or the time interval between the first administration of the second composition and the most adjacent administration of the first composition is 1-30 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 days). Preferably, the time interval between the first administration of the second composition and the most recent previous administration of the first composition is 3-14 days (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days).
[0215] In a preferred embodiment of the present invention, the first composition comprises the recombinant oncolytic adenovirus, and the administration dose of the recombinant oncolytic adenovirus is 5×10 7 -5×10 12 vp / day, 1-2 times a day, for 1-7 consecutive days, or any value between the above ranges.
[0216] In a preferred embodiment of the present invention, the administration dosage of the T cell receptor modified immune cells is such that the total dosage per course of treatment ranges from 1×10 3 -1×10 9 Preferably, the drug is administered 1 to 3 times a day for 1 to 7 consecutive days.
[0217] In certain embodiments, the method for treating tumors and / or cancers further comprises administering to the patient other drugs for treating tumors and / or cancers, and / or drugs for regulating the patient's immune system, so as to enhance the number and function of the T cell receptor-modified immune cells in vivo. The other drugs for treating tumors and / or cancers include, but are not limited to: chemotherapy drugs, such as cyclophosphamide, fludarabine; radiotherapy drugs; immunosuppressants, such as cyclosporine, azathioprine, methotrexate, mycophenolate, FK50; antibodies, such as antibodies against CD3, IL-2, IL-6, IL-17, TNFα.
[0218] In certain embodiments, the method for treating tumors and / or cancers further comprises administering to the patient other drugs for treating tumors and / or cancers, and / or drugs for regulating the patient's immune system, for removing the number and function of the T cell receptor-modified immune cells carrying the suicide gene in vivo when the T cell receptor-modified immune cells produce severe toxic side effects. The other drugs for treating tumors and / or cancers include, but are not limited to, chemically induced dimerization (CID) drugs, AP1903, phosphorylated ganciclovir, anti-Cd20 antibodies, anti-CMYC antibodies, and anti-EGFR antibodies.
[0219] The DNA can be formulated for administration by intratumoral injection, for example, directly injected into the tumor in the form of a plasmid, or injected into the tumor after packaging with liposomes, or injected into the tumor after being connected to nanoparticles (such as polymers such as poly-L-lysine, polyamino acids, polyethyleneimine and chitosan), or injected into the tumor after intratumoral injection by electrotransfection. The mRNA can also be formulated for administration by intratumoral injection in a similar manner.
[0220] The recombinant virus can be formulated for administration by intratumoral injection, intraperitoneal administration, subarachnoid administration, or intravenous administration.
[0221] The T cell receptor modified immune cells can be formulated for administration via artery, vein, subcutaneous, intradermal, intratumoral, intralymphatic, intralymph node, subarachnoid space, intramedullary, intramuscular or intraperitoneal routes.
[0222] The tumors and / or cancers include: head and neck tumors (including nasopharyngeal carcinoma), synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, blood cancer, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, esophageal cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, skin cancer, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer. The tumor and / or cancer may include HLA-A2 positive and Her2 / neu negative, HLA-A2 negative and Her2 / neu positive, HLA-A2 and Her2 / neu both positive, or HLA-A2 and Her2 / neu both negative. The method within the scope of the present invention can be provided to the patient according to the actual situation of the tumor and / or cancer patient.
[0223] The following further explains or illustrates the content of the present invention by way of examples, but these examples should not be construed as limiting the scope of protection of the present invention.
[0224] example
[0225] Unless otherwise stated, the experimental methods used in the following examples were performed using conventional experimental procedures, operations, materials, and conditions in the field of bioengineering.
[0226] Unless otherwise specified, the percentage concentration (%) of each reagent refers to the volume percentage concentration (% (v / v)) of the reagent.
[0227] Materials and methods
[0228] Cell line: The cell line used to prepare lentiviral particles is 293T cells (ATCC CRL-3216). The presenting cell line used to present antigenic peptides is T2 cells (174xCEM.T2, ATCC CRL-1992). The tumor cell lines used for functional testing are human colorectal cancer colo205 cells (ATCC CCL-222), HT-29 cells (HTB-38) and HCT116 cells (ATCC CCL-247), human breast cancer MDA-MB-231 cells (ATCC HTB-26) and MCF7 cells (ATCC HTB-22), human ovarian cancer SKOV3 cells (ATCC HTB-77), human pancreatic cancer PANC-1 cells (ATCC CRL-1469), human glioma U87MG cells (ATCC HTB-14), human hepatocellular carcinoma HepG2 cells (ATCC HB-8065), human non-small cell lung cancer NCI-H460 cells (ATCC HTB177), and small cell lung cancer NCI-H446 cells (ATCC HTB-171). The cell lines were maintained in RPMI-1640 complete medium (Lonza, cat#12-115F) supplemented with 10% fetal calf serum FBS (ATCC30-2020), 2 mmol / L L-glutamic acid, 100 μg / ml penicillin and 100 μg / ml streptomycin.
[0229] Peripheral blood: The human peripheral blood products from healthy donors used in the experiment were all from the Pacific Blood Center in San Francisco (#1 PBMC and #2 PBMC were Trima residual cell fractions #R32334 and #R33941 from the Apheresis collection kit, respectively).
[0230] Trypan blue staining method: Wash the cells with PBS, digest them with trypsin, suspend the cells in PBS, add trypan blue dye solution with a final concentration of 0.04% (w / v), count under a microscope, dead cells will be stained light blue, and live cells will not be stained. The number of live cells is taken as the final data.
[0231] In vitro induction of Her2 / neu 369-377 specific killer T cells (CTL): Peripheral blood was centrifuged (×400g) for 30 minutes on Ficoll-Paque Premium (Sigma-Aldrich, cat#GE-17-5442-02) to obtain mononuclear cells (PBMC). First, the HLA-A2 phenotype of the cells was detected by staining with fluorescein FITC-labeled anti-HLA-A2 antibody (Biolegend, cat#343303). After flow cytometry analysis (the flow cytometer was MACSQuant Analyzer 10 (Miltenyi Biotec), and the results were analyzed using Flowjo software (Flowjo)), RNA of positive cells was extracted, reverse transcribed into cDNA and cloned into a vector, and then HLA gene sequencing analysis was performed to determine that the cell type was HLA-A*0201. HLA-A2-positive PBMC cells were cultured in the culture wells of a 24-well culture plate, and the culture medium was the above-mentioned RPMI-1640 complete medium. 2×10e6 / ml PBMC were added to each well, Her2 / neu 369-377 polypeptide (Her2-E75, synthesized by Peptide2.0, 10 μg / ml dissolved in DMSO) was added to a final concentration of 1 μg / ml. After culturing in an incubator at 5% CO2 and 37°C for 16-24 hours, the following cytokines were added at a final concentration: human IL-2 (Peprotech, cat#200-02) 100 IU / ml, human IL-7 (Peprotech, cat#200-07) 5 ng / ml, and human IL-15 (Peprotech, cat#200-15) 5 ng / ml. After 10 to 14 days of culture, the cultured T cells were restimulated with antigens: 10e6 of the cultured cells obtained above were added to each well of a 24-well plate, and 2×10e6 HLA-A2-positive PBMC cells treated with 25 μg / ml mitomycin C (Santa Cruz Biotechnology, cat# SC-3514) for 2 hours were added as trophoblasts, Her2 / neu 369-377 polypeptide was added to each well at a final concentration of 1 μg / ml, and IL-2 100 IU / ml, IL-7 5 ng / ml, and IL-15 5 ng / ml (final concentration) were added after overnight culture. After two rounds of the above antigen stimulation and restimulation, the amplified T cells were collected for phenotypic analysis and T cell cloning.
[0232] Flow cytometry analysis and single cell isolation: The phenotype of T cells expressing Her2 / neu 369-377-specific TCR was analyzed by flow cytometry. The cells to be tested were collected and placed in a 1.5 ml tube (the number of cells was about 10e5), washed once with 1 ml DPBS solution (2.7 mM KCl, 1.5 mM KH2PO4, 136.9 mM NaCl, 8.9 mM Na2HPO4·7H2O, pH 7.4), and reset in 100 μl DPBS containing 1% calf serum, and 5 μl of fluorescein APC-labeled anti-human CD8 antibody (Biolegend, cat#300912) and 10 μl of fluorescein PE-labeled Her2-E75 / HLA-A2 tetramer (Her2-E75 tetramer, MBL International Co., cat#T01014) or Her2-E75 / HLA-A2 pentamer (Her2-E75 pentamer, Proimmune, cat#F214-2A-D), incubated on ice for 30 minutes, washed twice with DPBS solution, and resuspended in 100 μl PBS solution (8mM Na2HPO4, 136mM NaCl, 2mM KH2PO4, 2.6mM KCl, pH7.2-7.4) for flow cytometry analysis. The flow cytometer was MACSQuant Analyzer10 (Miltenyi Biotec), and the results were analyzed using Flowjo software (Flowjo). T cell clones were obtained by single cell separation and culture using a flow cytometer (FACS sorter). PBMCs stimulated with Her2 / neu369-377 polypeptide antigen were stained with APC-labeled anti-human CD8 antibody and PE-labeled Her2-E75 / HLA-A2 pentamer, and then separated by flow cytometry (model: Sony cell sorter SH800). + Her2-E75 / HLA-A2 pentamer + After the cells were sorted into a single well of a 96-well culture plate, HLA-A2-positive PBMC cells treated with 25 μg / ml mitomycin C for 2 hours were added, 10e5 cells per well, 1 μg / ml Her2 / neu 369-377 polypeptide was added and cultured overnight, and then RPMI-1640 complete culture medium containing IL-2 100 IU / ml, IL-7 5 ng / ml, and IL-15 5 ng / ml was added. Fresh culture medium containing the cytokines was replaced every 3-4 days, and the growth of T cell clones was observed under a microscope. The proliferated T cells were collected, and antigen restimulation was performed according to the above method to obtain a sufficient number of cells, phenotypic or functional detection was performed, and RNA was extracted for TCR gene cloning.
[0233] T cell function test: In order to detect the ability of T cells transfected with TCR genes to recognize antigen epitope peptides, 10e5 T cells transfected with TCR genes and 10e5 T2 cells were added to each well of a 96-well plate and mixed cultured in 100 μl / well RPMI-1640 complete medium, with each test group being duplicate wells. Then, Her2 / neu 369-377 peptides of different final concentrations (1 μg / ml, 0.5 μg / ml, 0.1 μg / ml, 0.05 μg / ml, 0.01 μg / ml, 0.005 μg / ml, 0.001 μg / ml and 0.0001 μg / ml) were added and placed in an incubator at 5% CO2 and 37°C for overnight culture.
[0234] In order to detect the ability of T cells transfected with TCR genes to recognize tumor cell lines, a certain number of PBMC cells transfected with TCR genes and tumor cells were added as target cells in each well of a 96-well plate according to different effector-target ratios. After culturing for 24 hours, the supernatant was collected to detect the secreted interferon-γ in the supernatant. Each test group was a duplicate well or triplicate well. In the antibody function blocking test, anti-human CD8 antibody (Biolegend, cat#300912) at a final concentration of 10 μg / ml was added to the cell culture wells at the same time, and the cells were placed in an incubator at 5% CO2 and 37°C for overnight culture. The cell supernatant was collected for 18-24 hours, and the IFN-γ in the supernatant was detected using the human IFN-γ ELISA Read-set-Go kit (eBioscience, cat#88-7316) or the human IFN-γ DuoSet ELISA kit (R&D Systems, cat#DY285B) according to the manufacturer's instructions.
[0235] In order to detect the ability of T cells transfected with TCR genes to kill tumor cells, 1×10e4 target cells were added to each well of a 24-well culture plate and cultured for 24 hours to allow the target cells to completely adhere to the wall. The suspended cells were removed and a certain number of T cells transfected with TCR genes were added according to the set effector-target ratio. After 24 hours of culture, the suspended cells were removed, and the adherent cells were collected by trypsin digestion and trypan blue staining to count the live cells. Killing rate (Cytotoxicity) % = ((the number of live cells of the initial target cells - the number of live cells of the target cells at the end of the culture) / the number of live cells of the initial target cells) × 100. Each experimental group was repeated or triplicate, and the significance of the difference was analyzed by Student's t-test.
[0236] MTT counting method:
[0237] Trypsin digested the cells in the logarithmic growth phase, collected them by centrifugation after termination, and evenly dispersed them to prepare a single cell suspension; the cell concentration was adjusted to 0.1-10×10 4 / ml (adjust the number of inoculated cells according to the growth conditions of different cells), inoculate in a 96-well cell culture plate, the culture system is 100μl / well, place in a 37℃, 5% CO2 incubator for overnight culture, so that the cells are completely attached to the wall, and reach 70-80% on the second day; the counting method is counted by counting plate, and the correctness of the counting is verified by countstar counter. Take out the 96-well plate, add 100μl of pre-prepared T cell and TCR-T cell suspension, vortex slightly before adding the sample, and add 100μl of serum-free medium for corresponding cell culture to the blank control well; place in a 37℃, 5% CO2 incubator and culture for 24 hours; take the cells after 24h, centrifuge at 400g, and after 10 minutes, absorb 180μl of culture medium and put it into a new 96-well plate, and keep the sample for the subsequent ELISA detection of supernatant IFN-γ level. The detection steps can refer to the detection instructions. Note: The supernatant can be frozen at -80℃ for subsequent detection. Add 100μl of new complete medium to each well, add 10μl of MTT solution (5mg / ml, i.e. 0.5% MTT) to each well, and continue to culture for 4-6h; set up the effector cell control group, 4 hours after adding MTT, centrifuge at 300g for 5 minutes, centrifuge the effector cells stained with MTT to the bottom of the plate, discard the supernatant, and then add DMSO for detection. Add 150μl of DMSO to each well, shake at low speed on a shaker for 10 minutes to fully dissolve the crystals, and detect its absorbance at 490nm on an enzyme marker.
[0238] Obtaining monoclonal TCR genes: Total RNA was purified from T cell clones using the Zymo Quick-RNA Microprep kit (Zymo Research, cat#R1050), and cDNA was obtained using the Smarter RACE 5' / 3' kit (Takara Bio, USA, cat#634858) using this as a template. PCR was performed using the 5'-CDS primer and the TCRβ chain 3' primer 5'-GCCTCTGGAATCCTTTCTCTTG-3' (SEQ ID NO:33) and the α chain 3' primer 5'-TCAGCTGGACCACAGCCGCAG-3' (SEQ ID NO:34) to amplify the full sequence gene fragments of TCRα and β, and cloned into the pRACE vector (Takara Bio, USA, cat#634858) respectively. Transform the competent bacteria Stellar (Takara Bio, USA, cat#636763) and obtain the plasmid for sequencing.
[0239] Preparation of recombinant TCR lentiviral expression vector: The viral vector used to express TCR is a replication-deficient lentiviral vector, including: a lentiviral vector pCDH-EF1α-MCS-(PGK-GFP) expressing GFP, which can be purchased from System Biosciences (Cat#CD811A-1); and a vector pCDH-EF1α-MCS that does not express GFP, which is obtained by removing the PGK promoter and GFP gene on the pCDH-EF1α-MCS-(PGK-GFP) vector using conventional techniques in the art. According to the obtained TCR gene sequence, the full gene sequence of the TCRβ chain and α chain and the cleavable F2A sequence and Furin enzyme fragment between them are synthesized and linked to the multiple cloning site downstream of the EF-1α promoter of the vector. The transcription order of the inserted TCR is TCRβ chain (without stop codon), Furin enzyme fragment, F2A fragment, TCRα chain (for methods, see the document "Gene Ther. 2008Nov; 15(21): 1411-1423"). The vector expressing GFP is driven by the PGK promoter in reverse. The vector not expressing GFP has the PGK promoter and GFP fragment removed.
[0240] Preparation of recombinant TCR lentiviral particles: TCR lentiviral particles were obtained by transfecting 293T / 293FT cells with Lipofectaine 2000 transfection reagent (invitrogen, #11668019). 293T / 293FT cells and transfection procedures were prepared according to the manufacturer's instructions. Transfection was performed in a 6-well culture plate. First, Opti-MEM 1 culture medium (Thermo Fisher, cat#51985091) was used to prepare a liposome mixed solution of the transfection plasmid. According to the manufacturer's instructions, 6 μl of lipofectaine 2000 reagent, 0.8 μg of TCR lentiviral vector plasmid and 1.8 μg of viral packaging plasmid of the pCDH system (SBI, cat#LV500A-1) were added to 250 μl of culture medium. After mixing and incubating for 25 minutes, the mixture was added to the 293T / 293FT cell culture wells. The cells were cultured at 5% CO2 and 37°C for 16 hours, then replaced with DMEM culture medium without FBS (Thermo Fisher, cat#11965092). The cells were cultured for 24 and 48 hours, and the supernatants were collected. The cells were centrifuged at 2000 g for 10 minutes and filtered with a 0.4 μm filter membrane. The viral supernatant was concentrated using a lentivirus concentrate (GeneCopoeiaTM#LPR-LCS-01) according to the manufacturer's instructions and then used to infect cells.
[0241] Recombinant TCR lentiviral transfection of human T cells: After thawing, the frozen primary PBMC cells were cultured in RPMI-1640 complete culture medium for 24 hours, and the dead cells were removed by Ficoll-Paque Premium density gradient centrifugation (×400g) for 30 minutes. The cells were placed in 24-well culture wells treated with 2μg / ml anti-human CD3 antibody (Biolegend, OKT3 clone cat#317303) and 2μg / ml anti-human CD28 antibody (Biolegend, cat#302914) for 24 hours (100μl of DPBS solution containing the above CD3 antibody and CD28 antibody was added to each well) at a cell concentration of 2×10e6 / ml. Dynabead human T-CD3 / CD8 magnetic beads (Thermo Fisher, cat#11131D) can also be used to stimulate and activate the PBMC cells according to the manufacturer's instructions. After 24 hours of culture, the cells were collected and 100 μl of concentrated TCR lentiviral particles (3×10e8Tu / ml) were added to the wells of a 24-well plate. The cells were cultured continuously with RPMI-1640 complete culture medium or X-VIVO15 (Lonza#04-418Q) containing IL-2100IU / ml, IL-7 5ng / ml, and IL-15 5ng / ml. The culture medium containing the above cytokines was replaced with fresh culture medium every 3 days. RestroNectin pretreated culture plates (Takara, cat#T110A) can also be used to infect activated PBMC cells with viruses according to the manufacturer's instructions. Phenotypic and functional tests can generally be performed after 72 hours. Transfection of T cell lines is also carried out according to the above steps. If the viral vector is marked with GFP, GFP-positive cells can generally be observed under a fluorescence microscope 48 hours after transfection.
[0242] Preparation Example 1: Preparation of a recombinant lentiviral vector expressing a marker polypeptide.
[0243] First, the exogenous expression gene was obtained. The HLA-A201 gene fragment was obtained by RT-PCR. +RNA was extracted from PBMC cells, and the HLA-A201 gene was obtained using a Superscript RT-PCR kit (Thermo Fisher, cat#12574018) according to the manufacturer's instructions, and sequencing confirmed that it was a complete sequence (its amino acid sequence is shown in SEQ ID NO:29, and its nucleotide sequence is shown in SEQ ID NO:35). The gene fragment of the marker polypeptide was obtained by DNA synthesis (Integrated DNA Technologies, gblocks Gene Fragments), including: marker polypeptide "E75×1" (without KDEL at the C-terminus) (its amino acid sequence is shown in SEQ ID NO:56, and its nucleotide sequence is shown in SEQ ID NO:57); marker polypeptide "E75×4" (without KDEL at the C-terminus) (its amino acid sequence is shown in SEQ ID NO:36, and its nucleotide sequence is shown in SEQ ID NO:58); marker polypeptide "E75×8" (without KDEL at the C-terminus) (its amino acid sequence is shown in SEQ ID NO:60, and its nucleotide sequence is shown in SEQ ID NO:61). The lentiviral vector pCDH-EF1α-MCS-(PGK-GFP) was purchased from System Biosciences (Cat#CD811A-1). The HLA-A2 gene fragment was inserted into the multiple cloning site downstream of the EF1a promoter by using conventional gene cloning techniques in the art. The plasmid was digested with Xcm-1 to remove the GFP gene fragment, and the gene fragments of the synthesized marker polypeptide were inserted into the downstream of the PGK promoter and replaced the GFP gene by using conventional gene cloning techniques in the art, and "pCDH-EF1p-A2-PKGp-E75×1", "pCDH-EF1p-A2-PKGp-E75×4" and "pCDH-EF1p-A2-PKGp-E75×8" were obtained respectively. The sequencing results of each plasmid were correct.
[0244] The HLA-A2 gene was connected via the furin restriction sequence, the F2A sequence and the coding sequence of the marker polypeptide "E75×8" (with KDEL at the C-terminus) to form an A2-Her2E75 sequence fragment (the nucleotide sequence of which is shown in SEQ ID NO: 26). PCR was performed using an In-fusion cloning kit (Takara Bio, cat#638909) according to the manufacturer's instructions. The primers used were 5'-AGAGCTAGCGAATTCAACATGGCCGTCATG-3' (SEQ ID NO:37) and 5'-TGATTGTCGACGCCCTTAAAGCTCGTCTTTAAGGAAG-3' (SEQ ID NO:38). After obtaining the gene fragment by high-fidelity PCR amplification, the A2-Her2E75 fragment was inserted into the multi-gene cloning site downstream of the EF1α promoter of the lentiviral vector pCDH-EF1α-MCS-(PGK-GFP) (purchased from System Biosciences, Cat#CD811A-1) by using conventional gene cloning techniques in the art to obtain the CD811-EF1a-A2-F2A-HerE75 plasmid.
[0245] Preparation Example 2: Preparation of replication-deficient recombinant adenovirus expressing marker polypeptide / HLA-A2.
[0246] 1) Preparation of replication-deficient recombinant adenoviral vector expressing marker polypeptide / HLA-A2
[0247] The recombinant adenovirus was prepared mainly according to the preparation method of the AdEasy system (see the document "Nature protocols 2007; 2: 1236-1247"). First, the exogenous expression gene was obtained. The HLA-A201 gene fragment was obtained by RT-PCR. +RNA was extracted from PBMC cells, and the HLA-A201 gene was obtained using a Superscript RT-PCR kit (ThermoFisher, cat#12574018) according to the manufacturer's instructions, and sequenced to confirm that it was a complete sequence. Other exogenous genes, such as the Her2-E75 minigene, or tandem minigenes and expression regulatory elements, were obtained by DNA synthesis to obtain gene fragments (Integrated DNA Technologies, gblocks Gene Fragments), including: a marker polypeptide "E75×8" (with KDEL at the C-terminus) (its amino acid sequence is shown in SEQ ID NO: 24, and its nucleotide sequence is shown in SEQ ID NO: 59). The HLA-A2 gene was cloned using the In-Fusion cloning technology through the furin enzyme sequence and the F2A sequence and the coding sequence of the marker polypeptide "E75×8" to form an A2-Her2E75 sequence fragment (its nucleotide sequence is shown in SEQ ID NO: 26). PCR was performed using an In-fusion cloning kit (Takara Bio, cat#638909) according to the manufacturer's instructions, and the primers used were 5'-TAGAGATCTGGTACCAACATGGCCGTCATGG-3' (SEQ ID NO:39) and 5'-GGCTCGAGCGGCCGCTTAAAGCTCGTCTTTAAGGAAG-3' (SEQ ID NO:40). After PCR amplification to obtain the gene fragment, the A2-Her2E75 fragment was inserted into the multi-gene cloning site of the pShttle-CMV vector (Agilenttechnologies, cat#24007) by using conventional gene cloning technology in the art to obtain pShuttle-CMV-A2E75-SV40pA. The pShuttle vector plasmid carrying the exogenous gene was purified, digested with Pme I enzyme (NEB Biolabs, cat#R0560s), and after purification, electrotransformed using an electroporator (Bio-Rad Gene Pulse) according to the manufacturer's instructions. Add BJ5183-AD-1 bacterial strain (Agilent technologies, cat#200157) and pShuttle vector plasmid carrying exogenous genes digested with Pme I into a 2mm cuvette. Add 0.5μg of plasmid to 50μl of strain and perform electroporation at 2500v, 200Ohms and 25micro-FD. After culturing overnight on an LB plate containing 50μg / ml kanamycin, pick out the colonies and culture them in small amounts to obtain plasmids for sequencing to determine whether exogenous gene fragments are inserted into the adenovirus vector plasmid through recombination. The sequencing results are correct.
[0248] 2) Preparation and infection of replication-defective recombinant adenovirus particles expressing marker peptide / HLA-A2
[0249] Virus particles were obtained by transfecting ADENO-X 293 cells (Takara, cat#632271) with Lipofectaine 3000 transfection reagent (Thermo Fisher, cat#L3000001). ADENO-X293 cells were cultured in 6-well plates until 50-75% confluence before transfection. The purified recombinant adenovirus plasmid was digested and purified with Pac I (NEB Biolabs, cat#R0547s), and then transfected with Lipofectaine 3000 according to the manufacturer's instructions. Fresh DMEN culture medium was replaced after 24 hours. Cytopathic effects began to appear on 10-14 days, manifested as cells suspended in plaques. The cells were collected and suspended in PBS solution, frozen and thawed 4 times in dry ice and 37°C water bath, and the supernatant after centrifugation was the initial preparation of the virus and stored at -80°C. In order to obtain high-titer virus, ADENO-X 293 cells were cultured in T75 culture dishes (Corning, cat#430661), and 30%-50% of the initially prepared virus cryopreservation solution was added after 75% confluence. After 3-5 days of cytopathic effect, the cells were collected and frozen and thawed as described above to obtain a virus suspension. The virus titer was determined using an adenovirus titer kit (Takara, cat#632270) according to the manufacturer's instructions. When infecting target cells, the target cells were resuspended in fresh culture medium, and adenovirus with a quantitative titer was added according to the number of cells. After 3-4 days of culture, the expression of the exogenous gene was detected. The results showed that the expression of the exogenous gene was positive.
[0250] Preparation Example 3: Preparation of recombinant oncolytic adenovirus expressing marker polypeptide and preparation of recombinant oncolytic adenovirus expressing marker polypeptide / HLA-A2.
[0251] 1) Construction of type 5 oncolytic adenovirus vector
[0252] First, the genomic DNA of commercial oncolytic adenovirus H101 (oncolytic adenovirus H101 was purchased from Shanghai Sanwei Biotechnology Co., Ltd.) was extracted as a template, and two primers (P26: 5'GGAAGATCTGGACTGAAAATGAG3' (SEQ ID NO: 41) and P27: 5'TGAGGTCAGATGTA ACCAAGATTA 3' (SEQ ID NO: 42)) were designed to amplify the E1A coding region of type 5 adenovirus by high-fidelity PCR, and the PCR product size was 1173 bp. The obtained PCR fragment was purified, digested with BglII, and then ligated between the BglII and EcoRV sites in the multiple cloning site on the pShuttle-CMV vector (purchased from Agilent technologies, cat#24007) to obtain pShuttle-E1A, and the E1A sequence therein was sequenced to confirm that it was correct.
[0253] Two primers (P36: 5'CGCGTCGACTACTGTAATAGTAATCAATTACG G3' (SEQ ID NO: 43) and P37: 5'GACGTCGACTAAGATACATTGATGAGTTTGGAC3') (SEQ ID NO: 44) were designed again, and a 2017 bp DNA fragment including the CMV promoter, E1A coding region and SV40 polyA sequence on the vector pShuttle-E1A was amplified by high-fidelity PCR using the vector pShuttle-E1A as a template. The obtained PCR fragment was purified, digested with SalI, and then ligated into the SalI site in the multiple cloning site on the pShuttle vector (purchased from Agilent, cat#240006) to obtain pShuttle-MCS-CMV-E1A-SV40polyA ( Fig. 9 ), and the CMV-E1A-SV40polyA sequence was sequenced and confirmed to be correct.
[0254] 2) Preparation of genomic DNA of oncolytic adenovirus expressing Her2-E75 minigene (with KDEL at the C-terminus) and co-expressing Her2-E75 minigene (with KDEL at the C-terminus) and HLA-A2
[0255] On the basis of the above-obtained type 5 oncolytic adenovirus backbone, gene expression cassettes capable of expressing the Her2-E75 minigene and co-expressing the Her2-E75 minigene and HLA-A2 were added respectively, and finally type 5 oncolytic adenovirus genomic DNA capable of expressing the Her2-E75 minigene alone ("OAd-E75") and two types of type 5 oncolytic adenovirus genomic DNAs co-expressing the Her2-E75 minigene and HLA-A2 ("OAd-E75-A2") were obtained (see Fig.10 ).
[0256] The target gene expression frame includes three parts: EF-1α promoter, Her2-E75 minigene (or Her2-E75 minigene and HLA-A2) coding region sequence and BGHpolyA sequence. After obtaining the above two fragments, they were inserted into the KpnI and XhoI sites on the type 5 oncolytic adenovirus backbone plasmid pShuttle-MCS-CMV-E1A-SV40pA respectively. The BGHpolyA sequence was amplified from the pcDNA3.1 plasmid (purchased from Invitrogen) by a high-fidelity PCR method. After obtaining the BGHpolyA fragment, it was inserted into the HindIII site on the type 5 oncolytic adenovirus backbone plasmid pShuttle-MCS-CMV-E1A-SV40polyA to obtain the pShuttle-EF1a-MCS-BGHpA-CMV-E1A-SV40pA plasmid.
[0257] Cloning of E75 (i.e., Her2-E75 minigene, referred to as "E75" in this section) and E75-HLAA2 fragments
[0258] Cloning of E75 fragment
[0259] Two primers (P105: 5'CCGCTCGAGATGAAAGGTTCCATCTTCACATTG 3' (SEQ ID NO: 45) and P106: 5'CCGCTCGAGTTAAAGCTCGTCTTTAAGGAAGGC 3' (SEQ ID NO: 46)) were designed, and the CD811-EF1a-A2-F2A-HerE75 plasmid obtained in Preparation Example 1 was used as a template. High-fidelity PCR was performed using the above primers, and finally an E75 fragment containing XhoI restriction sites on both sides was obtained, with a size of 399 bp. The obtained PCR fragment was purified, digested with XhoI, and then ligated into the XhoI site on the pShuttle-EF1a-MCS-BGHpA-CMV-E1A-SV40pA vector to obtain pShuttle-EF1a-E75-BGHpA-CMV-E1A-SV40pA, and the E75 sequence therein was sequenced to confirm that it was correct.
[0260] Cloning of E75-HLAA2 fragment
[0261] In this part of the work, the HLA-A2, Furin-F2A and E75 sequences were amplified by high-fidelity PCR using CD811-EF1a-A2-F2A-HerE75 plasmid as a template. In order to swap HLAA2 to the back of the Furin-F2A linker fragment and E75 to the front of the Furin-F2A linker fragment, the HLAA2 fragment, the Furin-F2A linker fragment and the E75 fragment were first amplified separately, and when amplifying the HLAA2 fragment, a stop codon needed to be added to its end, while the E75 fragment needed to remove the stop codon at its end. Finally, the three fragments were concatenated and merged in sequence according to the plan by overlapping extension PCR to obtain the E75-Furin-F2A-HLAA2 fragment.First design 5 primers (P107: 5'TTCCGGATCGCTTGGCACGAAGCTCGTCTTTAAGGAAGG 3' (SEQ ID NO: 47), P108: 5'CCTTCCTTAAAGACGAGCTTCGTGCCAAGCGATCCGGAA 3' (SEQ ID NO: 48), P109: 5'CGGGGCGCCATGACGGCCATGGGCCCAGGGTTGGACTC3' (SEQ ID NO: 49), P110: 5'GAGTCCAACCCTGGGCCCATGGCCGTCATGGCGCCCC G 3' (SEQ ID NO: 50) and P111: 5'CTTCTCGAGTCACACTTTACAAGCTGTGAGAG 3' (SEQ ID NO:51), using CD811-EF1a-A2-F2A-HerE75 plasmid as template, high-fidelity PCR was performed using primers P105 and P107 to amplify the E75 fragment that does not contain the stop codon but contains part of the 5' end repeat sequence of the Furin-F2A junction fragment. The fragment size is 406 bp; high-fidelity PCR was performed using primers P108 and P109 to amplify part of the E75 3' end repeat fragment and part of the HLA-A2 The Furin-F2A connecting fragment of the 5' end repeat fragment had a fragment size of 136bp; the HLAA2 fragment containing part of the 3' end repeat fragment of the Furin-F2A connecting fragment was amplified by high-fidelity PCR using primers P110 and P111, with a fragment size of 1125bp; then, the PCR product of the E75 and Furin-F2A connecting fragment was used as a template, and the E75-Furin-F2A fragment was amplified by primers P105 and P109 with high-fidelity PCR, with a fragment size of 503bp; again, the PCR product of E75-Furin-F2A and HLAA2 was used as a template, and the E75-Furin-F2A-HLAA2 fragment was amplified by primers P105 and P111 with high-fidelity PCR, with a fragment size of 1587bp. The final PCR fragment of E75-Furin-F2A-HLAA2 was purified, digested with XhoI, and ligated into the XhoI site on the pShuttle-EF1a-MCS-BGHpA-CMV-E1A-SV40pA vector to obtain pShuttle-EF1a-E75-HLA-A2-BGHpA-CMV-E1A-SV40pA, and the E75-HLAA2 fragment was sequenced to confirm its correctness.
[0262] 3) Obtaining oncolytic adenovirus genomic DNA expressing Her2-E75 minigene alone (with KDEL at the C-terminus) and co-expressing Her2-E75 minigene (with KDEL at the C-terminus) and HLA-A2
[0263] The pShuttle-EF1a-E75-BGHpA-CMV-E1A-SV40pA and pShuttle-EF1a-E75-HLA-A2-BGHpA-CMV-E1A-SV40pA plasmids (1 μg each) obtained in the previous step and confirmed by sequencing were digested with PmeI, reacted at 37°C for 2-3 hours, extracted with phenol / chloroform and precipitated with ethanol / ammonium acetate, rinsed three times with 70% ethanol and the supernatant was discarded. After drying at room temperature for 3 minutes, 10 μl of clean deionized water was added to completely dissolve the linearized DNA fragments; then 100 μl of super competent bacteria of BJ5183 (containing pAdEasy-1 plasmid) (purchased from Agilent) was added to each tube, mixed gently, and placed on ice for 30 minutes. After incubation at 42°C for 90 seconds, it was returned to ice and incubated for 2 minutes. 500 μl LB medium, 37℃, 150RPM shaking culture for 45 minutes, then spread it on the kanamycin-resistant LB plate and culture at 37℃ overnight. On the second day, pick the smaller clones that appear on the LB plate and inoculate them in 4ml of kanamycin-resistant LB medium, and culture them at 37℃, 200RPM shaking overnight. On the third day, use the plasmid small-scale extraction kit to extract the plasmid DNA from each tube of bacterial liquid. First, perform agarose gel electrophoresis analysis on the obtained plasmid DNA to discard the obviously smaller plasmids, and perform PacI enzyme digestion analysis on the larger plasmids. The pAdEasy plasmid with correct recombination will produce a smaller fragment of 4.5kb or 3kb after PacI enzyme digestion.
[0264] In this part, two correctly recombined plasmids were obtained (a smaller band of 4.5 kb was produced after PacI digestion): OAd-E75 and OAd-E75A2. The above two plasmids contain type 5 oncolytic adenovirus that can be used to package and express Her2-E75 or co-express HLA-A2 and Her2-E75.
[0265] 4) Packaging, amplification and purification of oncolytic adenoviruses expressing Her2-E75 minigene (with KDEL at the C-terminus) and co-expressing Her2-E75 minigene (with KDEL at the C-terminus) and HLA-A2
[0266] Linearization of adenovirus genomic DNA: 2-3 μg of plasmid DNA (OAd-E75 and OAd-E75A2) obtained in the previous step were completely digested with PacI, reacted at 37°C for 2-3 hours, extracted with phenol / chloroform and precipitated with ethanol ammonium acetate, rinsed the linearized DNA twice with 70% ethanol, dried at room temperature for 3 minutes, dissolved in 10 μl of clean deionized water, and used the DNA to directly transfect AD293 cells or stored the linearized DNA at -20°C for later use.
[0267] Adenovirus packaging: The day before adenovirus packaging, well-growing AD293 cells were inoculated in a 6-well plate. The cell density was preferably such that the cell coverage rate reached 70% when the transfection experiment was performed the next day. PacI linearized DNA was transfected into AD293 cells using Lipo2000 or similar transfection reagent (the transfection reagent does not need to be removed). The DNA-transfected AD293 cells were returned to the CO2 incubator and continued to be cultured for about 14 days, until the AD293 cells showed large-area lesions and floated, indicating that the adenovirus packaging was successful. The lesioned AD293 cells and virus mixture in the 6-well plate were blown to make them float completely and then collected into a clean centrifuge tube. The cell suspension can be briefly and violently shaken to release as much adenovirus as possible from the cells. The mixture can be stored at 4°C for a short time and -80°C for a long time.
[0268] Adenovirus amplification: AD293 cells with good growth were inoculated into a 60 mm culture dish one day before amplification. The cell coverage rate was about 80% when infected with adenovirus on the second day. Pipette about 1 ml of the adenovirus mixture collected from the 6-well plate and add it directly to the 60 mm culture dish inoculated with AD293. After slight shaking and mixing, return it to the CO2 incubator for continued cultivation. After about 2-3 days, most of the cells can be seen floating after lesions. In the same way, blow the cells to collect all the cell suspension in a clean centrifuge tube; then add the collected 2 ml of virus suspension to a 10 cm culture dish with an AD293 cell coverage rate of 80%. After continuing to culture in the CO2 incubator for about 2-3 days, most of the cells can be seen floating after lesions; collect the virus suspension in the 10 cm culture dish; similarly, pipette 2 ml of virus suspension and add it to a 10 cm culture dish with an AD293 cell coverage rate of 80%. After continuing to culture in the CO2 incubator for about 2-3 days, most of the cells can be seen floating after lesions; collect the virus suspension in the 15 cm culture dish. At this time, the adenovirus titer in the cell supernatant reaches about 10 8 PFU / ml. At this point, the virus suspension in the 15 cm culture dish can be used to amplify a large number of adenoviruses. Usually, depending on the experimental needs and the virus yield, it is necessary to amplify and collect the cell suspension of 40-80 15 cm culture dishes before purifying the adenovirus by CsCl density gradient centrifugation.
[0269] Purification of adenovirus: The virus suspension collected in the previous step was centrifuged and divided into two parts: supernatant and cell pellet. The adenovirus in the supernatant was precipitated with PEG8000 / NaCl and resuspended in 10mM Tris·Cl (pH8.0); the cell pellet was resuspended in 10mM Tris·Cl (pH8.0) and repeatedly frozen and thawed 3-5 times to completely release the adenovirus in the cells, and the cell suspension was centrifuged again, and the supernatant was retained for the following CsCl density gradient centrifugation purification. Next, the obtained adenovirus suspension was centrifuged twice with light CsCl (1.2g / ml) and heavy CsCl (1.45g / ml), respectively, and the white Ad band after the second centrifugation was aspirated with a syringe. Finally, the CsCl that dissolved the adenovirus was replaced with adenovirus preservation solution (10mM Tris (pH7.4), 1mMMgCl2, 10% Glycerol, filtered and sterilized, and stored at 4°C) using a PD-10 desalting column, and stored at -80°C after aliquoting.
[0270] Titration of adenovirus titer: Titration of adenovirus titer is done using an adenovirus titer titration kit. The basic principle is to dilute the adenovirus to a suitable titer and infect AD293 cells, and then detect the expression of Hexon protein on the cell surface 48 hours later. The titer (PFU / ml) of active adenovirus is determined by counting the number of cells expressing Hexon protein within a specified area.
[0271] 5) Detection of HLAA2 protein expression in adenovirus
[0272] A HLAA2-negative cell line (SKOV3) was selected, and cells were inoculated in a 24-well cell culture plate one day before the experiment. On the second day, adenovirus OAd-E75 and OAd-E75A2 were added to the wells inoculated with cells according to different infection multiplicities (MOI = 5, 10, and 20). In this experiment, H101 was used as a negative control virus. After mixing, the cells were cultured in a CO2 incubator for 48 hours, and then the cells were recovered. The cells were incubated with anti-HLAA2 flow cytometry antibodies according to the conventional FACS process and analyzed on the machine. Finally, the expression of HLA-A2 on the surface of SKOV3 cells was determined, and the result was positive.
[0273] Example 1: Induction of Her2 / neu369-377 polypeptide (Her2-E75 epitope polypeptide)-specific killer T cells from peripheral blood of HLA-A2-positive normal donors
[0274] In this example, a low concentration of 1 μg / ml Her2 / neu 369-377 peptide was used to induce peptide-specific killer T cells from HLA-A2 positive normal PBMC (#2) through two rounds of in vitro stimulation, and flow cytometry analysis and single cell isolation were performed. The specific method is as described above. The results are as follows:
[0275] Figure 1 A right figure shows that 0.024% of lymphocytes are CD8 positive killer T cells that can bind to Her2 / neu369-377 / HLA-A2 pentamer (i.e. Her2-E75 pentamer). In the left figure, the control cells that were not stimulated with Her2 polypeptide did not show CD8 positive pentamer positive cells. The results show that in the natural T cell pool, the number of specific T cells that recognize Her2 / neu 369-377 antigen polypeptide is very small. Despite the small number, this group of T cells that can recognize Her2 / neu 369-377 polypeptide can still be clearly distinguished. In addition, according to the fluorescence intensity of binding to Her2-E75 pentamer, the positive cells include high affinity T cells and low affinity T cells. 300 CD8-positive pentamer-positive cells were separated by flow cytometry and then cultured as monoclonal cells. After two rounds of antigen peptide restimulation and cytokine amplification, a proliferating T cell clone Her2 CTL clone 6A5 (referred to as Her2 CTL 6A5) was obtained from these 300 separated single T cells. Figure 1 B right figure shows 97.9% CD8 + CTL cells can bind to Her2 / neu 369-377 / HLA-A2 tetramers (i.e. Her2-E75 tetramers), indicating that this purified T cell clone is not mixed with other irrelevant cells. The left picture shows control T cells that cannot bind to Her2-E75 tetramers.
[0276] Example 2: Obtaining the complete sequence of Her2 / neu 369-377 polypeptide-specific TCR
[0277] In this example, total RNA was directly purified from a certain number of Her2 CTL 6A5 cells obtained in Example 1, and paired TCR α chain and β chain gene sequences (i.e., the two chains can together form a functional TCR that recognizes antigenic polypeptides) were obtained by 5'-RACE RT-PCR, and the encoded TCR was called "Her2 TCR-6A5". The amino acid sequence of the α chain of the TCR is shown in SEQ ID NO:4, the coding sequence is shown in SEQ ID NO:12, and the amino acid sequence of the β chain of the TCR is shown in SEQ ID NO:7, and the coding sequence is shown in SEQ ID NO:15. This TCR exists in the peripheral T cell pool of HLA-A2 positive normal people, and will not cross-react with normal cells that express Her2 / neu protein in trace amounts and cause autoimmune reactions. In order to detect the antigen specificity and function of the obtained TCR, the TCR α chain and β chain sequences were cloned into a replication-deficient lentiviral expression vector. Figure 1C shows a schematic diagram of the constructed TCR lentiviral vector structure fragment. The constant regions of the TCR α chain and β chain are replaced by mouse sequences from human sequences and connected by a cleavable connecting polypeptide. The expression of the 6A5 TCR α chain and β chain is driven by the EF-1α promoter. This promoter is a high-expression promoter in eukaryotic cells and will not be affected by factors such as methylation and cause loss of function. It is suitable for long-term expression of exogenous genes in vivo. The TCR α chain and β chain are connected by the F2A polypeptide sequence. The TCR α chain and β chain genes can be transcribed at the same time and translated by ribosome skipping, so that the TCR α chain and β chain polypeptides are separated from each other. This ensures the consistency of the expression of the TCR α chain and β chain, thereby forming the TCR dimer more efficiently. There is also a furin restriction site between the TCR α chain and the β chain to remove the redundant peptide segment at the carboxyl end of the β chain.
[0278] The nucleotide sequence of the TCR β chain and α chain (SEQ ID NO: 20) linked by a cleavable linking polypeptide and with the constant region replaced by the human sequence with the mouse sequence (the corresponding TCR is Her2 TCR-6A5-mC, and the amino acid sequence is shown in SEQ ID NO: 23) is connected to the above-mentioned vector to obtain a Her2 TCR-6A5-mC recombinant lentiviral vector. The Her2TCR-6A5-mC gene fragment was amplified by PCR and cloned into the downstream of the EF1-promoter of the above-mentioned lentiviral vector (i.e., pCDH-EF1α-MCS): the β fragment of Her2TCR-6A5-mC carrying the mouse constant region sequence was amplified by the 5' primer 5'-AGAGCTAGCGAATTCAACATGGGCTGCAGGCTGCTC-3' (SEQ ID NO: 52) and the 3' primer 5'-GGATCGCTTGGCACGTGAATTCTTTCTTTTGACCATAGCCAT-3' (SEQ ID NO: 53); the α gene of Her2TCR-6A5-mC carrying the mouse constant region sequence was amplified by the 5' primer 5'-TCCAACCCTGGGCCCATGCTCCTGTTGCTCATACCAGTG-3'
[0279] (SEQ ID NO:54) and 3' primer 5'-GTTGATTGTCGACGCCCTCAACTGGACCACAGCCT-3' (SEQID NO:55). PCR was performed using the Q5 High Fidelity PCR Kit (NEB, cat#M0543S) under the following reaction conditions: 98°C for 30 seconds, followed by 25 cycles of 98°C for 10 seconds, 65°C for 10 seconds, and 72°C for 3 minutes. The obtained TCR fragment was cloned into the MCS region downstream of the EF1α promoter of the pCDH-EF1α-MCS vector.
[0280] The constructed recombinant TCR lentiviral expression vector was prepared according to the above method to obtain the respective recombinant TCR lentiviral particles.
[0281] Example 3: Normal peripheral blood T cells were transfected with Her2 TCR-6A5-mC recombinant lentivirus to express a specific TCR that can recognize the Her2 / neu 369-377 polypeptide
[0282] In order to further verify whether the TCR obtained by the present invention can be expressed in primary T cells and has the function of recognizing Her2 / neu antigen polypeptide, peripheral blood T cells from two different normal donors activated by CD3 / CD28 antibodies were transfected with recombinant lentiviral particles carrying the Her2 TCR-6A5-mC gene (Her2 TCR-6A5-mC recombinant lentiviral vector), and the cells were collected 14 days later for Her2-E75 tetramer staining. The specific method is as described above. The results are as follows:
[0283] Figure 2 A shows that lymphocytes in the peripheral blood mononuclear cells of both donors (#1PBMC and #2PBMC) can bind to Her2-E75 tetramers, indicating that the Her2 TCR-6A5-mC expressed by these cells can specifically recognize the Her2 / neu antigen peptide presented by HLA-A2. The results also show that among the Her2-E75 tetramer-positive cells (i.e., cells expressing Her2 TCR-6A5-mC), CD8 + Positive rate of T killer cells and CD8 - The positive rates of lymphocytes are similar. - The lymphocytes are likely to be CD4 + T helper cells, if lentivirus-infected CD8 + and CD4 + The transfection efficiency of T cells is the same, indicating that CD4 +The exogenous Her2 / neu 369-377 specific TCR on the cell can effectively bind to the Her2-E75 tetramer. This further shows that the transfected Her2 TCR-6A5-mC can effectively bind to the Her2 / HLA-A2 complex without the auxiliary function of the CD8 molecule, that is, the recognition of the Her2 / neu 369-377 epitope peptide presented by HLA-A2 by Her2TCR-6A5-mC is CD8-independent. CD4 cells expressing Her2TCR-6A5-mC TCR secrete cytokines after recognizing the Her2 antigen, which can not only assist the function of killing T cells and the survival time in the body, but also induce specific T cells against endogenous tumor antigens by regulating the tumor microenvironment, thereby enhancing anti-tumor immunity.
[0284] 10e5 TCR-transfected PBMC cells were added to each well of a 96-well plate, and after mixed culture with different concentrations of Her2 / neu 369-377 antigen polypeptide presented by T2 cells (1×10e5 per well) (Her2 / neu 369-377 antigen polypeptide was diluted 10 times starting from 0.1 μg / ml, thereby obtaining different groups with final concentrations of 0.1 μg / ml, 0.01 μg / ml, 0.001 μg / ml and 0.0001 μg / ml), IFN-γ secreted by T cells in the supernatant was detected to determine the function of the TCR-expressing PBMC cells to specifically recognize the Her2 / neu 369-377 polypeptide. Figure 2B shows that PBMC expressing Her2 TCR-6A5-mC can be activated by Her2 / neu 369-377 antigen peptide presented by T2 cells to secrete IFN-γ, indicating that primary T cells expressing exogenous Her2TCR-6A5-mC can specifically recognize Her2 / neu 369-377 peptide presented by HLA-A2 molecules. The ability to recognize antigen peptides is related to the expression level of exogenous TCR on T cells. The half-maximum reaction (EC50) peptide concentrations of two different donors' PBMCs transfected with Her2 TCR-6A5-mC for recognizing antigen peptides were estimated by curve fitting to be approximately 1.6 ng / ml and 2.9 ng / ml, respectively (IC50 Tool program, http: / / www.ic50.tk / ). Although this reaction sensitivity is lower than the EC50 of high-affinity TCRs that recognize exogenous antigens such as viral antigens (EC50 is approximately 10e-10M) (see the literature "CANCERRESEARCH 1998, 58.4902-4908" and "HUMAN GENE THERAPY 2014, 25:730-739"), it is still within the medium-to-high TCR affinity range that can recognize common tumor-associated antigens (as described in the literature "Eur J Immunol (2012) 42:3174-9").
[0285] Figure 2 C shows that when T cells were co-cultured with antigenic polypeptides presented by T2 cells (T2+Her2-E75, i.e., Her2 / neu 369-377 polypeptide), the function of T cells to secrete IFN-γ was not significantly inhibited after adding anti-human CD8 antibodies. This indicates that the function of exogenous TCR to recognize Her2 / neu369-377 antigenic polypeptides does not require the auxiliary effect of CD8 molecules, and also shows that the recognition function of the Her2 TCR-6A5-mC TCR described in the present invention is a non-CD8 function-dependent TCR.
[0286] Example 4: Her2 / neu 369-377 peptide-specific TCR expressed by normal peripheral blood T cells after transfection with Her2 TCR-6A5-mC recombinant lentivirus can recognize HLA-A2 + Her2 / neu + Tumor cells
[0287] First, the expression of HLA-A2 and Her2 / neu in the selected tumor cell lines was detected. The tumor cell lines included colorectal cancer Colo205 and HCT116, breast cancer MDA-MB-231 and MCF-7, pancreatic cancer PANC-1, glioma U87MG, and small cell lung cancer NCI-H446. Tumor cells were stained with anti-HLA-A2 antibody (BD Bioscences, cat#561341) and anti-human CD340 (erbB2) antibody (Biolegend, cat#324406) and then analyzed by flow cytometry. Figure 3 A The results showed that Colo205, MDA-MB-231, MCF-7, HCT116, and PANC-1 were all HLA-A2 + Her / neu + ; U87MG is HLA-A2 + , Her2 / neu - ; NCI-H446 is negative for HLA-A2 and Her2 / neu. These tumor cell lines not only originate from different tissues, but also express different HLA-A2 and Her2 / neu. Among them, U87MG and NCI-H446 cells can be used as negative controls for Her2 TCR-6A5-mC T cell function detection.
[0288] After adding 1×10e4 tumor cells to each well of a 96-well plate, a certain number of PBMC cells transfected with Her2 TCR-6A5-mC TCR or PBMC cells not transfected with Her2 TCR-6A5-mCTCR were added to each well of the 96-well plate as a control group according to the effector-target ratio (5:1). The effector-target ratio was 5:1. T cells were mixed with different tumor cell lines, and then the secreted IFN-γ in the supernatant was detected. The specific method is as described above. The results are as follows:
[0289] Figure 3 B shows that T cells expressing Her2 TCR-6A5-mC can be identified by HLA-A2 + Her2 / neu + The tumor cell lines activated and secreted IFN-γ, including colon cancer Colo205 and HCT116, breast cancer MDA-MB-231 and MCF-7, and pancreatic cancer PANC-1. + Her2 / neu - Glioma U87MG, and HLA-A2 - Her2 / neu -The lung cancer NCI-H446 was unable to activate T cells transfected with Her2 TCR-6A5-mC, indicating that the Her2 TCR-6A5-mC TCR can specifically recognize the Her2 / neu antigen presented by HLA-A2 on the surface of tumor cells. The control group T cells derived from the same donor PBMC, cultured in parallel but not transfected with Her2 TCR-6A5-mC, could not be activated by the listed tumor cell lines, indicating that the response to tumor cells is not non-specific. The results also showed that the ability of Her2 TCR-6A5-mC T cells to recognize the Her2 / neu antigen presented by HLA-A2 is not closely related to the expression of HLA-A2 and Her2 / neu molecules on the surface of tumor cells. Different tumor cells may have different inhibitory effects on T cells. On the other hand, the expression level on the cell surface does not necessarily reflect the total expression level of Her2 / neu. The Her2 / neu expressed by some tumor cells is mainly present in the cell cytoplasm, and these antigens are more easily presented by HLA-A2 (see the literature "J Immunol 2006; 177:5088-5097").
[0290] 1×10e4 target cells were added to each well of the culture plate, and a certain number of PBMC cells transfected with TCR genes were added according to the set effector-target ratio (1:1, 5:1, 10:1, 20:1, 40:1). After 24 hours, the cytotoxic activity of T cells against tumor cells was measured. Figure 3 CK showed that T cells expressing Her2 TCR-6A5-mC TCR could specifically recognize and kill HLA-A2 compared with control T cells without TCR transfection. + Her2 / neu + The killing ability of tumor cell lines MCF-7, HCT116, PANC-1 and HEPG-2 was in a dose-dependent relationship with the number of Her2 TCR-6A5-mC T cells. + Her2 / neu - The glioma U87MG, HLA-A2-Her2 / neu+ SKOV3 and HT-29, and HLA-A2 - Her2 / neu - The lung cancer NCI-H446 could not be specifically killed by Her2 TCR-6A5-mC T cells. The results also showed that when Her2 TCR-6A5-mC T cells increased to a certain number, they could kill HLA-A2 + Her2 / neu +The tumor cells showed significant specific recognition and killing function. When the effector-target ratio was lower than 10:1, the specific killing function was not obvious, which may be related to the number of Her2 / neu epitope peptides presented by HLA-A2 on the surface of tumor cells. In order to further enhance the recognition and killing sensitivity of Her2 TCR-6A5-mC T cells to tumor cells, one strategy is to increase the number of tumor target cells expressing HLA-A2 and Her2 / neu.
[0291] Example 5: Transfection of gene vectors expressing HLA-A2 and Her2 / neu antigen epitope polypeptides can cause target cells to express exogenous HLA-A2 and Her2 / neu epitope polypeptides
[0292] In order to further enhance the recognition and killing sensitivity of Her2 TCR-6A5-mC T cells to tumor cells, it can be achieved by making tumor cells express exogenous Her2 / neu antigens to increase the Her2 / neu antigen epitopes presented by HLA-A2. Since tumor cells often have low expression or loss of endogenous HLA class I molecules, the transfection vector can simultaneously express exogenous HLA-A2 genes to increase the expression of HLA class I molecules. In addition, tumor cells often have functional defects in the HLA class I antigen presentation pathway. As a result, tumor antigen proteins cannot be effectively degraded into epitope peptides and presented to the cell surface by HLA class I molecules. If the epitope peptide is directly introduced into the endoplasmic reticulum through a signal peptide, it can be directly complexed with HLA molecules and β2 microglobulin in the endoplasmic reticulum without being degraded by intracytoplasmic proteases and the transport function of TAP molecules, and presented to the surface of tumor cells. Minigenes expressing antigen epitope polypeptides can be connected by furin enzyme cleavage fragments to form multiple minigenes of antigen epitope polypeptides in series. After entering the endoplasmic reticulum, more epitope polypeptides are released by furin enzymes. Adding the endoplasmic reticulum retention signal KDEL fragment at the end of the epitope polypeptide chain in series can prevent the epitope polypeptide chain from being transferred to the downstream secretory organelles, thereby increasing the chance of forming HLA / peptide complexes.
[0293] Three lentiviral vector plasmids were prepared according to the method of Preparation Example 1: "pCDH-EF1p-A2-PKGp-E75×1" (carrying the HLA-A2 coding sequence and 1 Her2-E75 antigen epitope polypeptide coding sequence), "pCDH-EF1p-A2-PKGp-E75×4" (carrying the HLA-A2 coding sequence and 4 repeated Her2-E75 antigen epitope polypeptide coding sequences) and "pCDH-EF1p-A2-PKGp-E75×8" (carrying the HLA-A2 coding sequence and 8 repeated Her2-E75 antigen epitope polypeptide coding sequences), collectively referred to as "pCDH-EF1p-A2-PKGp-E75 vector". Figure 4 B is a schematic diagram of the overall structure of the lentiviral vector containing HLA-A2 and Her2 / neu antigen epitope polypeptide (Her2-E75) minigenes (pCDH-EF1p-A2-PKGp-E75 vector). HLA-A2 is driven by the EF-1α promoter, and the antigen epitope polypeptide (Her2-E75 in the figure) minigene is driven by the PKG promoter. Figure 4 B The figure below is a schematic diagram of the composition of the Her2 / neu antigen epitope polypeptide minigene in "pCDH-EF1p-A2-PKGp-E75×8", showing 8 Her2-E75 antigen epitope polypeptides (Her2-E75×8 minigenes) connected by Furin enzyme cleavage fragments.
[0294] The three lentiviral plasmid vectors constructed above were used to transfect 293T cells respectively, and used as target cells to detect the recognition function of Her2TCR-6A5 T cells. 293T cells are human kidney epithelial cell lines, which are HLA-A2 negative and Her2 / neu negative. PBMC cells transfected with Her2TCR-6A5-mC TCR and 293T cells transfected with pCDH-EF1p-A2-PKGp-E75 were mixed and cultured, and the effector-target ratio was 10:1. After 24 hours, the supernatant was collected to detect the secretion of IFN-γ. The number of antigen epitope polypeptide minigenes on the plasmid pCDH-EF1p-A2-PKGp-E75 was 1, 4, and 8, respectively (shown in the figure as 293-A2-PKG-E75×1, 293-A2-PKG-E75×4, and 293-A2-PKG-E75×8, respectively). 293T cells without transfection of plasmid were used as negative control group (shown as 293 control in the figure), and T2 cells presenting 0.1 μg / ml of Her2 / neu 369-377 antigen polypeptide were used as positive control group (shown as T2+Her2-E75 in the figure). Figure 4A shows that Her2 TCR-6A5-mC T cells can specifically recognize 293T cells transfected with plasmid vectors expressing HLA-A2 and Her2 / neu antigen epitope peptides and secrete IFN-γ, indicating that HLA-A2 and Her2 / neu 369-377 epitope peptides are expressed by 293T cells and presented to the cell surface in the form of HLA / peptide complexes and recognized by Her2 TCR-6A5-mC TCR. In addition, the more epitope peptides there are in the minigene, the stronger the recognition activity of T cells is, indicating that the number of HLA-A2 / epitope peptide complexes presented on the cell surface can increase with the increase in the expression of Her2 / neu antigen epitope peptides.
[0295] In order to enable the replication-defective adenovirus vector to express HLA-A2 and Her2 / neu antigen epitope polypeptides, the HLA-A2 gene and the Her2 / neu antigen epitope polypeptide minigene (with KDEL at the C-terminus) were loaded into the E1 region of the type 5 adenovirus vector. The replication-defective adenovirus Adeasy-A2-Her2 E75 (abbreviated as "Adeasy-A2E75") was prepared according to the method described in Preparation Example 2. It is a replication-defective adenovirus expressing HLA-A2 and 8 Her2 / neu antigen epitope polypeptides. The vector schematic diagram is shown in Figure 4 D (Adeasy-A2E75 vector). This adenovirus vector is derived from adenovirus type 5 lacking the E1 and E3 region sequences (see the document "Nature Protocols 2007; 2: 1236-1247"). The expression of the HLA-A2 gene and the Her2 / neu antigen epitope polypeptide minigene is driven by an exogenous CMV promoter. The HLA-A2 gene and the Her2 / neu antigen epitope polypeptide minigene are divided by the cleavable fragment Furin enzyme recognition fragment and the F2A fragment. This ensures that the expression levels of the HLA-A2 and Her2 / neu antigen epitope polypeptides are similar, and the length of the exogenous gene nucleic acid sequence can also be kept within the size range of the exogenous gene allowed to be loaded by the adenovirus genome. In addition, the endoplasmic reticulum retention signal KDEL fragment is added to the end of the tandem epitope polypeptide chain to increase the chance of forming an HLA / polypeptide complex. Since the E3-19K protein inhibits the antigen presentation function of HLA, the adenovirus lacking the E3 region sequence will not interfere with the presentation of the expressed exogenous antigen epitope polypeptide after infecting cells.
[0296] In order to verify whether the replication-deficient adenoviral vector Adeasy-A2-Her2 E75 can express foreign genes, the ovarian cancer cell SKOV3 was infected with Adeasy-A2-Her2 E75 adenoviral particles. SKOV3 cells are HLA-A2 negative, and the expression of HLA-A2 on the surface of SKOV3 cells can be detected to determine whether the Adeasy-A2-Her2 E75 adenoviral vector can express foreign genes. SKOV3 cell line was cultured in a 10 cm culture dish. When the confluence was about 80%, the cell was digested with trypsin and then washed with culture medium once. After centrifugation, the cell was resuspended with culture medium McCony5A (Gibco #16600-082) and plated in a 24-well plate, 1×10e5 per well, 500 μl culture medium per well. After 24 hours, Adeasy-A2-Her2 E75 adenovirus was added, and the same volume of virus preparation solution was added at 0 MOI, 5 MOI, 10 MOI, and 20 MOI. After further culturing for 24 hours, the supernatant was discarded, the cell was harvested after trypsin digestion, and the cell was resuspended in 100 μl PBS into a 1.5 ml EP tube. 2 μl APC-anti-human HLA-A2 antibody (BD #561341) was added to each tube. After incubation for 30 minutes, the cell was washed with PBS containing 1% BSA and then detected by flow cytometry. After detection, the cell was analyzed by Flowjo software. Figure 4 C shows that SKOV3 cells can express HLA-A2 24 hours after being infected with Adeasy-A2-Her2 E75 adenovirus, and the amount of HLA-A2 expressed is in a dose-response relationship with the titer of the infected virus. SKOV3 cells infected with a control adenovirus that does not express exogenous genes (shown as Ad control in the figure) do not express HLA-A2, indicating that adenovirus carrying the HLA-A2 gene and the Her2 / neu antigen epitope polypeptide minigene can effectively express exogenous HLA-A2 molecules.
[0297] Example 6: Infecting tumor cells with a replication-deficient adenovirus expressing HLA-A2 and Her2 / neu antigen epitope polypeptide minigenes can significantly enhance the recognition and killing sensitivity of Her2 TCR-6A5-mC T cells to tumor cells.
[0298] To further verify whether the replication-defective adenovirus vector Adeasy-A2-Her2 E75 can increase the number of HLA-A2 / Her2 antigen epitope peptide complexes on the cell surface that can be recognized by Her2 TCR-6A5-mC T cells after infection of tumor cells, thereby enhancing the recognition and killing sensitivity of T cells to tumor cells, tumor cell lines SKOV3, MCF-7 and NCI-H446 were infected with Adeasy-A2-Her2 E75 adenovirus, respectively. After 24 hours, they were mixed with PBMC cells transfected with Her2 TCR-6A5-mC TCR and co-cultured for another 24 hours. The function of Her2 TCR-6A5-mC T cells in specifically secreting IFN-γ and killing target cells was detected.
[0299] Figure 5 A shows that tumor cells infected with Adeasy-A2-Her2 E75 adenovirus can significantly stimulate Her2 TCR-6A5-mC T cells to specifically secrete IFN-γ. The adenovirus infection multiplicity of infection of tumor cells was 10, and the effector-target ratio of co-cultured with PBMC cells transfected with Her2TCR-6A5-mC TCR was 5:1. The tumor cell line is HLA-A2 + Her2 / neu + MCF-7 cells, HLA-A2 - Her2 / neu + SKOV3 cells and HLA-A2 - Her2 / neu - The results showed that tumor cells infected with Adeasy-A2-Her2 E75 adenovirus alone almost secreted no interferon-γ (experimental group "Adeasy-A2E75"). PBMC cells transfected with Her2 TCR-6A5-mC TCR could not effectively recognize HLA-A2 at a low target ratio. + Her2 / neu +MCF-7 cells with Her2TCR-6A5 secrete interferon-γ (experimental group "PBMC with Her2TCR-6A5"). For SKOV3 cells, PBMC cells transfected with Her2 TCR-6A5-mC TCR ("PBMC with Her2TCR-6A5") also failed to specifically secrete interferon-γ compared with control PBMC (experimental group "PBMC control"). However, when tumor cells were infected with Adeasy-A2-Her2E75 adenovirus, the recognition function of Her2TCR-6A5-mC T cells was significantly enhanced, regardless of whether the tumor cells expressed endogenous HLA-A2 and Her2 / neu (experimental group "PBMC with Her2TCR-6A5+Adeasy-A2E75"). In each target cell group, the activity of Her2 TCR-6A5-mC T cells in recognizing tumor cells infected with Adeasy-A2-Her2 E75 adenovirus was significantly higher than that of target cells not infected with the virus (p<=0.001). However, tumor cells infected with Adeasy-A2-Her2 E75 adenovirus could not increase the recognition activity of control PBMC cells not transfected with Her2TCR-6A5-mC TCR (experimental groups "PBMC control" and "PBMC control + Adeasy-A2E75") against tumor cells, indicating that the increase in the secretion of interferon-γ after adenovirus infection was produced by enhancing the recognition activity of Her2 TCR-6A5-mC TCR against tumor cells. The results showed that after Adeasy-A2-Her2 E75 adenovirus infected tumor cells, it not only made HLA-A2-negative cells SKOV3 and NCI-H446 express exogenous HLA-A2, but also increased the number of HLA-A2 / Her2 / neu 369-377 polypeptide complexes recognized by Her2 TCR-6A5-mC T cells on the surface of tumor cells by expressing the Her2 / neu antigen epitope polypeptide minigene, thereby enhancing the recognition sensitivity of Her2 TCR-6A5-mC T cells.
[0300] In order to further verify whether the replication-defective adenovirus vector Adeasy-A2-Her2 E75 increases the killing function of Her2 TCR-6A5-mC T cells against target cells after infecting tumor cells, tumor cell lines SKOV3, MCF-7 and NCI-H446 were infected with Adeasy-A2-Her2 E75 adenovirus, and 24 hours later, they were mixed with PBMC cells transfected with Her2 TCR-6A5-mC TCR and cultured for another 24 hours. The number of surviving adherent cells was detected by trypan blue to determine the killing function of T cells against target cells. The virus infection multiplicity MOI of tumor cells was 10, and the effector-target ratio of mixed culture was 8:1.
[0301] Figure 5 B shows that Adeasy-A2-Her2 E75 adenovirus alone can cause the death of most NCI-H446 cells (target cells are NCI-H446 experimental group Adeasy-A2E75). This may be because E1 / E3-deficient replication-deficient adenovirus can sometimes cause apoptosis of certain cells, especially when the infection titer is high (see the document "Gene Ther. 1999 Jun; 6 (6): 1054-63"). Figure 5 The adenovirus-infected NCI-H446 cells shown in A can stimulate the Her2 TCR-6A5-mC T cells co-cultured with them to secrete interferon-γ, but since this target cell is too sensitive to Adeasy-A2-Her2E75, Figure 5 The experimental results shown in B cannot determine whether the target cell death is the killing of target cells infected with adenovirus by Her2 TCR-6A5-mCT cells or adenovirus-induced cell apoptosis (the target cells are the experimental group "PBMC with Her2 TCR-6A5+Adeasy-A2E75" of NCI-H446). Figure 5 B It can be seen that when the target cells in this experiment are MCF-7, the cell killing rate of the replication-deficient adenovirus expressing HLA-A2 and Her2 E75 polypeptides alone is about 32.8%, and the cell killing rate of the peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone is about 30.9%. Compared with the cell killing rate of the single drug, the cell killing rate of the two drugs at the same time is improved, and the cell killing rate is about 95.8%, showing a significant synergistic effect. When the target cells in this experiment are SKOV3, the cell killing rate of the replication-deficient adenovirus expressing HLA-A2 and Her2 E75 polypeptides alone is about 29.7%, and the cell killing rate of the peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone is about 34.3%. Compared with the cell killing rate of the single drug, the cell killing rate of the two drugs at the same time is improved, and the cell killing rate is about 66%, also showing a significant synergistic effect.
[0302] These results show that Her2 TCR-6A5-mC T cells can specifically kill tumor cells infected with Adeasy-A2-Her2 E75 adenovirus, regardless of whether the tumor cells express endogenous HLA-A2 and Her2 / neu antigens. If the adenovirus expressing HLA class I molecules and tumor antigen epitope polypeptide minigenes is an oncolytic adenovirus, tumor cells infected with oncolytic viruses can not only be selectively killed by oncolytic viruses, but also tumor cells that cannot be effectively lysed by oncolytic viruses can be recognized and killed by T cells transfected with TCRs that can recognize specific tumor antigen epitopes by expressing specific exogenous tumor antigen epitope polypeptides. This is the theoretical and experimental basis for the combined use of Adeasy-A2-Her2 E75 adenovirus and Her2 TCR-6A5-mC T cells described in the present invention to enhance tumor killing function.
[0303] Example 7: Infecting tumor cells with an oncolytic adenovirus expressing a Her2 / neu antigen epitope polypeptide minigene can significantly enhance the recognition and killing sensitivity of Her2 TCR-6A5-mC T cells to tumor cells.
[0304] In order to further verify whether the oncolytic adenovirus Ad-E75 expressing the Her2 / neu antigen epitope polypeptide minigene alone increases the number of HLA-A2 / Her2 antigen epitope polypeptide complexes that can be recognized by Her2TCR-6A5-mC T cells on the cell surface after infecting tumor cells, thereby enhancing the recognition and killing sensitivity of T cells to tumor cells, firstly, an oncolytic adenovirus (OAd-E75, also referred to as "Ad-E75") expressing the Her2 / neu antigen epitope polypeptide minigene (with KDEL at the C-terminus) was prepared according to the method described in Preparation Example 3. The Her2 / neu antigen epitope polypeptide minigene driven by the CMV promoter and the adenovirus E1A gene driven by the EF-1α promoter were simultaneously inserted into the E1 region of the replication-deficient adenovirus. The continuously expressed E1A protein can cause the E1B-deficient adenovirus to selectively replicate and proliferate in certain tumor cells to produce an oncolytic effect. The tumor cell lines MCF-7, SKOV3 and NCI-H446 were infected with Ad-E75 oncolytic adenovirus, and then co-cultured with PBMC cells transfected with Her2TCR-6A5-mC TCR for 24 hours to detect the function of Her2TCR-6A5-mC T cells in specifically secreting IFN-γ and killing target cells.
[0305] Figure 6A shows that HLA-A2 positive tumor cell MCF-7 can significantly stimulate the secretion of IFN-γ by Her2TCR-6A5-mC T cells after infection with Ad-E75 oncolytic adenovirus, while HLA-A2 negative cells SKOV3 and NCI-H446 cannot increase the sensitivity of Her2 TCR-6A5-mC T cell specific recognition after infection with Ad-E75 virus. The adenovirus infection multiplicity MOI of tumor cells was 10, and the effector-target ratio of co-culture with PBMC cells transfected with Her2 TCR-6A5-mC TCR was 5:1. The tumor cell line is HLA-A2 + Her2 / neu + MCF-7 cells, HLA-A2 - Her2 / neu + SKOV3 cells and HLA-A2 - Her2 / neu -NCI-H446 cells. The results showed that tumor cells almost did not secrete interferon-γ after being infected with Ad-E75 adenovirus alone (experimental group "Ad-E75"). PBMC cells transfected with Her2 TCR-6A5-mC TCR could not effectively recognize MCF-7 and secrete interferon-γ under the condition of low efficiency target ratio ("PBMC with Her2TCR-6A5"). However, when HLA-A2-positive tumor cells were infected with Ad-E75 oncolytic adenovirus, the recognition function of Her2 TCR-6A5-mC T cells was significantly enhanced (experimental group "PBMC with Her2TCR-6A5+Ad-E75"), and the activity of Her2 TCR-6A5-mC T cells in recognizing tumor cells infected with Ad-E75 oncolytic adenovirus was significantly higher than that of target cells not infected with the virus (p<=0.01). However, Ad-E75 oncolytic adenovirus infection of tumor cells could not increase the recognition activity of control PBMC cells that were not transfected with Her2 TCR-6A5-mC TCR against tumor cells (experimental groups "PBMC control" and "PBMC control + Ad-E75"), indicating that the increase in the secretion of interferon-γ after adenovirus infection was produced by enhancing the recognition activity of Her2 TCR-6A5-mC TCR against tumor cells. The results show that after Ad-E75 oncolytic adenovirus infection of tumor cells, it can increase the number of HLA-A2 / Her2 / neu 369-377 polypeptide complexes recognized by Her2 TCR-6A5-mC T cells on the surface of HLA-A2-positive tumor cells by expressing the Her2 / neu antigen epitope polypeptide minigene, thereby enhancing the recognition sensitivity of Her2TCR-6A5-mC T cells. Infection of HLA-A2-negative cells SKOV3 and NCI-H446 with Ad-E75 oncolytic adenovirus did not enhance the cells' recognition sensitivity to Her2TCR-6A5-mC T cells, indicating that Her2 / neu antigen epitope peptides require presentation by endogenous HLA-A2 molecules, further showing that Her2 TCR-6A5-mC T cells' recognition of Her2 / neu antigen epitopes is HLA-A2-restricted specific recognition.
[0306] In order to further verify whether the oncolytic adenovirus Ad-E75 increases the killing function of Her2 TCR-6A5-mCT cells against target cells after infecting tumor cells, tumor cell lines SKOV3, MCF-7 and NCI-H446 were infected with Ad-E75 oncolytic adenovirus, mixed with PBMC cells transfected with Her2 TCR-6A5-mC TCR after 24 hours and cultured for another 24 hours. The number of surviving adherent living cells was detected by trypan blue to determine the killing function of T cells against target cells. The virus infection multiplicity MOI of tumor cells was 10, and the effector-target ratio of mixed culture was 5:1.
[0307] Figure 6 B shows that Ad-E75 oncolytic adenovirus alone can cause the death of most SKOV3 and NCI-H446 cells (the experimental group "Ad-E75" of SKOV3, U87MG and NCI-H446). This shows that Ad-E75 has a significant oncolytic effect on these tumor cells. In this experiment, when the target cells were MCF-7, the cell killing rate of Ad-E75 oncolytic adenovirus alone was about 20.9%, and the cell killing rate of peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone was about 30.9%. Compared with the cell killing rate of applying one drug alone, the cell killing rate of the two drugs at the same time was increased, and the cell killing rate was about 85.4%, showing a significant synergistic effect. Because other target cells SKOV3 and NCI-H446 are too sensitive to Ad-E75 oncolytic adenovirus, under this MOI condition, when Her2 TCR-6A5-mC T cells are mixed with these target cells infected with Ad-E75, the killing function they show is temporarily no different from that of cells infected with oncolytic adenovirus alone, indicating that the killing activity is mainly caused by the oncolytic effect of the oncolytic virus.
[0308] These results indicate that Her2 TCR-6A5-mC T cells can specifically recognize the Her2 / neu antigen epitope expressed by the oncolytic adenovirus presented by endogenous HLA-A2, thereby killing tumor cells infected with Ad-E75 oncolytic adenovirus. And these results show that after the oncolytic adenovirus carrying the Her2 / neu antigen epitope polypeptide minigene infects tumor cells, the Her2 / neu antigen epitope polypeptide can be expressed and presented by endogenous HLA-A2 molecules, thereby enhancing the recognition and killing sensitivity of T cells to tumor cells. It also shows that the killing function of Her2 TCR-6A5-mC T cells on target cells and the oncolytic effect of oncolytic viruses have a certain synergistic effect.
[0309] Example 8: Infecting tumor cells with an oncolytic adenovirus that simultaneously expresses the Her2 / neu antigen epitope polypeptide minigene and exogenous HLA-A2 can not only significantly enhance the recognition and killing sensitivity of Her2TCR-6A5-mC T cells to tumor cells, but also recognize HLA-A2 negative tumor cell lines.
[0310] In order to further verify whether the oncolytic adenovirus vector Ad-E75A2 expressing Her2 / neu antigen epitope polypeptide minigene and HLA-A2 simultaneously infects tumor cells, whether the number of HLA-A2 / Her2 antigen epitope polypeptide complexes on the cell surface that can be recognized by Her2 TCR-6A5-mC T cells is increased, thereby enhancing the recognition and killing sensitivity of T cells to tumor cells, firstly, an oncolytic adenovirus (OAd-E75A2, also referred to as Ad-E75A2) expressing Her2 / neu antigen epitope polypeptide minigene (with KDEL at the C-terminus) and HLA-A2 was prepared according to the method described in Preparation Example 3. In Example 6, it has been shown that the replication-deficient adenovirus (Adeasy-A2E75) in which the HLA-A2 gene connected by the Furin-F2A linker fragment is inserted upstream of the Her2 / neu antigen epitope polypeptide minigene can express HLA-A2 and Her2 / neu antigen epitopes when infecting target cells, and significantly enhances the recognition activity of Her2 TCR-6A5-mC T cells to target cells. The oncolytic adenovirus constructed in this example is derived from the oncolytic adenovirus described in Example 7, except that the HLA-A2 gene connected by the F2A linker fragment is inserted downstream of the Her2 / neu antigen epitope polypeptide minigene to construct the oncolytic adenovirus Ad-E75A2. The tumor cell lines HLA-A2 positive Her2 negative U87MG, HLA-A2 negative Her2 positive NCI-H460 and HT-29 cells were infected with Adeasy-A2E75 replication-deficient adenovirus and Ad-E75A2 oncolytic adenovirus, respectively, and 24 hours later, they were mixed with PBMC cells transfected with Her2TCR-6A5-mC TCR and co-cultured for another 24 hours to detect the function of Her2TCR-6A5-mC T cells to specifically secrete IFN-γ and kill target cells.
[0311] First, we tested whether exogenous HLA-A2 was expressed after tumor cell lines were infected with adenovirus carrying the HLA-A2 gene. U87MG, NCI-H460, and HT-29 cells were infected with Adeasy-A2E75 and Ad-E75A2 adenoviruses, respectively, and cells not infected with adenoviruses served as controls. Cells were collected 24 hours after virus infection and stained with HLA-A2 antibodies and analyzed by flow cytometry. Figure 7 C shows that U87MG expresses endogenous HLA-A2, while NCI-H460 and HT-29 do not express HLA-A2. Infection with replication-deficient adenovirus Adeasy-A2E75 and oncolytic adenovirus Ad-E75A2 can increase the expression of HLA-A2 on the cell surface.
[0312] Figure 7A shows that tumor cells U87MG, NCI-H460 and HT-29 cells infected with replication-deficient adenovirus Adeasy-A2E75 can significantly stimulate Her2 TCR-6A5-mC T cells to specifically secrete IFN-γ, regardless of whether the target cells express endogenous HLA-A2 or Her2 antigen. Figure 5 The recognition activity against other target cells shown in A is consistent. The MOI of adenovirus infection of tumor cells is 10, and the effector-target ratio of co-culture with PBMC cells transfected with Her2TCR-6A5-mC TCR is 10:1. The tumor cell line is HLA-A2 + Her2 / neu - U87MG cells, HLA-A2 - Her2 / neu + NCI-H460 and HT-29 cells. The results showed that tumor cells almost did not secrete interferon-γ after being infected with Adeasy-A2E75 replication-deficient adenovirus alone (experimental group "Adeasy-A2E75"). PBMC cells transfected with Her2 TCR-6A5-mC TCR were also unable to effectively recognize target cells and secrete interferon-γ (experimental group "PBMC with Her2TCR-6A5"). However, when tumor cells were infected with Adeasy-A2E75 adenovirus, the recognition function of Her2TCR-6A5-mC T cells was significantly enhanced (experimental group "PBMC with Her2TCR-6A5+Adeasy-A2E75"). The activity of Her2 TCR-6A5-mC T cells in recognizing tumor cells infected with Adeasy-A2E75 adenovirus was significantly higher than that of target cells not infected with the virus (p<=0.01), and was also significantly higher than that of the experimental group infected with replication-deficient virus alone.
[0313] Figure 8A shows that after tumor cells U87MG, NCI-H460 and HT-29 were infected with oncolytic adenovirus Ad-E75A2, although the activity of Her2 TCR-6A5-mC T cells in secreting IFN-γ after recognizing NCI-H460 was not significantly enhanced, the recognition activity of U87MG and HT-29 was more significantly increased compared with that infected with replication-deficient Adeasy-A2E75 virus (U87MG experimental group "PBMC with Her2 TCR-6A5+Ad-E75A2", p<=0.001; HT-29 experimental group "PBMC with Her2 TCR-6A5+Ad-E75A2", p<=0.0001). This indicates that after infecting tumor cells, oncolytic adenovirus carrying the HLA-A2 gene and the Her2 / neu antigen epitope polypeptide minigene can express exogenous HLA-A2 and Her2 / neu antigen epitopes, thereby enabling Her2 TCR-6A5-mC T cells to recognize HLA-A2-negative or Her2-negative target cells.
[0314] In order to further verify whether the oncolytic adenovirus vector Ad-E75A2 increases the killing function of Her2 TCR-6A5-mC T cells against target cells after infecting tumor cells, tumor cell lines U87MG, NCI-H460 and HT-29 cells were infected with replication-deficient adenovirus Adeasy-A2E75 and oncolytic adenovirus Ad-E75A2, respectively, and mixed with PBMC cells transfected with Her2TCR-6A5-mCTCR 24 hours later and cultured for another 24 hours. The killing function of T cells against target cells was detected by trypan blue. The virus infection multiplicity MOI of tumor cells was 10, and the effector-target ratio of mixed culture was 10:1.
[0315] Figure 7 B and Figure 8 B shows that under the MOI conditions used, infection with replication-deficient adenovirus Adeasy-A2E75 and oncolytic adenovirus Ad-E75A2 alone both showed a certain oncolytic effect ( Figure 7 B. In each experimental group, "Adeasy-A2E75" and Figure 8 After infection with adenovirus, the killing function of Her2 TCR-6A5-mC T cells on target cells was significantly enhanced.
[0316] Infection with replication-deficient adenovirus Adeasy-A2E75 can enhance the killing function of Her2TCR-6A5-mC T cells against all target cells, regardless of whether it is compared with the experimental group infected with adenovirus alone ( Figure 7B each experimental group "Adeasy-A2E75"; U87MG experimental group p < = 0.01, NCI-H460 experimental group p < = 0.05, HT-29 experimental group p < = 0.001) or compared with the experimental group using Her2 TCR-6A5-mC T cells alone ( Figure 7 Compared with the experimental groups "PBMC with Her2 TCR-6A5" in B; U87MG experimental group p <= 0.001, NCI-H460 experimental group p <= 0.05, HT-29 experimental group p <= 0.001), the killing function of Her2 TCR-6A5-mC T cells on target cells infected with the replication-deficient adenovirus Adeasy-A2E75 was significantly enhanced. Infection with oncolytic adenovirus Ad-E75A2 can also enhance the killing function of Her2 TCR-6A5-mC T cells on target cells. Further, Figure 7 In the experiment shown in B, when the target cells were U87MG, the cell killing rate of the replication-deficient adenovirus alone was about 9.8%, and the cell killing rate of the peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone was about 8.8%. Compared with the cell killing rate of administering one drug alone, the cell killing rate of the simultaneous administration of the two drugs was increased, and the cell killing rate was about 83.6%, showing a significant synergistic effect. Figure 7 In the experiment shown in B, when the target cells were NCI-H460, the cell killing rate of the replication-deficient adenovirus alone was about 5.4%, and the cell killing rate of the peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone was about 7%. Compared with the cell killing rate of administering one drug alone, the cell killing rate of administering both drugs simultaneously was increased to about 33.4%, also showing a significant synergistic effect. Figure 7 In the experiment shown in B, when the target cells were HT-29, the cell killing rate of the replication-deficient adenovirus alone was about 8.4%, and the cell killing rate of the peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone was about 12.9%. Compared with the cell killing rate of administering one drug alone, the cell killing rate of the simultaneous administration of the two drugs was increased, and the cell killing rate was about 74.2%, which also showed a significant synergistic effect.
[0317] Compared with the group infected with oncolytic adenovirus alone ( Figure 8 B Each experimental group "Ad-E75A2"; U87MG experimental group p <= 0.01, NCI-H460 experimental group p <= 0.05, HT-29 experimental group p <= 0.01) compared with the Her2 TCR-6A5-mC T cells against all target cells infected with oncolytic adenovirus. Compared with the experimental group using Her2 TCR-6A5-mC T cells alone ( Figure 8Compared with the experimental groups "BPMC with Her2 TCR-6A5" in B; U87MG experimental group p <= 0.05, HT-29 experimental group p <= 0.01), Her2TCR-6A5-mC T cells showed significant killing activity against U87MG and HT-29 cells infected with oncolytic adenovirus. Further, Figure 8 In the experiment shown in B, when the target cells were U87MG, the cell killing rate of the oncolytic adenovirus alone was about 10.6%, and the cell killing rate of the peripheral blood mononuclear cells expressing Her2TCR-6A5-mC TCR alone was about 8.7%. Compared with the cell killing rate of administering one drug alone, the cell killing rate of the simultaneous administration of the two drugs was increased to about 38.4%, showing a significant synergistic effect. Figure 8 In the experiment shown in B, when the target cells were HT-29, the cell killing rate of the oncolytic adenovirus alone was about 6.5%, and the cell killing rate of the peripheral blood mononuclear cells expressing Her2 TCR-6A5-mC TCR alone was about 9.8%. Compared with the cell killing rate of administering one drug alone, the cell killing rate of the simultaneous administration of the two drugs was increased to about 44.2%, which also showed a significant synergistic effect.
[0318] It can be seen that the oncolytic adenovirus vector that simultaneously expresses the Her2 / neu antigen epitope polypeptide minigene and HLA-A2 can significantly enhance the killing sensitivity of Her2 TCR-6A5-mC T cells after infecting tumor target cells, regardless of whether the target cells express endogenous HLA-A2 and Her2 antigens. The combined use of the oncolytic adenovirus and the TCR-T cells showed a synergistic effect in killing tumor cells.
[0319] discuss:
[0320] Adoptive transfer of T cells modified with tumor-specific TCR genes is the most promising immune cell therapy (TCR-T therapy) for the treatment of malignant solid tumors. If the tumor antigen targeted by TCR-T is a tumor-associated antigen derived from self-protein, the affinity of the specific TCR of TCR-T may not be sufficient to recognize the trace HLA / antigen epitope polypeptide complex presented by tumor cells and effectively kill tumor cells. In addition, the tumor microenvironment can not only cause the immunosuppressive state in tumor tissue, but also lead to reduced or absent expression of HLA class I molecules in tumor cells, and the class I antigen presentation mechanism in tumor cells may also be defective, so that tumor antigen epitopes cannot be effectively presented by MHC class I molecules, which also limits the function of TCR-T to recognize and kill tumor cells. Oncolytic viruses can not only selectively replicate and lyse tumor cells in tumor cells, but also alleviate the local immunosuppressive state of tumors through their own immunogenicity. Oncolytic viruses can also be used as gene carriers to selectively express exogenous genes in tumor cells. If HLA class I molecules and tumor antigen epitope polypeptides are selectively expressed in tumor cells by oncolytic adenovirus, the number of HLA class I molecules and antigen epitope polypeptide complexes on the surface of tumor cells can be increased, thereby enhancing the sensitivity of TCR-T to recognize and kill tumor cells. In addition, the combined use of TCR-T and oncolytic viruses expressing HLA class I molecules and antigen epitope polypeptides not only shows the synergistic effect of the two in the process of specific killing of tumor cells, but also can expand the scope of application of TCR-T. For example, when the TCR-T expressing the Her2 TCR described in the present invention is used alone, it can only be used for HLA-A2 positive Her2 / neu positive tumor patients due to the restriction of HLA-A2. If combined with the oncolytic adenovirus described in the present invention, by selectively infecting tumor cells and expressing exogenous HLA-A2 molecules and Her2 / neu antigen epitope polypeptides, HLA-A2-negative tumors and tumor cells that lowly express or even do not express Her2 / neu antigens can all become target cells for TCR-T based on Her2 TCR, thus avoiding the limitations of HLA restriction faced by adoptive TCR-T cell therapy, thereby greatly increasing the scope of application of TCR-T.
[0321] In summary, the technology and method described in the present invention provide a new approach for treating tumors by combining adoptive transfer of T cells modified with specific TCRs and oncolytic viruses expressing HLA class I molecules and tumor antigen epitope peptides. SEQUENCE LISTING <110> Synimmune, Inc. Hangzhou Kangwanda Pharmaceutical Technology Co., Ltd. <120> Therapeutic agent containing nucleic acid and TCR-modified immune cells and its application <130> FI-183579-59:52 / C <160> 61 <170> PatentIn version 3.5 <210> 1 <211> 132 <212> PRT <213> Homo sapiens <400> 1 Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg 1 5 10 15 Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu 20 25 30 Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly 35 40 45 Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln 50 55 60 Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys 65 70 75 80 Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg 85 90 95 Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val 100 105 110 Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr 115 120 125 Val Arg Ala Asn 130 <210> 2 <211> 133 <212> PRT <213> Homo sapiens <400> 2 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu 130 <210> 3 <211> 9 <212> PRT <213> Humans (Homo sapiens) <400> 3 Lys Ile Phe Gly Ser Leu Ala Phe Leu 1 5 <210> 4 <211> 272 <212> PRT <213> Humans (Homo sapiens) <400> 4 Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg 1 5 10 15 Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu 20 25 30 Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly 35 40 45 Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln 50 55 60 Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys 65 70 75 80 Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg 85 90 95 Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val 100 105 110 Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr 115 120 125 Val Arg Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg 130 135 140 Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp 145 150 155 160 Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr 165 170 175 Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser 180 185 190 Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe 195 200 205 Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser 210 215 220 Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn 225 230 235 240 Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu 245 250 255 Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser 260 265 270 <210> 5 <211> 272 <212> PRT <213> Artificial sequence <400> 5 Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg 1 5 10 15 Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu 20 25 30 Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly 35 40 45 Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln 50 55 60 Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys 65 70 75 80 Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg 85 90 95 Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val 100 105 110 Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr 115 120 125 Val Arg Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg 130 135 140 Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp 145 150 155 160 Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr 165 170 175 Asp Lys Cys Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser 180 185 190 Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe 195 200 205 Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser 210 215 220 Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn 225 230 235 240 Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu 245 250 255 Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser 260 265 270 <210> 6 <211> 268 <212> PRT <213> artificial sequence <400> 6 Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg 1 5 10 15 Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu 20 25 30 Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly 35 40 45 Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln 50 55 60 Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys 65 70 75 80 Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg 85 90 95 Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val 100 105 110 Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr 115 120 125 Val Arg Ala Asn Ile Gln Asn Pro Glu Pro Ala Val Tyr Gln Leu Lys 130 135 140 Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr Asp Phe Asp 145 150 155 160 Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr Phe Ile Thr 165 170 175 Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys Ser Asn Gly 180 185 190 Ala Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln Asp Ile Phe 195 200 205 Lys Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro Cys Asp Ala 210 215 220 Thr Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu Asn Phe Gln 225 230 235 240 Asn Leu Ser Val Met Gly Leu Arg Ile Leu Leu Leu Lys Val Ala Gly 245 250 255 Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser 260 265 <210> 7 <211> 312 <212> PRT <213> Human (Homo sapiens) <400> 7 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val 130 135 140 Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala 145 150 155 160 Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu 165 170 175 Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp 180 185 190 Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys 195 200 205 Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg 210 215 220 Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp 225 230 235 240 Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala 245 250 255 Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln 260 265 270 Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys 275 280 285 Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met 290 295 300 Val Lys Arg Lys Asp Ser Arg Gly 305 310 <210> 8 <211> 312 <212> PRT <213> artificial sequence <400> 8 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val 130 135 140 Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala 145 150 155 160 Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu 165 170 175 Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp 180 185 190 Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys 195 200 205 Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg 210 215 220 Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp 225 230 235 240 Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala 245 250 255 Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln 260 265 270 Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys 275 280 285 Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met 290 295 300 Val Lys Arg Lys Asp Ser Arg Gly 305 310 <210> 9 <211> 306 <212> PRT <213> artificial sequence <400> 9 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu Glu Asp Leu Arg Asn Val Thr Pro Pro Lys Val 130 135 140 Ser Leu Phe Glu Pro Ser Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala 145 150 155 160 Thr Leu Val Cys Leu Ala Arg Gly Phe Phe Pro Asp His Val Glu Leu 165 170 175 Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp 180 185 190 Pro Gln Ala Tyr Lys Glu Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg 195 200 205 Leu Arg Val Ser Ala Thr Phe Trp His Asn Pro Arg Asn His Phe Arg 210 215 220 Cys Gln Val Gln Phe His Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu 225 230 235 240 Gly Ser Pro Lys Pro Val Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly 245 250 255 Arg Ala Asp Cys Gly Ile Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu 260 265 270 Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr 275 280 285 Ala Val Leu Val Ser Thr Leu Val Val Met Ala Met Val Lys Arg Lys 290 295 300 Asn Ser 305 <210> 10 <211> 396 <212> DNA <213> Homo sapiens <400> 10 atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60 cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120 ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180 caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240 ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300 cagtggagtg acacagctga gtacttctgt gccgtgaatg ataacgacta caagctcagc 360 tttggagccg gaaccacagt aactgtaaga gcaaac 396 <210> 11 <211> 399 <212> DNA <213> Homo sapiens <400> 11 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgcta 399 <210> 12 <211> 819 <212> DNA <213> Human (Homo sapiens) <400> 12 atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60 cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120 ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180 caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240 ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300 cagtggagtg acacagctga gtacttctgt gccgtgaatg ataacgacta caagctcagc 360 tttggagccg gaaccacagt aactgtaaga gcaaatatcc agaaccctga ccctgccgtg 420 taccagctga gagactctaa atccagtgac aagtctgtct gcctattcac cgattttgat 480 tctcaaacaa atgtgtcaca aagtaaggat tctgatgtgt atatcacaga caaaaccgtg 540 ctagacatga ggtctatgga cttcaagagc aacagtgctg tggcctggag caacaaatct 600 gactttgcat gtgcaaacgc cttcaacaac agcattattc cagaagacac cttcttcccc 660 agcccagaaa gttcctgtga tgtcaagctg gtcgagaaaa gctttgaaac agatacgaac 720 ctaaactttc aaaacctgtc agtgattggg ttccgaatcc tcctcctgaa agtggccggg 780 tttaatctgc tcatgacgct gcggctgtgg tccagctga 819 <210> 13 <211> 819 <212> DNA <213> artificial sequence <400> 13 atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60 cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120 ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180 caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240 ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300 cagtggagtg acacagctga gtacttctgt gccgtgaatg ataacgacta caagctcagc 360 tttggagccg gaaccacagt aactgtaaga gcaaatatcc agaaccctga ccctgccgtg 420 taccagctga gagactctaa atccagtgac aagtctgtct gcctattcac cgattttgat 480 tctcaaacaa atgtgtcaca aagtaaggat tctgatgtgt atatcacaga caaatgcgtg 540 ctagacatga ggtctatgga cttcaagagc aacagtgctg tggcctggag caacaaatct 600 gactttgcat gtgcaaacgc cttcaacaac agcattattc cagaagacac cttcttcccc 660 agcccagaaa gttcctgtga tgtcaagctg gtcgagaaaa gctttgaaac agatacgaac 720 ctaaactttc aaaacctgtc agtgattggg ttccgaatcc tcctcctgaa agtggccggg 780 tttaatctgc tcatgacgct gcggctgtgg tccagctga 819 <210> 14 <211> 807 <212> DNA <213> artificial sequence <400> 14 atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60 cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120 ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180 caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240 ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300 cagtggagtg acacagctga gtacttctgt gccgtgaatg ataacgacta caagctcagc 360 tttggagccg gaaccacagt aactgtaaga gcaaacatcc agaacccaga acctgctgtg 420 taccagttaa aagatcctcg gtctcaggac agcaccctct gcctgttcac cgactttgac 480 tcccaaatca atgtgccgaa aaccatggaa tctggaacgt tcatcactga caaaactgtg 540 ctggacatga aagctatgga ttccaagagc aatggggcca ttgcctggag caaccagaca 600 agcttcacct gccaagatat cttcaaagag accaacgcca cctaccccag ttcagacgtt 660 ccctgtgatg ccacgttgac cgagaaaagc tttgaaacag atatgaacct aaactttcaa 720 aacctgtcag ttatgggact ccgaatcctc ctgctgaaag tagcgggatt taacctgctc 780 atgacgctga ggctgtggtc cagttga 807 <210> 15 <211> 939 <212> DNA <213> Homo sapiens <400> 15 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgctag aggacctgaa aaacgtgttc 420 ccacccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc 480 acactggtat gcctggccac aggcttctac cccgaccacg tggagctgag ctggtgggtg 540 aatgggaagg aggtgcacag tggggtcagc acagacccgc agcccctcaa ggagcagccc 600 gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660 cagaaccccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac 720 gagtggaccc aggatagggc caaacccgtc acccagatcg tcagcgccga ggcctggggt 780 agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc 840 ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg 900 ctgatggcca tggtcaagag aaaggattcc agaggctaa 939 <210> 16 <211> 939 <212> DNA <213> Homo sapiens <400> 16 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 360. actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat gagcagttct tcgggccagg gacacggctc accgtgctag aggacctgaa aaacgtgttc 420 480. cccccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc acactggtat gcctggccac aggcttctac cccgaccacg tggagctgag ctggtgggtg 540 aatgggaagg aggtgcacag tggggtctgc acagacccgc agcccctcaa ggagcagccc gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660 cagaacccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac gagtggaccc aggatagggc caaacccgtc acccagatcg tcagcgccga ggcctggggt 780 840. agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg ctgatggcca tggtcaagag aaaggattcc agaggctaa <210> 17 <211> 921 <212> DNA <213> Homo sapiens <400> 17 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgctag aggatctgag aaatgtgact 420 ccacccaagg tctccttgtt tgagccatca aaagcagaga ttgcaaacaa acaaaaggct 480 accctcgtgt gcttggccag gggcttcttc cctgaccacg tggagctgag ctggtgggtg 540 aatggcaagg aggtccacag tggggtcagc acggaccctc aggcctacaa ggagagcaat 600 tatagctact gcctgagcag ccgcctgagg gtctctgcta ccttctggca caatcctcgc 660 aaccacttcc gctgccaagt gcagttccat gggctttcag aggaggacaa gtggccagag 720 ggctcaccca aacctgtcac acagaacatc agtgcagagg cctggggccg agcagactgt 780 gggattacct cagcatccta tcaacaaggg gtcttgtctg ccaccatcct ctatgagatc 840 ctgctaggga aagccaccct gtatgctgtg cttgtcagta cactggtggt gatggctatg 900 gtcaaaagaa agaattcata a 921 <210> 18 <211> 1851 <212> DNA <213> artificial sequence <400> 18 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgctag aggacctgaa aaacgtgttc 420 480. cccccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc acactggtat gcctggccac aggcttctac cccgaccacg tggagctgag ctggtgggtg 540 aatgggaagg aggtgcacag tggggtcagc acagacccgc agcccctcaa ggagcagccc gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660 cagaacccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac gagtggaccc aggatagggc caaacccgtc acccagatcg tcagcgccga ggcctggggt 780 840. agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg ctgatggcca tggtcaagag aaaggattcc agaggccgtg ccaagcgatc cggaagcgga 960 gcccctgtaa agcagacttt gaatttgac cttctcaagt tggcgggaga cgtcgagtcc aaccctgggc ccatgctcct gttgctcata ccagtgctgg ggatgatttt tgccctgaga 1080 gatgccagag cccagtctgt gagccagcat aaccaccacg taattctctc tgaagcagcc 1140 tcactggagt tgggatgcaa ctattcctat ggtggaactg ttaatctctt ctggtatgtc 1200 cagtaccctg gtcaacacct tcagcttctc ctcaagtact tttcagggga tccactggtt 1260 aaaggcatca agggctttga ggctgaattt ataaagagta aattctcctt taatctgagg 1320 aaaccctctg tgcagtggag tgacacagct gagtacttct gtgccgtgaa tgataacgac 1380 tacaagctca gctttggagc cggaaccaca gtaactgtaa gagcaaatat ccagaaccct 1440 gaccctgccg tgtaccagct gagagactct aaatccagtg acaagtctgt ctgcctattc 1500 accgattttg attctcaaac aaatgtgtca caaagtaagg attctgatgt gtatatcaca 1560 gacaaaaccg tgctagacat gaggtctatg gacttcaaga gcaacagtgc tgtggcctgg 1620 agcaacaaat ctgactttgc atgtgcaaac gccttcaaca acagcattat tccagaagac 1680 accttcttcc ccagcccaga aagttcctgt gatgtcaagc tggtcgagaa aagctttgaa 1740 acagatacga acctaaactt tcaaaacctg tcagtgattg ggttccgaat cctcctcctg 1800 aaagtggccg ggtttaatct gctcatgacg ctgcggctgt ggtccagctg a 1851 <210> 19 <211> 1851 <212> DNA <213> artificial sequence <400> 19 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgctag aggacctgaa aaacgtgttc 420 ccacccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc 480 acactggtat gcctggccac aggctctac cccgaccacg tggagctgag ctggtgggtg 540 aatgggaagg aggtgcacag tggggtctgc acagacccgc agcccctcaa ggagcagccc gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660 cagaacccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac gagtggaccc aggatagggc caaacccgtc acccagatcg tcagcgccga ggcctggggt 780 840. agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg ctgatggcca tggtcaagag aaaggattcc agaggccgtg ccaagcgatc cggaagcgga 960 gcccctgtaa agcagacttt gaatttgac cttctcaagt tggcgggaga cgtcgagtcc aaccctgggc ccatgctcct gttgctcata ccagtgctgg ggatgatttt tgccctgaga 1080 1140. gatgccagag cccagtctgt gagccagcat aaccaccacg taattctctc tgaagcagcc tcactggagt tgggatgcaa ctattcctat ggtggaactg ttaatctctt ctggtatgtc cagtaccctg gtcaacacct tcagcttctc ctcaagtact tttcagggga tccactggtt 1260 aaaggcatca agggctttga ggctgaattt ataaagagta aattctcctt taatctgagg 1320 aaaccctctg tgcagtggag tgacacagct gagtacttct gtgccgtgaa tgataacgac 1380 tacaagctca gctttggagc cggaaccaca gtaactgtaa gagcaaatat ccagaaccct 1440 gaccctgccg tgtaccagct gagagactct aaatccagtg acaagtctgt ctgcctattc 1500 accgatttg attctcaaac aaatgtgtca caaagtaagg attctgatgt gtatatcaca 1560 gacaaatgcg tgctagacat gaggtctatg gacttcaaga gcaacagtgc tgtggcctgg 1620 agcaacaaat ctgactttgc atgtgcaaac gccttcaaca acagcattat tccagaagac 1680 accttcttcc ccagcccaga aagttcctgt gatgtcaagc tggtcgagaa aagctttgaa 1740 acagatacga acctaaactt tcaaaacctg tcagtgattg ggttccgaat cctcctcctg 1800 aaagtggccg ggtttaatct gctcatgacg ctgcggctgt ggtccagctg a 1851 <210> 20 <211> 1821 <212> DNA <213> artificial sequence <400> 20 atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcggt ccccatggaa 60 acgggagtta cgcagacacc aagacacctg gtcatgggaa tgacaaataa gaagtctttg 120 aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180 ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240 agtcgcttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300 cagccagaag actcggccct gtatctctgc gccagcagcc aagaagccgg ttcctacaat 360 gagcagttct tcgggccagg gacacggctc accgtgctag aggatctgag aaatgtgact 420 ccacccaagg tctccttgtt tgagccatca aaagcagaga ttgcaaacaa acaaaaggct 480 accctcgtgt gcttggccag gggctttctc cctgaccacg tggagctgag ctggtgggtg 540 aatggcaagg aggtccacag tggggtcagc acggaccctc aggcctacaa ggagagcaat 600 tatagctact gcctgagcag ccgcctgagg gtctctgcta cttctggca caatcctcgc 660 aaccacttcc gctgccaagt gcagttccat gggctttcag aggaggacaa gtggccagag 720 ggctcaccca aacctgtcac agaaacatc agtgcagagg cctggggccg agcagactgt 780 gggattacct cagcatccta tcaacaaggg gtcttgtctg ccaccatcct ctatgagatc 840 ctgctaggga aagccaccct gtatgctgtg cttgtcagta cactggtggt gatggctatg 900 gtcaaaagaa agaattcacg tgccaagcga tccggaagcg gagcccctgt aaagcagact 960 ttgaattttg accttctcaa gttggcggga gacgtcgagt ccaaccctgg gcccatgctc 1020 ctgttgctca taccagtgct ggggatgatt tttgccctga gagatgccag agcccagtct 1080 gtgagccagc ataaccacca cgtaattctc tctgaagcag cctcactgga gttgggatgc 1140 aactattcct atggtggaac tgttaatctc ttctggtatg tccagtaccc tggtcaacac 1200 cttcagcttc tcctcaagta cttttcaggg gatccactgg ttaaaggcat caagggcttt 1260 gaggctgaat ttaaaagag taaattctcc tttaatctga ggaaaccctc tgtgcagtgg 1320 agtgacacag ctgagtactt ctgtgccgtg aatgataacg actacaagct cagcttttgga 1380 gccggaacca cagtaactgt aagagcaaac atccagaacc cagaacctgc tgtgtaccag 1440 ttaaaagatc ctcggtctca ggacagcacc ctctgcctgt tcaccgactt tgactcccaa 1500 atcaatgtgc cgaaaaccat ggaatctgga acgttcatca ctgacaaaac tgtgctggac 1560 atgaaagcta tggattccaa gagcaatggg gccattgcct ggagcaacca gacaagcttc 1620 acctgccaag atatcttcaa agagaccaac gccacctacc ccagttcaga cgttccctgt 1680 gatgccacgt tgaccgagaa aagctttgaa acagatatga acctaaactt tcaaaacctg 1740 tcagttatgg gactccgaat cctcctgctg aaagtagcgg gatttaacct gctcatgacg 1800 ctgaggctgt ggtccagttg a 1821 <210> 21 <211> 1255 <212> PRT <213> Homo sapiens <400> 21 Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu 1 5 10 15 Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys 20 25 30 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His 35 40 45 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr 50 55 60 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val 65 70 75 80 Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu 85 90 95 Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr 100 105 110 Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro 115 120 125 Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser 130 135 140 Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln 145 150 155 160 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn 165 170 175 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys 180 185 190 His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser 195 200 205 Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys 210 215 220 Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys 225 230 235 240 Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu 245 250 255 His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val 260 265 270 Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg 275 280 285 Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu 290 295 300 Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln 305 310 315 320 Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys 325 330 335 Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu 340 345 350 Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys 355 360 365 Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp 370 375 380 Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe 385 390 395 400 Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro 405 410 415 Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg 420 425 430 Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu 435 440 445 Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly 450 455 460 Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val 465 470 475 480 Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr 485 490 495 Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His 500 505 510 Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys 515 520 525 Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys 530 535 540 Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys 545 550 555 560 Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys 565 570 575 Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp 580 585 590 Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu 595 600 605 Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln 610 615 620 Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys 625 630 635 640 Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Ile Ser 645 650 655 Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly 660 665 670 Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg 675 680 685 Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly 690 695 700 Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu 705 710 715 720 Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys 725 730 735 Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile 740 745 750 Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu 755 760 765 Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg 770 775 780 Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu 785 790 795 800 Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg 805 810 815 Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly 820 825 830 Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala 835 840 845 Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe 850 855 860 Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp 865 870 875 880 Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg 885 890 895 Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val 900 905 910 Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala 915 920 925 Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro 930 935 940 Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met 945 950 955 960 Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe 965 970 975 Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu 980 985 990 Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu 995 1000 1005 Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr 1010 1015 1020 Leu Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly 1025 1030 1035 Ala Gly Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg 1040 1045 1050 Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu 1055 1060 1065 Glu Ala Pro Arg Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser 1070 1075 1080 Asp Val Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu 1085 1090 1095 Gln Ser Leu Pro Thr His Asp Pro Ser Pro Leu Gln Arg Tyr Ser 1100 1105 1110 Glu Asp Pro Thr Val Pro Leu Pro Ser Glu Thr Asp Gly Tyr Val 1115 1120 1125 Ala Pro Leu Thr Cys Ser Pro Gln Pro Glu Tyr Val Asn Gln Pro 1130 1135 1140 Asp Val Arg Pro Gln Pro Pro Ser Pro Arg Glu Gly Pro Leu Pro 1145 1150 1155 Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu Arg Pro Lys Thr Leu 1160 1165 1170 Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val Phe Ala Phe Gly 1175 1180 1185 Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln Gly Gly Ala 1190 1195 1200 Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala Phe Asp 1205 1210 1215 Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala Pro 1220 1225 1230 Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr 1235 1240 1245 Leu Gly Leu Asp Val Pro Val 1250 1255 <210> 22 <211> 10 <212> PRT <213> Homo sapiens <400> 22 Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp 1 5 10 <210> 23 <211> 606 <212> PRT <213> Artificial sequence <400> 23 Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala 1 5 10 15 Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met 20 25 30 Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His 35 40 45 Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu 50 55 60 Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro 65 70 75 80 Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His 85 90 95 Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser 100 105 110 Ser Gln Glu Ala Gly Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr 115 120 125 Arg Leu Thr Val Leu Glu Asp Leu Arg Asn Val Thr Pro Pro Lys Val 130 135 140 Ser Leu Phe Glu Pro Ser Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala 145 150 155 160 Thr Leu Val Cys Leu Ala Arg Gly Phe Phe Pro Asp His Val Glu Leu 165 170 175 Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp 180 185 190 Pro Gln Ala Tyr Lys Glu Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg 195 200 205 Leu Arg Val Ser Ala Thr Phe Trp His Asn Pro Arg Asn His Phe Arg 210 215 220 Cys Gln Val Gln Phe His Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu 225 230 235 240 Gly Ser Pro Lys Pro Val Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly 245 250 255 Arg Ala Asp Cys Gly Ile Thr Ser Ala Ser Tyr Gln Gln Gly Val Leu 260 265 270 Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr 275 280 285 Ala Val Leu Val Ser Thr Leu Val Val Met Ala Met Val Lys Arg Lys 290 295 300 Asn Ser Arg Ala Lys Arg Ser Gly Ser Gly Ala Pro Val Lys Gln Thr 305 310 315 320 Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro 325 330 335 Gly Pro Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala 340 345 350 Leu Arg Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val 355 360 365 Ile Leu Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr 370 375 380 Gly Gly Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His 385 390 395 400 Leu Gln Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly 405 410 415 Ile Lys Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn 420 425 430 Leu Arg Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys 435 440 445 Ala Val Asn Asp Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr 450 455 460 Val Thr Val Arg Ala Asn Ile Gln Asn Pro Glu Pro Ala Val Tyr Gln 465 470 475 480 Leu Lys Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr Asp 485 490 495 Phe Asp Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr Phe 500 505 510 Ile Thr Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys Ser 515 520 525 Asn Gly Ala Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln Asp 530 535 540 Ile Phe Lys Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro Cys 545 550 555 560 Asp Ala Thr Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu Asn 565 570 575 Phe Gln Asn Leu Ser Val Met Gly Leu Arg Ile Leu Leu Leu Lys Val 580 585 590 Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser 595 600 605 <210> 24 <211> 126 <212> PRT <213> Artificial sequence <400> 24 Met Lys Gly Ser Ile Phe Thr Leu Phe Leu Phe Ser Val Leu Phe Ala 1 5 10 15 Ile Ser Glu Val Arg Ser Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg 20 25 30 Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg 35 40 45 Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe 50 55 60 Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu 65 70 75 80 Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu 85 90 95 Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys 100 105 110 Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Lys Asp Glu Leu 115 120 125 <210> 25 <211> 378 <212> DNA <213> Artificial sequence <400> 25 atgaaaggtt ccatcttcac attgttttg ttctccgtat tgttcgcaat cagcgaagtc 60 cgatcaaaaa tatttgggtc tctcgcattc ctccgcagaa agaggaaaat cttcggtagt 120 ttggccttcc ttaggcgaaa gagaaagata ttggaagcc tggccttcct gcgacgcaaa 180 cggaaaatct tcggctcact ggcattcttg aggagaaagc gcaaaatatt cgggtctttg 240 gccttctgc gccggaagcg caagatctttc gggtccttg cttcttgag acgaaaacgc 300 aaaatttg ggtctcttgc cttcctcagg cgaaagcgga agattttcgg ttcccttgcc 360 ttccttaaag acgagctt 378 <210> 26 <211> 1569 <212> DNA <213> artificial sequence <400> 26 atggccgtca tggcgccccg aaccctcgtc ctgctactct cgggggctct ggccctgacc 60 cagacctggg cgggctctca ctccatgagg tatttcttca catccgtgtc ccggcccggc 120 cgcggggagc cccgcttcat cgcagtgggc tacgtggacg acacgcagtt cgtgcggttc 180 gacagcgacg ccgcgagcca gaggatggag ccgcgggcgc cgtggataga gcaggagggt 240 ccggagtatt gggacgggga gacacggaaa gtgaaggccc actcacagac tcaccgagtg 300 gacctgggga ccctgcgcgg ctactacaac cagagcgagg ccggttctca caccgtccag 360 aggatgtatg gctgcgacgt ggggtcggac tggcgcttcc tccgcgggta ccaccagtac 420 gcctacgacg gcaaggatta catcgccctg aaagaggacc tgcgctcttg gaccgcggcg 480 gacatggcag ctcagaccac caagcacaag tgggaggcgg cccatgtggc ggagcagttg 540 agagcctacc tggagggcac gtgcgtggag tggctccgca gatacctgga gaacgggaag 600 gagacgctgc agcgcacgga cgcccccaaa acgcatatga ctcaccacgc tgtctctgac 660 catgaagcca ccctgaggtg ctgggccctg agcttctacc ctgcggagat cacactgacc 720 tggcagcggg atggggagga ccagacccag gacacggagc tcgtggagac caggcctgca 780 ggggatggaa ccttccagaa gtgggcggct gtggtggtgc cttctggaca ggagcagaga 840 tacacctgcc atgtgcagca tgagggtttg cccaagcccc tcaccctgag atgggagccg 900 tcttcccagc ccaccatccc catcgtgggc atcattgctg gcctggttct ctttggagct 960 gtgatcactg gagctgtggt cgctgctgtg atgtggagga ggaagagctc agatagaaaaa 1020 ggagggagct actctcaggc tgcaagcagt gacagtgccc agggctctga tgtgtctctc 1080 acagcttgta aagtgcgtgc caagcgatcc ggaagcggag cccctgtaaa gcagactttg 1140 aatttgacc ttctcaagtt ggcggggagac gtcgagtcca accctgggcc catgaaaggt 1200 tccatcttca cattgttttt gttctccgta ttgttcgcaa tcagcgaagt ccgatcaaaa 1260 atattgggt ctctcgcatt cctccgcaga aagaggaaaa tcttcggtag tttggccttc 1320 cttaggcgaa agagaaagat atttggaagc ctggccttcc tgcgacgcaa acggaaaatc 1380 ttcggctcac tggcattctt gaggagaaag cgcaaaatat tcgggtcttt ggcctttctg 1440 cgccggaagc gcaagatctt cgggtccttg gctttcttga gacgaaaacg caaaatattt 1500 gggtctcttg ccttcctcag gcgaaagcgg aagattttcg gttcccttgc cttccttaaa 1560 gacgagctt 1569 <210> 27 <211> 1572 <212> DNA <213> artificial sequence <400> 27 atgaaaggtt ccatcttcac attgtttttg ttctccgtat tgttcgcaat cagcgaagtc 60 cgatcaaaaa tatttgggtc tctcgcattc ctccgcagaa agaggaaaat cttcggtagt 120 ttggccttcc ttaggcgaaa gagaaagata tttggaagcc tggccttcct gcgacgcaaa 180 cggaaaatct tcggctcact ggcattcttg aggagaaagc gcaaaatatt cgggtctttg 240 gcctttctgc gccggaagcg caagatcttc gggtccttgg ctttcttgag acgaaaacgc 300 aaaatatttg ggtctcttgc cttcctcagg cgaaagcgga agattttcgg ttcccttgcc 360 ttccttaaag acgagcttcg tgccaagcga tccggaagcg gagcccctgt aaagcagact 420 ttgaattttg accttctcaa gttggcggga gacgtcgagt ccaaccctgg gcccatggcc 480 gtcatggcgc cccgaaccct cgtcctgcta ctctcggggg ctctggccct gacccagacc 540 tgggcgggct ctcactccat gaggtatttc ttcacatccg tgtcccggcc cggccgcggg 600 gagccccgct tcatcgcagt gggctacgtg gacgacacgc agttcgtgcg gttcgacagc 660 gacgccgcga gccagaggat ggagccgcgg gcgccgtgga tagagcagga gggtccggag 720 tattgggacg gggagacacg gaaagtgaag gcccactcac agactcaccg agtggacctg 780 gggaccctgc gcggctacta caaccagagc gaggccggtt ctcacaccgt ccagaggatg 840 tatggctgcg acgtggggtc ggactggcgc ttcctccgcg ggtaccacca gtacgcctac 900 gacggcaagg attacatcgc cctgaaagag gacctgcgct cttggaccgc ggcggacatg 960 gcagctcaga ccaccaagca caagtgggag gcggcccatg tggcggagca gttgagagcc 1020 tacctggagg gcacgtgcgt ggagtggctc cgcagatacc tggagaacgg gaaggagacg 1080 ctgcagcgca cggacgcccc caaaacgcat atgactcacc acgctgtctc tgaccatgaa 1140 gccaccctga ggtgctgggc cctgagcttc taccctgcgg agatcacact gacctggcag 1200 cgggatgggg aggaccagac ccaggacacg gagctcgtgg agaccaggcc tgcaggggat 1260 ggaaccttcc agaagtgggc ggctgtggtg gtgccttctg gacaggagca gagatacacc 1320 tgccatgtgc agcatgaggg tttgcccaag cccctcaccc tgagatggga gccgtcttcc 1380 cagcccacca tccccatcgt gggcatcatt gctggcctgg ttctctttgg agctgtgatc 1440 actggagctg tggtcgctgc tgtgatgtgg aggaggaaga gctcagatag aaaaggaggg 1500 agctactctc aggctgcaag cagtgacagt gcccagggct ctgatgtgtc tctcacagct 1560 tgtaaagtgt ga 1572 <210> 28 <211> 22 <212> PRT <213> Homo sapiens <400> 28 Met Lys Gly Ser Ile Phe Thr Leu Phe Leu Phe Ser Val Leu Phe Ala 1 5 10 15 Ile Ser Glu Val Arg Ser 20 <210> 29 <211> 365 <212> PRT <213> Homo sapiens <400> 29 Met Ala Val Met Ala Pro Arg Thr Leu Val Leu Leu Leu Ser Gly Ala 1 5 10 15 Leu Ala Leu Thr Gln Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe 20 25 30 Phe Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala 35 40 45 Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala 50 55 60 Ala Ser Gln Arg Met Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly 65 70 75 80 Pro Glu Tyr Trp Asp Gly Glu Thr Arg Lys Val Lys Ala His Ser Gln 85 90 95 Thr His Arg Val Asp Leu Gly Thr Leu Arg Gly Tyr Tyr Asn Gln Ser 100 105 110 Glu Ala Gly Ser His Thr Val Gln Arg Met Tyr Gly Cys Asp Val Gly 115 120 125 Ser Asp Trp Arg Phe Leu Arg Gly Tyr His Gln Tyr Ala Tyr Asp Gly 130 135 140 Lys Asp Tyr Ile Ala Leu Lys Glu Asp Leu Arg Ser Trp Thr Ala Ala 145 150 155 160 Asp Met Ala Ala Gln Thr Thr Lys His Lys Trp Glu Ala Ala His Val 165 170 175 Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu 180 185 190 Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Thr Asp Ala 195 200 205 Pro Lys Thr His Met Thr His His Ala Val Ser Asp His Glu Ala Thr 210 215 220 Leu Arg Cys Trp Ala Leu Ser Phe Tyr Pro Ala Glu Ile Thr Leu Thr 225 230 235 240 Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu 245 250 255 Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val 260 265 270 Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Val Gln His Glu 275 280 285 Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro Ser Ser Gln Pro 290 295 300 Thr Ile Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu Phe Gly Ala 305 310 315 320 Val Ile Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Arg Lys Ser 325 330 335 Ser Asp Arg Lys Gly Gly Ser Tyr Ser Gln Ala Ala Ser Ser Asp Ser 340 345 350 Ala Gln Gly Ser Asp Val Ser Leu Thr Ala Cys Lys Val 355 360 365 <210> 30 <211> 264 <212> DNA <213> Homo sapiens <400> 30 catccggaca aagcctgcgc gcgccccgcc ccgccattgg ccgtaccgcc ccgcgccgcc 60 gccccatctc gcccctcgcc gccgggtccg gcgcgttaaa gccaatagga accgccgccg 120 ttgttcccgt cacggccggg gcagccaatt gtggcggcgc tcggcggctc gtggctcttt 180 cgcggcaaaa aggatttggc gcgtaaaagt ggccgggact ttgcaggcag cggcggccgg 240 gggcggagcg ggatcgagcc ctcg 264 <210> 31 <211> 523 <212> PRT <213> Artificial Sequence <400> 31 Met Ala Val Met Ala Pro Arg Thr Leu Val Leu Leu Leu Ser Gly Ala 1 5 10 15 Leu Ala Leu Thr Gln Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe 20 25 30 Phe Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala 35 40 45 Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala 50 55 60 Ala Ser Gln Arg Met Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly 65 70 75 80 Pro Glu Tyr Trp Asp Gly Glu Thr Arg Lys Val Lys Ala His Ser Gln 85 90 95 Thr His Arg Val Asp Leu Gly Thr Leu Arg Gly Tyr Tyr Asn Gln Ser 100 105 110 Glu Ala Gly Ser His Thr Val Gln Arg Met Tyr Gly Cys Asp Val Gly 115 120 125 Ser Asp Trp Arg Phe Leu Arg Gly Tyr His Gln Tyr Ala Tyr Asp Gly 130 135 140 Lys Asp Tyr Ile Ala Leu Lys Glu Asp Leu Arg Ser Trp Thr Ala Ala 145 150 155 160 Asp Met Ala Ala Gln Thr Thr Lys His Lys Trp Glu Ala Ala His Val 165 170 175 Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu 180 185 190 Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Thr Asp Ala 195 200 205 Pro Lys Thr His Met Thr His His Ala Val Ser Asp His Glu Ala Thr 210 215 220 Leu Arg Cys Trp Ala Leu Ser Phe Tyr Pro Ala Glu Ile Thr Leu Thr 225 230 235 240 Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu 245 250 255 Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val 260 265 270 Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Val Gln His Glu 275 280 285 Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro Ser Ser Gln Pro 290 295 300 Thr Ile Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu Phe Gly Ala 305 310 315 320 Val Ile Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Arg Lys Ser 325 330 335 Ser Asp Arg Lys Gly Gly Ser Tyr Ser Gln Ala Ala Ser Ser Asp Ser 340 345 350 Ala Gln Gly Ser Asp Val Ser Leu Thr Ala Cys Lys Val Arg Ala Lys 355 360 365 Arg Ser Gly Ser Gly Ala Pro Val Lys Gln Thr Leu Asn Phe Asp Leu 370 375 380 Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly Pro Met Lys Gly 385 390 395 400 Ser Ile Phe Thr Leu Phe Leu Phe Ser Val Leu Phe Ala Ile Ser Glu 405 410 415 Val Arg Ser Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg 420 425 430 Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe 435 440 445 Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu 450 455 460 Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu 465 470 475 480 Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys 485 490 495 Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile 500 505 510 Phe Gly Ser Leu Ala Phe Leu Lys Asp Glu Leu 515 520 <210> 32 <211> 523 <212> PRT <213> Artificial Sequence <400> 32 Met Lys Gly Ser Ile Phe Thr Leu Phe Leu Phe Ser Val Leu Phe Ala 1 5 10 15 Ile Glu Val Arg Ile Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg 20 25 30 Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg 35 40 45 Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe 50 55 60 Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe Phe Gly Ser Leu 65 70 75 80 Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu 85 90 95 Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys 100 105 110 Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Lys Asp Glu Leu Arg Ala 115 120 125 Lys Arg Ser Gly Ser Gly Ala Pro Val Lys Gln Thr Leu Asn Phe Asp 130 135 140 Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly Pro Met Ala 145 150 155 160 Val Met Ala Pro Arg Thr Leu Val Leu Leu Leu Ser Gly Ala Leu Ala 165 170 175 Leu Thr Gln Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe Phe Thr 180 185 190 Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala Val Gly 195 200 205 Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala Ala Ser 210 215 220 Gln Arg Met Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu 225 230 235 240 Tyr Trp Asp Gly Glu Thr Arg Lys Val Lys Ala His Ser Gln Thr His 245 250 255 Arg Val Asp Leu Gly Thr Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala 260 265 270 Gly Ser His Thr Val Gln Arg Met Tyr Gly Cys Asp Val Gly Ser Asp 275 280 285 Trp Arg Phe Leu Arg Gly Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp 290 295 300 Tyr Ile Ala Leu Lys Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Met 305 310 315 320 Ala Ala Gln Thr Thr Lys His Lys Trp Glu Ala Ala His Val Ala Glu 325 330 335 Gln Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu Arg Arg 340 345 350 Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys 355 360 365 Thr His Met Thr His His Ala Val Ser Asp His Glu Ala Thr Leu Arg 370 375 380 Cys Trp Ala Leu Ser Phe Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln 385 390 395 400 Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu Thr Arg 405 410 415 Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro 420 425 430 Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Val Gln His Glu Gly Leu 435 440 445 Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro Ser Ser Gln Pro Thr Ile 450 455 460 Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu Phe Gly Ala Val Ile 465 470 475 480 Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Arg Lys Ser Ser Asp 485 490 495 Arg Lys Gly Gly Ser Tyr Ser Gln Ala Ala Ser Ser Asp Ser Ala Gln 500 505 510 Gly Ser Asp Val Ser Leu Thr Ala Cys Lys Val 515 520 <210> 33 <211> 22 <212> DNA <213> Artificial Sequence <400> 33 gcctctggaa tcctttctct tg 22 <210> 34 <211> 21 <212> DNA <213> Artificial Sequence <400> 34 tcagctggac cacagccgca g 21 <210> 35 <211> 1098 <212> DNA <213> Homo sapiens <400> 35 atggccgtca tggcgccccg aaccctcgtc ctgctactct cgggggctct ggccctgacc 60 cagacctggg cgggctctca ctccatgagg tatttcttca catccgtgtc ccggcccggc 120 cgcggggagc cccgcttcat cgcagtgggc tacgtggacg acacgcagtt cgtgcggttc 180 gacagcgacg ccgcgagcca gaggatggag ccgcgggcgc cgtggataga gcaggagggt 240 ccggagtatt gggacgggga gacacggaaa gtgaaggccc actcacagac tcaccgagtg 300 gacctgggga ccctgcgcgg ctactacaac cagagcgagg ccggttctca caccgtccag 360 aggatgtatg gctgcgacgt ggggtcggac tggcgcttcc tccgcgggta ccaccagtac 420 gcctacgacg gcaaggatta catcgccctg aaagaggacc tgcgctcttg gaccgcggcg 480 gacatggcag ctcagaccac caagcacaag tgggaggcgg cccatgtggc ggagcagttg 540 agagcctacc tggagggcac gtgcgtggag tggctccgca gatacctgga gaacgggaag 600 gagacgctgc agcgcacgga cgcccccaaa acgcatatga ctcaccacgc tgtctctgac 660 catgaagcca ccctgaggtg ctgggccctg agcttctacc ctgcggagat cacactgacc 720 tggcagcggg atggggagga ccagacccag gacacggagc tcgtggagac caggcctgca 780 ggggatggaa ccttccagaa gtgggcggct gtggtggtgc cttctggaca ggagcagaga 840 tacacctgcc atgtgcagca tgagggtttg cccaagcccc tcaccctgag atgggagccg 900 tcttcccagc ccaccatccc catcgtgggc atcattgctg gcctggttct ctttggagct 960 gtgatcactg gagctgtggt cgctgctgtg atgtggagga ggaagagctc agatagaaaaa 1020 ggagggagct actctcaggc tgcaagcagt gacagtgccc agggctctga tgtgtctctc 1080 acagcttgta aagtgtga 1098 <210> 36 <211> 70 <212> PRT <213> artificial sequence <400> 36 Met Lys Gly Ser Ile Phe Thr Leu Phe Leu Phe Ser Val Leu Phe Ala 1 5 10 15 Ile Ser Glu Val Arg Ser Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg 20 25 30 Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg 35 40 45 Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe 50 55 60 Gly Ser Leu Ala Phe Leu 65 70 <210> 37 <211> 30 <212> DNA <213> artificial sequence <400> 37 agagctagcg aattcaacat ggccgtcatg 30 <210> 38 <211> 37 <212> DNA <213> Artificial sequence <400> 38 tgattgtcga cgcccttaaa gctcgtcttt aaggaag 37 <210> 39 <211> 31 <212> DNA <213> Artificial sequence <400> 39 tagagatctg gtaccaacat ggccgtcatg g 31 <210> 40 <211> 37 <212> DNA <213> Artificial sequence <400> 40 ggctcgagcg gccgcttaaa gctcgtcttt aaggaag 37 <210> 41 <211> twenty three <212> DNA <213> Artificial sequence <400> 41 ggaagatctg gactgaaaat gag 23 <210> 42 <211> twenty four <212> DNA <213> Artificial sequence <400> 42 tgaggtcaga tgtaaccaag atta 24 <210> 43 <211> 33 <212> DNA <213> Artificial sequence <400> 43 cgcgtcgact actgtaatag taatcaatta cgg 33 <210> 44 <211> 33 <212> DNA <213> Artificial sequence <400> 44 gacgtcgact aagatacatt gatgagtttg gac 33 <210> 45 <211> 33 <212> DNA <213> Artificial sequence <400> 45 ccgctcgaga tgaaaggttc catcttcaca ttg 33 <210> 46 <211> 33 <212> DNA <213> Artificial sequence <400> 46 ccgctcgagt taaagctcgt ctttaaggaa ggc 33 <210> 47 <211> 39 <212> DNA <213> Artificial sequence <400> 47 ttccggatcg cttggcacga agctcgtctt taaggaagg 39 <210> 48 <211> 39 <212> DNA <213> Artificial sequence <400> 48 ccttccttaa agacgagctt cgtgccaagc gatccggaa 39 <210> 49 <211> 38 <212> DNA <213> Artificial sequence <400> 49 cggggcgcca tgacggccat gggcccagggg ttggactc 38 <210> 50 <211> 38 <212> DNA <213> Artificial sequence <400> 50 gagtccaacc ctgggcccat ggccgtcatg gcgccccg 38 <210> 51 <211> 32 <212> DNA <213> Artificial sequence <400> 51 cttctcgagt cacactttac aagctgtgag ag 32 <210> 52 <211> 36 <212> DNA <213> Artificial sequence <400> 52 agagctagcg aattcaacat gggctgcagg ctgctc 36 <210> 53 <211> 42 <212> DNA <213> Artificial sequence <400> 53 ggatcgcttg gcacgtgaat tctttctttt gaccatagcc at 42 <210> 54 <211> 39 <212> DNA <213> Artificial sequence <400> 54 tccaaccctg ggcccatgct cctgttgctc ataccagtg 39 <210> 55 <211> 35 <212> DNA <213> Artificial sequence <400> 55 gttgattgtc gacgccctca actggacccac agcct 35 <210> 56 <211> 31 <212> PRT <213> Artificial sequence <400> 56 Met Lys Gly Ser Ile Phe Thr Leu Phe Leu Phe Ser Val Leu Phe Ala 1 5 10 15 Ile Ser Glu Val Arg Ser Lys Ile Phe Gly Ser Leu Ala Phe Leu 20 25 30 <210> 57 <211> 93 <212> DNA <213> Artificial sequence <400> 57 atgaaaggtt ccatcttcac attgtttttg ttctccgtat tgttcgcaat cagcgaagtc 60 cgatcaaaaa tatttgggtc tctcgcattc ctc 93 <210> 58 <211> 210 <212> DNA <213> artificial sequence <400> 58 atgaaaggtt ccatcttcac attgttttg ttctccgtat tgttcgcaat cagcgaagtc 60 cgatcaaaaa tatttgggtc tctcgcattc ctccgcagaa agaggaaaat cttcggtagt 120 ttggccttcc ttaggcgaaa gagaaagata ttggaagcc tggccttcct gcgacgcaaa 180 cggaaaatct tcggctcact ggcattcttg 210 <210> 59 <211> 378 <212> DNA <213> artificial sequence <400> 59 atgaaaggtt ccatcttcac attgttttg ttctccgtat tgttcgcaat cagcgaagtc 60 cgatcaaaaa tatttgggtc tctcgcattc ctccgcagaa agaggaaaat cttcggtagt 120 ttggccttcc ttaggcgaaa gagaaagata ttggaagcc tggccttcct gcgacgcaaa 180 cggaaaatct tcggctcact ggcattcttg aggagaaagc gcaaaatatt cgggtctttg 240 gccttctgc gccggaagcg caagatctttc gggtccttg cttcttgag acgaaaacgc 300 aaaatttg ggtctcttgc cttcctcagg cgaaagcgga agattttcgg ttcccttgcc 360 ttccttaaag acgagctt 378 <210> 60 <211> 122 <212> PRT <213> artificial sequence <400> 60 Met Lys Gly Ser Ile Phe Thr Leu Phe Leu Phe Ser Val Leu Phe Ala 1 5 10 15 Ile Ser Glu Val Arg Ser Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg 20 25 30 Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg 35 40 45 Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe 50 55 60 Gly Ser Leu Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu 65 70 75 80 Ala Phe Leu Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu 85 90 95 Arg Arg Lys Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu Arg Arg Lys 100 105 110 Arg Lys Ile Phe Gly Ser Leu Ala Phe Leu 115 120 <210> 61 <211> 366 <212> DNA <213> artificial sequence <400> 61 atgaaaggtt ccatcttcac attgttttg ttctccgtat tgttcgcaat cagcgaagtc 60 cgatcaaaaa tatttgggtc tctcgcattc ctccgcagaa agaggaaaat cttcggtagt 120 ttggccttcc ttaggcgaaa gagaaagata ttggaagcc tggccttcct gcgacgcaaa 180 cggaaaatct tcggctcact ggcattcttg aggagaaagc gcaaaatatt cgggtctttg 240 gccttctgc gccggaagcg caagatctttc gggtccttg cttcttgag acgaaaacgc 300 aaaatttg ggtctcttgc cttcctcagg cgaaagcgga agattttcgg ttcccttgcc 360 ttcctt 366
Claims
1. A therapeutic agent for treating a tumor, comprising: (a) a first composition, wherein the first composition comprises a first active ingredient in a first pharmaceutically acceptable carrier, the first active ingredient comprising a nucleic acid having a marker polypeptide coding sequence for introduction into tumor cells; the marker polypeptide has an amino acid sequence of 4 to 8 identical antigen epitope polypeptides, the antigen epitope polypeptides can be presented on the surface of the tumor cells by MHC class I molecules, and the amino acid sequence of the antigen epitope polypeptide is derived from the amino acid sequence of a tumor-associated antigen or a tumor-specific antigen; and (b) a second composition, wherein the second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier, wherein the second active ingredient comprises a T cell receptor-modified T cell; the T cell receptor-modified T cell is capable of specifically recognizing and binding to the antigen epitope polypeptide presented by the MHC class I molecule; The antigen epitope polypeptide is Her2 / neu 369-377 with an amino acid sequence as shown in SEQ ID NO: 3, and the nucleic acid also has an HLA-A2 protein coding sequence.
2. The therapeutic agent according to claim 1, wherein the marker polypeptide comprises the following amino acid sequences which are operably connected and connected in series: the amino acid sequence of the N-terminal signal peptide, the amino acid sequence of the 4-8 identical antigenic epitope polypeptides, wherein every two adjacent amino acid sequences of the antigenic epitope polypeptides are connected by the amino acid sequence of a cleavable connecting polypeptide. 3 . The therapeutic agent according to claim 2 , wherein the marker polypeptide further comprises an amino acid sequence of a C-terminal endoplasmic reticulum retention signal.
4. The therapeutic agent according to claim 1, wherein the HLA-A2 protein coding sequence and the marker polypeptide coding sequence are respectively under the control of respective promoters, or the HLA-A2 protein coding sequence and the marker polypeptide coding sequence are under the control of the same promoter and the HLA-A2 protein coding sequence is operably linked to the marker polypeptide coding sequence via a cleavable linker polypeptide coding sequence.
5. The therapeutic agent according to claim 1, wherein the amino acid sequence of HLA-A2 is shown as SEQ ID NO:
29.
6. The therapeutic agent according to claim 1, wherein the first composition and the second composition are each independently present in the therapeutic agent without mixing with each other.
7. The therapeutic agent according to claim 1, wherein the nucleic acid comprises DNA or RNA; and the RNA comprises mRNA transcribed from the DNA.
8. The therapeutic agent according to claim 1, wherein the first active ingredient is a recombinant virus, and the genome of the recombinant virus has the marker polypeptide coding sequence; wherein, The recombinant virus includes a selectively replicable recombinant oncolytic virus or a replication-deficient recombinant virus.
9. The therapeutic agent of claim 8, wherein the replication-defective recombinant virus is derived from adenovirus, adenovirus-associated virus (AAV), herpes simplex virus, poxvirus, influenza virus, alphavirus, or Sendai virus.
10. The therapeutic agent according to claim 8, wherein the replication-deficient recombinant virus is a recombinant adenovirus obtained by genetically modifying adenovirus type 5, the E1 gene is deleted in the genome of the recombinant adenovirus, and the marker polypeptide coding sequence is contained at the position of the deleted E1 gene. 11 . The therapeutic agent according to claim 10 , wherein the recombinant adenovirus comprises the HLA-A2 protein coding sequence at the location of the deleted E1 gene.
12. The therapeutic agent according to claim 8, wherein the selective replication-type recombinant oncolytic virus is derived from a gene-mutated virus with oncolytic effect and a wild-type virus with oncolytic effect.
13. The therapeutic agent of claim 8, wherein the selective replication-competent recombinant oncolytic virus is derived from an oncolytic adenovirus, poxvirus, herpes simplex virus, measles virus, Semliki Forest virus, vesicular stomatitis virus, poliovirus, retrovirus, reovirus, Seneca Valley virus, echovirus, coxsackievirus, Newcastle disease virus, and Maraba virus.
14. The therapeutic agent according to claim 8, wherein the selective replication-type recombinant oncolytic virus is a recombinant oncolytic adenovirus obtained by genetically modifying type 5 adenovirus, the genome of the recombinant oncolytic adenovirus is deleted from the E1B-55K gene and / or the E1B-19K gene, and the genome of the recombinant oncolytic adenovirus contains the E1A gene coding sequence.
15. The therapeutic agent according to claim 14, wherein the E1A gene coding sequence is under the control of an exogenous promoter.
16. The therapeutic agent according to claim 8, wherein the selective replication-competent recombinant oncolytic virus is a recombinant oncolytic adenovirus obtained by genetically modifying adenovirus type 5, and the E1A gene of the recombinant oncolytic adenovirus is changed so that the expressed E1A protein cannot bind to the pRb protein.
17. The therapeutic agent according to claim 16, wherein the E1A gene is under the control of an exogenous promoter.
18. The therapeutic agent according to claim 14 or 16, wherein the E3 gene of the recombinant oncolytic adenovirus is completely or partially deleted.
19. The therapeutic agent according to claim 1, wherein the T cells comprise naive T cells or NKT cells.
20. The therapeutic agent of claim 7, wherein the first composition comprises a therapeutically effective amount of the DNA, or a therapeutically effective amount of the mRNA.
21. The therapeutic agent of claim 8, wherein the first composition comprises a therapeutically effective amount of the recombinant virus.
22. The therapeutic agent of claim 1, wherein the second composition comprises a therapeutically effective amount of the T cell receptor-modified T cells.
23. The therapeutic agent of claim 1, wherein the therapeutic agent consists of the first composition and the second composition.
24. Use of the therapeutic agent according to any one of claims 1 to 23 in the preparation of a medicament for treating a tumor.
25. The use according to claim 24, wherein the tumor comprises: Breast cancer, head and neck cancer, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, Liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, cervical cancer, gallbladder cancer, eye cancer, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.
26. The use according to claim 25, wherein the brain cancer is pituitary cancer; the soft tissue sarcoma is fibrosarcoma or Kaposi's sarcoma; and the breast cancer is Paget's disease.
27. A kit of combined drugs with synergistic effects for treating tumors, comprising: a first container containing a first composition of the therapeutic agent according to any one of claims 1-23; a second container containing a second composition in a therapeutic agent according to any one of claims 1-23, wherein the first container and the second container are separate; and Instructions for use that specify when and how to administer the drug.
28. Use of the medicine kit according to claim 27 in preparing a medicine for treating tumors.
29. The use according to claim 28, wherein the tumor comprises: Breast cancer, head and neck cancer, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, Liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, neuroblastoma, meningioma, spinal cord tumors, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, cervical cancer, gallbladder cancer, eye cancer, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiapical myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, blood cancer, peritoneal cancer, and pleural cancer.
30. The use according to claim 29, wherein the brain cancer is pituitary cancer; the soft tissue sarcoma is fibrosarcoma or Kaposi's sarcoma; and the breast cancer is Paget's disease.
Citation Information
Patent Citations
Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment
WO2016178167A1
Immunological therapy method and device for in-vivo individual system
CN104415335A
Pharmaceutical composition and application in medicines for treating tumors and / or cancers thereof
CN108261426A
Leveraging immune memory from common childhood vaccines to fight disease
WO2017177204A1
